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Abstract 
 
The current obesity epidemic poses a major challenge to public health. Apart from bariatric 
surgery, a safe and effective long-term treatment for obesity has yet to be identified. 
Therefore, an improved understanding of the physiology of energy homeostasis is now more 
critical than ever.  
Epidemiologically, there is an inverse association between consumption of fermentable fibre 
and weight gain. This is supported by experimental studies, which demonstrate that 
increasing the consumption of fermentable fibre can reduce appetite and body weight. It is 
thought that these effects may be attributable, at least in part, to the bacterial fermentation of 
fibre in the colon yielding short chain fatty acids (SCFAs). SCFAs have been identified as 
ligands for the G-protein coupled receptors GPR41 and GPR43.  
There are fundamental gaps in our current understanding of the physiological roles of 
SCFAs and their receptors in energy homeostasis, and of their specific effects in different 
endocrine tissues. This thesis investigates the effects of colonic SCFAs on anorectic gut 
hormone release from enteroendocrine L cells, and the role of GPR43 in mediating these 
effects.   
I established mouse and human primary L cell models in our laboratory and used them to 
demonstrate that SCFAs, and particularly propionate, stimulate the release of anorectic gut 
hormones peptide YY (PYY) and glucagon-like peptide 1 (GLP-1). I confirmed that colonic 
administration of propionate increases plasma gut hormone concentrations in vivo, in rats 
and mice. I then explored the mechanisms underlying propionate-induced gut hormone 
release in vitro. I demonstrated that Gpr43-/- L cells exhibit significantly attenuated PYY and 
GLP-1 secretion in response to propionate; a result which was also confirmed for the first 
time in vivo using Gpr43-/- mice. 
These findings suggest that colonic SCFA signalling via GPR43 may play an important 
physiological role. Further investigation is now required to characterise the intracellular 
signalling mechanisms underlying GPR43-activated gut hormone secretion and to determine 
the wider role of GPR43 in energy homeostasis.  
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1.1 Obesity 
1.1.1 Definition, prevalence and economic burden  
The World Health Organisation (WHO) defines overweight and obesity as “abnormal or 
excessive fat accumulation that may impair health” (WHO 2012). The most commonly used 
index for the classification of overweight and obesity is the body mass index (BMI), 
calculated as weight divided by height squared (kg/m2) (Table 1.1), which is arguably the 
most efficient method of measuring the prevalence of obesity at a population level.  
 
Table 1.1 Body Mass Index (BMI) definitions (NHS 2012b) 
Definition BMI range (kg/m2) 
Underweight Under 18.5 
Normal 18.5 to less than 25 
Overweight 25 to less than 30 
Obese 30 to less than 40 
Morbidly obese 40 and over 
 
 
Obesity, which has more than doubled worldwide since 1980 (WHO 2012), is a major public 
health challenge. Based on an analysis of epidemiological studies from 199 countries, 1.46 
billion adults were estimated to be overweight in 2008, of which just over half a billion would 
be classified as obese (Finucane et al. 2011). Despite signs of stabilisation in some 
populations (Rokholm et al. 2010, Sperrin et al. 2013), the consequences of obesity remain 
extensive.  
The UK is amongst the countries which have experienced a dramatic rise in the prevalence 
of overweight and obesity in the past few decades (Wang et al. 2011b). Consequently, ~25% 
of the adult population in England is now classified as obese, with a further 41% of men and 
33% of women classified as overweight (HSE 2011). Furthermore, a report published in the 
22 
Lancet in 2011, projected that there would be 11 million additional obese adults in the UK by 
2030 (Wang et al. 2011b). This projection was based on historic trends in BMI obtained from 
data published in the Health Survey for England (HSE, 1993-2008).  
According to the WHO, obesity is the fifth leading risk for deaths globally. The WHO 
estimates that at least 2.8 million adults die every year as a consequence of being 
overweight or obese (WHO 2012). Excess body weight within populations foreshadows 
increased prevalence of several chronic diseases, most notably cardiovascular diseases 
(Wormser et al. 2011), type 2 diabetes (Vazquez et al. 2007) and certain cancers (e.g. 
endometrial, breast and colon) (Renehan et al. 2008). Excess body weight also contributes 
to non-fatal but expensive and disabling disorders such as osteoarthritis (Guh et al. 2009). 
As a result, Western societies, many of which have ageing populations, suffer from 
premature mortality, obesity-associated morbidities and reduced productivity and quality of 
life.  
The sheer scale of obesity and its multiple associated co-morbidities, translate into a 
substantial economic burden for national healthcare systems. A report produced by the UK’s 
Office for Science Foresight Programme in 2007 projected that the continuing rise in obesity 
will add £5.5 billion in medical costs to the National Health Service (NHS) by 2050 
(Kopelman et al. 2007).  
 
1.1.2 Aetiology  
By definition, the cause of excess weight gain is deceptively simple; it is an energy 
imbalance between calories consumed and calories expended (WHO 2012). However, the 
aetiology of obesity is highly complex and has multiple determinants. The dramatic rise in 
obesity has been linked to changes in food production and the increased availability of 
energy-dense foods, and at the same time to a decrease in physical activity and energy 
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expenditure due to the increasingly sedentary nature of urban life (Butland et al. 2007). This 
‘obesogenic environment’ (Swinburn & Egger 2002), has exposed the propensity of humans 
to accumulate energy and conserve it (Yeo & Heisler 2012). Our drive to consume food is a 
very powerful instinct, intimately linked with the promotion of survival. As such, multiple 
redundant mechanisms have evolved to respond to, and deal with, frequent periods of food 
scarcity (Yeo & Heisler 2012). Therefore, at the core of the problem is a now ill-adapted 
physiological system, which has been unable to cope with rapid environmental change.  
Due to the complex nature of the aetiology of obesity, the development of anti-obesity 
treatments has proved challenging.  
 
1.1.3 Treatment 
 
Lifestyle modification 
The first line of treatment for the management of overweight and obesity is lifestyle 
intervention, incorporating dietary restriction and increased physical activity to improve 
energy balance. Lifestyle interventions can be successful in inducing weight loss 
(Tuomilehto et al. 2001). However, more often than not, individuals struggle with maintaining 
this weight loss (Crawford et al. 2000, Weiss et al. 2007). Therefore, at a population level, 
anti-obesity agents appear necessary as an adjunctive therapy to lifestyle modification to 
ensure successful weight loss and maintenance. 
 
Pharmacotherapy 
The only anti-obesity drug currently licensed for prescription use in the UK and within the 
European Union is Orlistat. Orlistat is a pancreatic lipase inhibitor that acts within the 
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gastrointestinal tract to inhibit the absorption of fat by approximately 30% (Drew et al. 2007). 
Orlistat is associated with a modest but significant weight reduction (~3%) above that 
achieved with dietary modification alone in obese individuals (Drew et al. 2007). A Cochrane 
meta-analysis encompassing 11 randomised controlled trials (RCTs) found that a larger 
number of subjects in the Orlistat group achieved clinically significant weight loss: 21% and 
12% achieved ≥5% and ≥10% weight loss, respectively (Padwal et al. 2003). However, the 
Cochrane review also reported high attrition rates (14-52%) during the Orlistat studies. 
Orlistat treatment is associated with adverse gastrointestinal effects, experienced by 16-40% 
patients (Padwal et al. 2003). One of the unpleasant and unavoidable consequences of fat 
malabsorption in the gut is steatorrhea. In addition, the magnitude of weight loss achieved is, 
in many cases, insufficient to prevent the development of complications associated with 
obesity (Field et al. 2010a, Powell et al. 2011). 
The development of pharmacological treatments to combat obesity has been riddled with 
setbacks related to efficacy and safety issues. As a consequence, no new drugs were 
licensed for the treatment of obesity in over a decade. However, the summer of 2012 saw 
the approval of two novel anti-obesity drugs by the United States Food and Drugs 
Administration (FDA). The first drug to be granted approval was Lorcaserin, commercially 
marketed as Belviq, which is an entirely centrally-acting serotonin 2c (5-HT2c) receptor 
agonist (Yao 2012). Lorcaserin selectively activates central 5-HT2c receptors and increases 
satiety via effects on the melanocortin system (Lam et al. 2008, Xu et al. 2008). A recent 
meta-analysis of three RCTs (lasting ≥1 year, total sample size: 7,789) demonstrated that 
the use of lorcaserin results in statistically significant but moderate absolute weight loss 
compared with placebo (~3%), similar in magnitude to the weight loss following orlistat 
treatment (Chan et al. 2013). However, lorcaserin too is associated with adverse effects, the 
most common ones being transient headache, nausea and dizziness, which were found to 
be statistically significant in the meta-analysis (Chan et al. 2013). 
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The second anti-obesity drug approved by the FDA in July 2012 was Qsymia, previously 
known as Qnexa. Qsymia is a combination of two drugs: the appetite suppressant, 
phentermine and the anticonvulsant, topiramate. The SEQUEL study of 
phentermine/topiramate (PHEN/TPM, Qsymia) demonstrated sustained weight loss over 108 
weeks of treatment in combination with lifestyle modification. A significant weight loss of 10% 
was achieved by >50% of PHEN/TPM-treated subjects, whereas less than 12% of 
individuals receiving placebo achieved this goal (Garvey et al. 2012). Phentermine is a well-
established drug which reduces appetite by stimulating hypothalamic release of 
noradrenaline (Powell et al. 2011). As with many centrally acting drugs, Qsymia is not 
without unwanted side effects; patients reported depression and/or anxiety-related adverse 
events. The safety profile of drugs is currently the biggest obstacle in anti-obesity drug 
development (McGavigan & Murphy 2012). 
 
Bariatric surgery 
Advances in the field of bariatric surgery over the past decade have been a major 
breakthrough in the treatment of the very obese. Bariatric surgery is now well-recognised as 
the most effective therapeutic option currently available for morbidly obese individuals. It 
results in significant and sustained weight loss in the region of ~30% (Maggard et al. 2005, 
Sjostrom et al. 2007) with a demonstrated mortality benefit [adjusted all cause long term 
mortality ~40% (Adams et al. 2007)].  The Roux-en-Y gastric bypass (RYGB) procedure, 
which involves the creation of a small stomach pouch and bypass of the proximal small 
intestine (Fig. 1.1), is considered the gold-standard operative treatment for morbid obesity 
(Buchwald & Oien 2009, 2013). 
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Figure 1.1. The Roux-en-Y gastric bypass surgical procedure. This surgery creates a 
small gastric pouch (~30ml) directly linked to the distal jejunum by the Roux limb. The distal 
stomach, duodenum and proximal part of the jejunum are subsequently anastomosed 1.5m 
below the gastrojejunal anastomosis. Adapted from: (Aron-Wisnewsky et al. 2012) 
 
 
However, bariatric surgery is highly invasive and carries a mortality rate in the region of 0.5-
2% (Flancbaum & Belsley 2007). Furthermore, in the UK, obesity surgery is only available to 
morbidly obese individuals on the NHS, who currently only account for ~2-4% of total obese 
and overweight in England (NHS 2012a). For those who do not meet the requirements for 
the procedure, and yet who are at significant risk from the complications of being obese, the 
options remaining are limited and largely ineffective. Consequently, understanding the 
mechanisms by which gastric bypass induces and maintains weight loss, in order to 
potentially target these mechanisms pharmacologically, would be invaluable.  
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Initially it was thought that RYBG-induced weight loss was mediated by mechanical 
restriction and malabsorption. However, additional mechanisms are now emerging, including 
bile flow alterations (Pournaras et al. 2012), increased satiety (Borg et al. 2006), altered 
taste (Burge et al. 1995, Tichansky et al. 2006) and a reduced preference for energy dense 
foods (Olbers et al. 2006). Furthermore, a recent study by Liou et al. provided the first 
empirical evidence to suggest that alterations in gut microbiota following RYGB in mice are 
involved in inducing RYGB-weight loss (Liou et al. 2013). RYGB, but not sham surgery or 
caloric restriction, led to a rapid and sustained modulation of the relative abundance of 
certain microbial populations, particularly in the distal gut. Transplantation of gut microbiota 
from the RYGB group to non-operated germ-free mice resulted in weight loss and reduced 
adiposity in the recipient mice, compared to the recipients of gut microbiota from the sham 
surgery group (Liou et al. 2013). This effect may have been mediated, at least in part, by an 
alteration in the microbial production of short chain fatty acids (discussed in greater detail in 
Section 1.4).  
 
The rearrangement of the gastrointestinal tract has also been proposed to increase satiety 
via increased delivery of nutrients to distal regions of the small intestine, thereby enhancing 
the secretion of appetite-suppressing gut hormones (Beckman et al. 2011, Korner et al. 
2005, le Roux et al. 2006, le Roux et al. 2007). These peripherally-derived signals stimulate 
central anorexigenic pathways to reduce food intake via the so-called gut-brain axis.  
 
An improved understanding of the physiology of energy homeostasis and appetite regulation 
would potentially enable us to mimic the physiological consequences of gastric bypass, such 
as the favourable SCFA and anorectic gut hormone profile, without the need for invasive 
surgery, which would have profound implications for the development of anti-obesity 
treatments. 
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1.2 The Gut-Brain Axis in the Regulation of Appetite 
 
Appetite is regulated by a sophisticated homeostatic system, at the centre of which lies a 
complex neuroendocrine network known as the gut-brain axis (Dockray 1988, Track 1980). 
The gut-brain axis is a bidirectional communication system that relays information between 
the gut and the brain to tailor gastrointestinal function (secretion and motility) and food intake 
to the nutrient content of the intestinal milieu. This serves to maximise the efficient digestion 
and assimilation of ingested nutrients and to induce postprandial satiety, which ultimately 
contributes to the long term maintenance of energy balance. The major regions orchestrating 
appetite modulation within the brain are the hypothalamus and the brainstem, which 
integrate peripherally-derived neural and hormonal signals (Fig. 1.2).  
 
 
1.2.1 The hypothalamus  
The hypothalamus is a major site of peripheral signal integration within the central nervous 
system (CNS); receiving information from metabolic, endocrine and neural pathways, which 
concertedly modulate feeding behaviour. The hypothalamus is situated at the base of the 
brain, surrounding the third ventricle, and comprises several distinct but highly 
interconnected nuclei and regions, including the arcuate nucleus (ARC), paraventricular 
nucleus (PVN), ventromedial nucleus (VMN), dorsomedial nucleus (DMN) and the lateral 
hypothalamic area (LHA), all of which are implicated in the regulation of energy 
homeostasis. Of these hypothalamic regions, the ARC perhaps has the most prominent role 
in energy homeostasis.   
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The arcuate nucleus (ARC) 
The ARC is pivotal to the convergence and integration of peripheral energy homeostatic 
signals (Stanley et al. 2005). This is partly due to its anatomical location, adjacent to the 
median eminence, an area of incomplete blood-brain barrier, enabling the ARC to interact 
with circulating metabolic and endocrine signals. These signals include nutrients, and 
hormones derived from the gut, pancreas and adipose tissue (Lam et al. 2005, Murphy & 
Bloom 2006, Porte et al. 2002, Wang et al. 1997). The ARC also receives input from the 
caudal brainstem and is thus indirectly privy to neural signals originating from the 
gastrointestinal tract. These collated signals act on two distinct neuronal populations within 
the ARC to modulate appetite.  
 
A population of neurons in the medial ARC co-express the orexigenic neuropeptides agouti-
related peptide (AgRP) and neuropeptide Y (NPY) (Broberger et al. 1998), whereas a 
population in the lateral ARC co-express the anorexigenic neuropeptides cocaine- and 
amphetamine-regulated transcript (CART) peptide and pro-opiomelanocortin (POMC) (Elias 
et al. 1998). These neurons are known as “first-order” neurons, the axons of which project to 
“second-order” neurons within the ARC, other hypothalamic nuclei and extra-hypothalamic 
regions.  
 
 
POMC and CART 
POMC is the polypeptide precursor of several molecules including the melanocyte-
stimulating hormones (α-, β-, and γ-MSH), of which α-MSH has the most prominent role in 
energy homeostasis, as an anorexigenic agent (Tsujii & Bray 1989). MSH hormones act on 
the melanocortin receptors and particularly the melanocortin 4 receptor (MC4R), which is 
widely expressed in the CNS, including in the PVN and ARC (Mountjoy et al. 1994). 
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Melanocortin receptor agonism is fundamental in the regulation of energy homeostasis 
(Cone 1999, 2005). In humans, specific mutations affecting components of the melanocortin 
system are associated with morbid obesity (Farooqi et al. 2003, Krude et al. 1998, Yeo et al. 
1998, Yeo & Heisler 2012) . 
CART was originally identified as a consequence of its upregulation by cocaine and 
amphetamine (Kuhar & Dall Vechia 1999). However, 90% of CART neurons are co-localised 
with POMC neurons in the ARC, which suggested a prominent role in energy homeostasis. 
Consistent with its co-localisation with POMC, CART has been demonstrated to possess 
strong anorexigenic qualities. Central administration of CART in rodents leads to a reduction 
in food intake, an effect reversed by central infusion of anti-CART antibodies (Lambert et al. 
1998). Fasting, on the other hand, reduces CART levels in the ARC of lean animals 
(Kristensen et al. 1998).    
 
NPY and AgRP 
NPY is one of the most potent central enhancers of appetite identified to date. It is widely 
expressed in the CNS (Allen et al. 1983), and its expression is abundant in the ARC where 
~90% of NPY neurons co-express AgRP. Central administration of NPY induces marked 
hyperphagia and reduces energy expenditure (Billington et al. 1991, Clark et al. 1984, 
Stanley & Leibowitz 1985). Furthermore, fasting increases NPY mRNA expression in the 
ARC (White & Kershaw 1990). The hyperphagic effects of NPY are mediated by specific 
NPY receptor subtypes. To date, five NPY receptors have been identified. The present 
consensus is that Y1 and Y5 act synergistically to mediate the orexigenic effects of NPY 
(Harrold et al. 2012, Mashiko et al. 2009).  
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AgRP is another potent orexigenic peptide. Its expression is restricted to the ARC of the 
hypothalamus, where it is co-synthesised in NPY neurons (Ollmann et al. 1997). As with 
NPY, AgRP expression in the ARC is elevated following fasting (Hahn et al. 1998). 
Moreover, central administration of AgRP also induces prolonged hyperphagia and body 
weight gain (Ebihara et al. 1999, Small et al. 2001). AgRP is thought to stimulate food intake 
mainly via competitive antagonism/inverse agonism of central melanocortin receptors 
(Ollmann et al. 1997), though alternative mechanisms of action have also been suggested 
(Schwartz et al. 2000, Wu et al. 2008). 
 
 
1.2.2 The caudal brainstem and the vagus nerve  
 
The brainstem 
The caudal brainstem is another region of fundamental importance to the regulation of 
energy homeostasis and the relaying and integration of information in the gut-brain axis. The 
brainstem, located in the hindbrain, receives neural signals from vagal nerve afferents and 
cervical spine afferents from the gastrointestinal tract, the abdominal viscera and the oral 
cavity (Young 2012). Ingestion of a meal generates mechanosensory, chemosensory and 
endocrine signals from the gastrointestinal tract, which slow gastric emptying and gut motility 
to ensure efficient digestion and absorption, and bring about a sense of fullness and 
satiation. These signals mediate their effects predominantly by activating vagal afferent 
fibres which synapse in the brainstem (van der Kooy et al. 1984). The brainstem contains 
three structures which are important in the control of energy balance; the nucleus tractus 
solitarius (NTS), the dorsal motor nucleus of the vagus (DMX) and the area postrema 
(AP)(Young 2012). The NTS, situated in the dorsal medulla, is the primary sensory relay 
nucleus for the gastrointestinal tract (and other viscera). It integrates information related to 
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the gustatory properties of food (Travers et al. 1987) as well as neural input stimulated by 
gastrointestinal distension (Emond et al. 2001, Traub et al. 1996), intraluminal nutrients 
(Zittel et al. 1994) and gut hormones.  
 
The NTS also receives projections from the adjacent AP, an anatomically discrete 
chemosensory structure surrounded by the NTS. Like the median eminence of the 
hypothalamus, the AP is a circumventricular organ with fenestrated capillaries and is 
therefore capable of sensing blood- and cerebrospinal fluid-borne signals (Ellacott & Cone 
2004). The AP possesses a plethora of receptors for such signals, including receptors for gut 
hormones. 
 
The third component of the gut-brain axis within the brainstem is the DMX, which lies directly 
ventral to the NTS. The DMX is the orchestrator of the major descending limb of the vagus 
and functions as a centre for the integration of motor and secretory drive to the viscera 
(Young 2012). The AP, NTS and DMX are extensively interconnected. The NTS and DMX 
therefore form a relatively simple reflex arc for the regulation of gastrointestinal function. 
 
The vagus nerve 
The vagus nerve is a major pathway for signals originating from the small intestine and 
proximal colon, whereas sacral parasympathetic nerves innervate the distal colon. 
Subdiaphragmatic vagotomy or abdominal afferent denervation, using the neurotoxin 
capsaicin, significantly suppresses or completely abolishes nutrient-induced satiety (Walls et 
al. 1995, Yox & Ritter 1988). Vagal sensory innervation of the gastrointestinal tract arises 
from afferent neurons with cell bodies in the nodose and jugular ganglia, the endings of 
which are concentrated either within the muscular layers or the intestinal mucosa. Mucosal 
vagal afferent terminals are located within the parenchyma of mucosal villi in close proximity 
to the basal lamina, but not the epithelial surface (Berthoud et al. 1995) and can be either 
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mechanosensitive or chemosensitive. They typically receive signals from specialised 
epithelial endocrine cells in a paracrine manner. Many gut hormones are thought to act, at 
least in part, by activating receptors on vagal nerve afferents (Abbott et al. 2005a, Date et al. 
2002, Moran et al. 1990).  
1.2.3 Gut hormones 
The gastrointestinal tract responds to the presence of intra-luminal nutrients in a coordinated 
manner, with multiple physiological responses occurring to maximise the efficient digestion 
and assimilation of ingested food. Enteroendocrine cells (EECs) are the primary sensors of 
luminal content; they are specialised endocrine epithelial cells that secrete regulatory gut 
peptides, which in turn modulate the gut-brain axis. Anticipation of a meal, gastrointestinal 
distension and luminal nutrient composition all affect the secretion of these gut hormones, 
which in turn tailor gastrointestinal function (secretion and motility) and tend to suppress 
further food intake. An impressive number of gut hormones have been implicated in these 
processes and multiple examples of overlapping functions and redundancy can be observed 
(Cummings & Overduin 2007, Murphy & Bloom 2006). However, certain gut hormones have 
emerged as instrumental components of homeostatic appetite regulation and these are 
discussed below.  
 
1.2.3.1 Ghrelin 
Ghrelin is the only orexigenic gut hormone isolated so far; a 28-amino acid acylated peptide 
secreted by “A-X like” cells of the oxyntic glands in the stomach. Ghrelin may be partly 
responsible for the initiation of hunger; circulating ghrelin levels increase almost two-fold 
prior to the ingestion of food and fall rapidly in the postprandial phase (Tschop et al. 2001). 
Peripheral or central administration of ghrelin to rodents acutely stimulates food intake (Wren 
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et al. 2000), and chronically, promotes weight gain (Tschop et al. 2000, Wren et al. 2001b). 
In humans, intravenous infusion of ghrelin at physiological doses stimulates hunger and 
increases food intake acutely (Wren et al. 2001a). Ghrelin exists in one of two forms: an 
acylated or a des-acylated peptide (Kojima et al. 1999). The enzyme responsible for the 
acylation of ghrelin is gastric O-acyl transferase (GOAT). The acylated form of ghrelin is 
thought to account for the gut hormone’s potent orexigenic effects, while the role of des-
acylated ghrelin remains contentious.  
Ghrelin is the main endogenous ligand for the growth hormone secretagogue receptors 
(GHS-Rs) and particularly the GHS-R1a receptor, which is expressed in the hypothalamus 
and the anterior pituitary.  Within the hypothalamus, the GHS-R1a receptor is expressed on 
NPY neurons (Date et al. 2000, Lucidi et al. 2005), and in accordance with this, the 
orexigenic action of ghrelin is thought to be mediated by the stimulation of NPY/AgRP 
pathways and the inhibition of POMC neurons in the ARC (Lucidi et al. 2005, Nakazato et al. 
2001). However, the vagus nerve is also likely to be a critical facilitator of the appetite-
enhancing effects of ghrelin (Date et al. 2002, van der Lely et al. 2004).  
 
1.2.3.2 Cholecystokinin (CCK) 
CCK is the prototypical gut hormone (Gibbs et al. 1973, Jorpes & Mutt 1959). It is produced 
and secreted from a subset of enteroendocrine cells known as I cells, located within the 
duodenal and jejunal mucosa, in response to intraluminal protein and lipids (Liddle et al. 
1985, Polak et al. 1975). Multiple bioactive forms of CCK exist, depending on the specific 
post-translational processing of the polypeptide precursor, preprocholecystokinin. CCK 
delays gastric emptying, slows intestinal transit, stimulates pancreatic enzyme secretion and 
gall bladder contraction and induces a sense of fullness (Dockray 2012). Peripheral 
administration of CCK-8 has been demonstrated to reduce food intake in both lean and 
obese individuals (Kissileff et al. 1981, Lieverse et al. 1995, Pi-Sunyer et al. 1982). The 
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anorexigenic effects of CCK are predominantly mediated through activation of CCK-1 
receptors on vagal afferent fibres and the subsequent innervation of the NTS in the 
brainstem (Gutzwiller et al. 2000, Moran et al. 1990). In accordance with this, interruption of 
the vagus nerve in rats abolishes the satiating effect of CCK (Lorenz & Goldman 1982, 
Smith et al. 1981). Furthermore, CCK-1R antagonism has been demonstrated to increase 
food intake in both animals and humans (Beglinger et al. 2001, Hewson et al. 1988, Moran 
et al. 1993). 
 
1.2.3.3 Glucagon-like peptide-1 (GLP-1) and Oxyntomodulin (OXM) 
The gut peptides glucagon-like peptide 1 (GLP-1) and oxyntomodulin (OXM) are products of 
the post-translational processing of proglucagon, a 160-amino acid polypeptide precursor 
synthesised by enteroendocrine L cells in the gastrointestinal tract, pancreatic α-cells, and 
neurons within the NTS (Holst 2007, Kieffer & Habener 1999).   
GLP-1 
GLP-1 is secreted by enteroendocrine L cells, found throughout the gastrointestinal tract but 
in highest density in the colon, in response to nutrients, especially carbohydrates and fatty 
acids (Kreymann et al. 1987, Layer et al. 1995, Orskov et al. 1994).  GLP-1 circulates in two 
different forms: GLP-17-37 and the major circulating form, GLP-17-36 amide. Both forms are 
equally potent at the GLP-1 receptor (GLP-1R) (Orskov et al. 1994). GLP-1 has multiple 
physiological roles: it delays gastric emptying and inhibits gastric acid secretion (Tolessa et 
al. 1998), acts as an endogenous incretin (Kreymann et al. 1987), suppresses glucagon 
secretion (Naslund et al. 1999) and has trophic effects in pancreatic cells (Edvell & 
Lindstrom 1999). GLP-1 also has an established role in the induction of satiety. Peripheral 
administration of GLP-1 reduces acute food intake in rodents and in humans (Abbott et al. 
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2005a, Flint et al. 1998), whereas the opposite effect is observed with peripheral 
administration of the GLP-1R antagonist Exendin 9-39 (Williams et al. 2009).  
The mechanisms through which GLP-1 inhibits food intake, however, require further 
investigation. As GLP-1 is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) on its route 
into the circulation, newly secreted GLP-1 is likely to at last partly mediate its anorexigenic 
effects through activation of peripheral GLP-1 receptors expressed on vagal nerve afferents 
in the gastrointestinal tract or even in the hepatoportal region (Hansen et al. 1999, Holst & 
Deacon 2005, Vahl et al. 2007, Williams et al. 2009). In accordance with this, brainstem NTS 
neurons are activated in response to peripheral GLP-1 administration (Baumgartner et al. 
2010). Furthermore, either subdiaphragmatic vagotomy (Abbott et al. 2005a), or selective 
vagal deafferentation (Hayes et al. 2011, Ruttimann et al. 2009), significantly inhibit 
peripheral GLP-1-induced hypophagia. In humans, the acute inhibitory effect of peripheral 
GLP-1 on food intake is lost in patients who have had a truncal vagotomy (Plamboeck et al. 
2013). 
However, there is also evidence to support the concept that GLP-1 may have direct CNS 
effects (Pannacciulli et al. 2007, van Dijk & Thiele 1999) as it is able to reach the brainstem 
via the AP, where GLP-1Rs are also expressed (Kastin et al. 2002). A direct central effect of 
GLP-1 is supported by the observation that only the anorectic effect of intraperitoneal, and 
not intravenous, GLP-1 requires vagal afferent signalling (Ruttimann et al. 2009). In fact, the 
GLP-1R is widely expressed in the brain (Goke et al. 1995), including the brainstem (Larsen 
et al. 1997), and work by Turton et al. and Tang-Christensen et al. has established central 
GLP-1 as a physiological regulator of appetite in its own right (Tang-Christensen et al. 1996, 
Turton et al. 1996). They demonstrated potent reduction in food intake following central 
administration of GLP-1, an effect inhibited by Exendin 9-39. Furthermore, knockdown of 
GLP-1 producing neurons, and chronic administration of Exendin 9-39, are associated with 
hyperphagia and increased adiposity in rats on a high fat diet (Barrera et al. 2011). The 
effects of ICV administration of GLP-1 likely reflect the action of GLP-1 produced and 
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released by neurons of the NTS which express the proglucagon gene and display a 
processing pattern similar to that of enteroendocrine L cells (Holst 2013, Larsen et al. 1997, 
Shimizu et al. 1987). However, the relationship between the peripheral and central GLP-1 
systems, and their contribution to nutrient-stimulated appetite suppression, are currently 
unclear.  
OXM 
OXM is another anorexigenic gut hormone synthesised by enteroendocrine L cells along 
with GLP-1, and released in proportion to the energy content of ingested food (Le Quellec et 
al. 1992). As with GLP-1, OXM has also been shown to delay gastric emptying and reduce 
food intake (Dakin et al. 2001, Schjoldager et al. 1989). Both central and peripheral 
administration of OXM potently reduce food intake and induce weight loss in rats (Dakin et 
al. 2001, Dakin et al. 2004, Dakin et al. 2002). Similarly in humans, peripheral OXM 
promotes satiety and results in long-term weight loss (Cohen et al. 2003, Wynne et al. 2006, 
Wynne et al. 2005). OXM has been demonstrated to bind to the GLP-1R, though with much 
lower affinity than GLP-1 (Fehmann et al. 1994), and the glucagon receptor (Baggio et al. 
2004). However, there are discrepancies between the pathways mediating the effects of 
GLP-1 and OXM (Badman & Flier 2005, Parkinson et al. 2009) and at present, the precise 
mechanisms underlying the hypophagic action of OXM remain obscure.  
 
1.2.3.4 Peptide YY (PYY) 
PYY is a 36-amino acid peptide that belongs to the PP fold family, along with pancreatic 
polypeptide (PP) and NPY. All three peptides bind to the Y family of receptors (Y1-Y5), albeit 
with varying affinities (Blomqvist & Herzog 1997). PYY is an anorexigenic peptide 
synthesised and secreted from enteroendocrine L cells in response to luminal nutrients 
(Adrian et al. 1985). High concentrations of PYY are found in the terminal ileum, colon and 
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rectum (Adrian et al. 1985). Two forms of PYY exist: PYY1-36 and the truncated PYY3-36, 
which is produced from the cleavage of full length PYY by DPP-IV (Eberlein et al. 1989, 
Mentlein et al. 1993) and is the major circulating form (Grandt et al. 1994). 
PYY has several physiological functions, including the delay of gastric emptying, the slowing 
of gut transit and the induction of satiety. Peripheral administration of PYY3-36 at 
physiological doses significantly reduces food intake in both lean and obese individuals 
(Batterham et al. 2003, Batterham et al. 2002, Chelikani et al. 2005). Surprisingly, ICV 
administration of PYY3-36 has the opposite effect and increases food intake (Morley et al. 
1985). This orexigenic effect has been attributed to pharmacological activation of Y1 or Y5 
receptors in the PVN (Hagan 2002).   
PYY3-36 selectively binds to and activates the Y2 receptor (Y2R) (Browning & Travagli 2009, 
Grandt et al. 1992, Keire et al. 2000). However, the exact mechanisms underlying the 
anorectic effects of PYY3-36 remain unclear. PYY3-36 may reduce appetite by inhibiting the 
release of orexigenic NPY via autoinhibitory Y2Rs and by disinhibiting POMC neurons in the 
ARC (Acuna-Goycolea & van den Pol 2005, Batterham et al. 2002). Central administration of 
a Y2R agonist has been demonstrated to suppress food intake in rodents (Leibowitz & 
Alexander 1991). Furthermore, Y2R-deficient mice are hyperphagic and PYY3-36 is unable to 
reduce food intake in these animals, suggesting that the anorectic effects of PYY are 
mediated by this receptor (Naveilhan et al. 1999).  
Peripheral PYY3-36 administration increases c-fos expression in the ARC and reduces 
hypothalamic NPY mRNA expression (Batterham et al. 2002). Furthermore, intra-arcuate 
administration of a specific Y2R antagonist attenuates the anorectic effect of peripherally 
administered PYY3-36 in rats (Abbott et al. 2005b). However, peripherally administered PYY3-
36 is also thought to act via Y2Rs expressed on vagal afferent fibres. In support of this, 
vagotomy abolishes the reduction in food intake induced by peripheral PYY3-36 (Abbott et al. 
2005a, Koda et al. 2005). 
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Figure 1.2. The regulation of appetite and energy homeostasis. The brain integrates 
peripheral and neural signals to regulate energy homeostasis. Peripheral factors indicative of long-
term energy status are produced by adipose tissue (leptin, adiponectin) and the pancreas (insulin), 
whereas the acute hunger signal ghrelin, and satiety signals such as the gut hormones peptide YY3-36 
(PYY3-36), pancreatic polypeptide (PP) and oxyntomodulin (OXM) indicate short term energy status. 
The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide 
(GIP) improve the response of the endocrine pancreas to absorbed nutrients. Further feedback is 
provided by nutrient receptors in the upper small intestine, and neural signals indicating distension of 
the stomach’s stretch receptors, which are primarily conveyed by the vagal afferent and sympathetic 
nerves to the nucleus of the tractus solitarius (NTS) in the brain stem. The arcuate nucleus (ARC) of 
the hypothalamus integrates these energy homeostatic signals. Two distinct subsets of neurons 
control food intake in the ARC; the first co-expresses the orexigenic agouti-related peptide (AgRP) 
and neuropeptide Y (NPY) neurotransmitters, the second co-expresses the anorexigenic cocaine- and 
amphetamine-regulated transcript (CART) and pro-opiomelanocortin (POMC) peptide 
neurotransmitters. Both neuronal populations innervate the paraventricular nucleus (PVN) followed by 
other areas of the brain. CCK, cholecystokinin; MCR, melanocortin receptor; NPY YR, neuropeptide Y 
receptor Y. Adapted from: (Cooke & Bloom 2006) 
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1.2.3.5 Current understanding of gut hormone expression in EECs 
The enteroendocrine cell population represents just 1% of intestinal epithelial cells and their 
lack of specific cell-surface markers has made these cells challenging to study. However, 
our understanding of EECs has evolved significantly in recent years. This has been driven 
by the engineering of transgenic mouse models possessing fluorescently-tagged gut 
hormone genes enabling the isolation and characterisation of these previously elusive cell 
populations (Liou et al. 2011, Parker et al. 2009, Reimann et al. 2008, Sykaras et al. 2012, 
Wang et al. 2011a). The adoption of this enabling technology by the field of gastrointestinal 
endocrinology has already provided invaluable insights.  
 
Recent work revealed extensive overlap in the gut hormone content of small intestinal (SI) L 
cells and K cells, the EECs which secrete the gut hormone and incretin glucose-dependent 
insulinotropic polypeptide (GIP) (Baggio & Drucker 2007, Brown et al. 1975, Pederson et al. 
1975). Surprisingly, colonic and upper SI proglucagon-expressing L cells appeared to share 
less in common, despite being considered the same cell type, than the traditionally distinct 
cell subtypes of upper SI L cells and K cells (Habib et al. 2012). Using intestinal tissue from 
transgenic mice in which the expression of the yellow fluorescent protein (YFP) Venus is 
driven by the proglucagon promoter, upper SI L cell populations were demonstrated to 
express mRNA for gut hormones classically found in different enteroendocrine cell types, 
including GIP, CCK, secretin and neurotensin (Habib et al. 2012). By immunostaining and 
fluorescence-activated cell sorting (FACS) analysis, the majority of proglucagon-expressing 
colonic L cells were shown to contain GLP-1 and PYY, as anticipated. In contrast, in the 
upper SI, most proglucagon-expressing L cells also contained CCK, ~10% were GIP-positive 
and only ~20% were PYY-positive (Habib et al. 2012). A similar pattern of expression was 
also demonstrated using small intestinal tissue from transgenic mice expressing enhanced 
green fluorescent protein (eGFP) under the control of the CCK promoter (Egerod et al. 
2012). Further work is required to address the issue of whether SI L cells store and release 
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these peptides at physiologically meaningful levels. However, these data enable the 
speculation that upper SI L, K and I cells may in fact comprise a single cell type, with 
individual cells exhibiting a ‘hormonal spectrum’, potentially influenced by their location along 
the gastrointestinal tract and exposure to different luminal factors.   
 
1.2.4 Beyond the gut brain-axis: non-homeostatic influences on food intake  
The homeostatic mechanisms controlling food intake evolved during frequent periods of food 
scarcity and as a result, are highly efficient at defending the lower limits of body weight and 
adiposity. However, as previously alluded to, we currently live in an ‘obesogenic’ 
environment, saturated with highly-palatable and energy-dense foods (Berthoud 2012). The 
ability to override anorectic homeostatic signals and ‘overconsume’ calorie-dense palatable 
foods, demonstrates that food consumption goes beyond meeting metabolic demand and 
points towards the presence of a non-homeostatic component. This is referred to as 
‘hedonic’ food intake and is driven by the pleasure-reward system (Berthoud 2011, Petersen 
et al. 2013). Therefore, the current consensus is that eating behaviour is co-ordinated by a 
combination of both homeostatic and non-homeostatic inputs. The crosstalk between 
homeostatic feedback and hedonic circuits provides a mechanism by which highly palatable 
food may overwhelm energy regulation but also opens up the possibility of strengthening 
satiety signals to assist with resisting the urge to overindulge (Petersen et al. 2013).    
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1.3 Non-Digestible Carbohydrates (NDCs) and Obesity 
1.3.1 NDC nomenclature and classification   
Traditionally, carbohydrate classification and terminology have been based on chemical 
divisions. In 1998, a joint expert consultation by the Food and Agriculture Organisation of the 
United Nations (FAO) and the WHO on carbohydrates in human nutrition proposed the use 
of the terms “sugars, oligosaccharides and polysaccharides” with appropriate subgroups to 
include all dietary carbohydrates (Clausen & Mortensen 1995) (Table 1.2).  
 
The terms dietary fibre, non-digestible carbohydrate (NDC) and fermentable carbohydrate, 
all allude to carbohydrates which escape digestion in the mammalian small intestine and 
reach the caecum (Cummings 1997). These include members of the oligosaccharide and 
polysaccharide groups, which contain glycosidic linkages that cannot by hydrolysed by 
amylases (Table 1.2). Examples include the β 1-4 linkages in cellulose and the α-
galactosidic linkages of raffinose (Flint et al. 2012a). In addition to the nature of the 
glycosidic bond, the rate and extent of carbohydrate digestion are also determined by the 
structure of the starch granule, the amylose:amylopectin ratio, the degree of gelitinisation 
and the integrity of the plant cell wall (Chambers et al. 2011, Flint et al. 2012a). All of these 
factors will ultimately affect the susceptibility of the carbohydrate to enzymatic digestion.  
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Table 1.2 Classification of dietary carbohydrates  
 
(1) DP, degree of polymerisation 
Adapted from: (Cummings 1997) 
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1.3.2 The beneficial effects of NDCs on metabolic health 
Epidemiological evidence suggests that there is an inverse correlation between consumption 
of NDCs and weight gain (Liu et al. 2003, Ludwig et al. 1999), and with fat mass (Kromhout 
et al. 2001, Nelson & Tucker 1996, Tucker & Thomas 2009). This is supported by 
experimental studies in both animals and humans, which demonstrate that increasing the 
consumption of NDCs can reduce appetite, body weight (Cani et al. 2004a, Cani et al. 2006, 
Cani et al. 2005, Perrigue et al. 2009, Rigaud et al. 1990, Ryttig et al. 1989) and adiposity 
(Keenan et al. 2006, Pawlak et al. 2004, So et al. 2007). There is also evidence to suggest 
that a high intake of NDCs may improve insulin sensitivity independently of effects on body 
weight and adiposity (Robertson et al. 2005, Robertson et al. 2003).  
 
As reviewed by Howarth et al., the majority of NDC intervention studies indicate that an 
increase in NDC intake is associated with enhanced post-meal satiety and a decrease in 
subsequent hunger (Howarth et al. 2001). However, while evidence from NDC 
supplementation studies in animals is largely consistent, not all NDC intervention studies in 
humans have demonstrated that NDC consumption increases perceived satiety or weight 
loss (Howarth et al. 2003). This observation may be accounted for by the use of insufficient 
NDC levels in human studies compared to animal studies (Chambers et al. 2011, Parnell & 
Reimer 2009).  
 
NDCs have been proposed to reduce caloric intake by a number of different mechanisms. 
These include the displacement of energy-dense foods from the diet, interference with the 
absorption of macronutrients from the gut lumen, an altered luminal environment, and 
increased gastric distension (Heaton 1973). However, the hypophagic effects of NDCs are 
also thought to be mediated by the release of anorexigenic gut hormones (Sleeth et al. 
2010). NDC supplementation has been associated with increased circulating PYY and GLP-
1 levels (Cani et al. 2006, Cani et al. 2009, Delzenne et al. 2005, Keenan et al. 2006, Zhou 
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et al. 2008) as well as with enhanced PYY and proglucagon intestinal gene expression 
(Zhou et al. 2006, Zhou et al. 2008).  
 
The molecular mechanisms underlying the beneficial metabolic effects of NDCs are poorly 
understood. However, these effects may be attributable, at least in part, to the bacterial 
fermentation of NDCs in the colon yielding short chain fatty acids.  
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1.4 Short Chain Fatty Acids (SCFAs) 
1.4.1 Sources and production 
The mammalian gastrointestinal tract is host to over one hundred trillion (1014) bacteria and 
approximately 1,000 bacterial species have been identified to date (Turnbaugh et al. 2007). 
The majority of the gut microbiota (>90%) belong to the Bateroidetes (gram-negative) and 
Firmicutes (gram-positive) phyla. The species and quantities of gut bacteria vary along the 
gastrointestinal tract (Fig. 1.3). By far the largest and most diverse population of gut bacteria 
is found in the large intestine. Despite a considerable degree of inter-individual variation in 
gut microbiota, humans share an underlying common ‘core microbiome’ (Arumugam et al. 
2011, Qin et al. 2010, Turnbaugh & Gordon 2009). 
Short chain fatty acids (SCFAs), along with gases (H2, CO2, CH4), are the major end-
products of the colonic fermentation of NDCs by gut microbiota. In this context, fermentation 
refers to the anaerobic, energy-yielding process by which organic compounds are broken 
down into simpler compounds. The majority of this fermentation occurs in the proximal large 
intestine, mainly due to substrate availability (Macfarlane & Macfarlane 2003). The straight-
chain SCFAs acetate (C2), propionate (C3) and butyrate (4) account for over 85% of total 
SCFAs produced (Fig. 1.4). Concentrations of SCFAs in the lumen are in the range of 70-
130mmol/L (Cummings et al. 1987, Mortensen & Clausen 1996) and occur in the 
approximate molar ratio of 60% acetate, 25% propionate and 15% butyrate (McNeil et al. 
1978). However, the production of SCFAs is subject to great inter-individual variation, 
predominantly dependent on the type of fermentable NDC (chemical composition, physical 
form, quantity), the profile of the host’s microbiota and gut transit time (Macfarlane & 
Macfarlane 2003). In addition, there are numerous other host-related factors affecting 
bacterial fermentation and SCFA production at any given time, including luminal contents, 
mucus production, stress, disease and antibiotics (Cho et al. 2012, Macfarlane & Macfarlane 
2003). 
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Figure 1.3. Characteristics of the normal gastrointestinal tract. The various organs of the 
gastrointestinal tract differ according to digestive secretions and pH. Different species and 
quantities of bacteria are found at different points along the digestive tract according to these 
major variations in the environmental niche. Adapted from: (Aron-Wisnewsky et al. 2012) 
 
 
 
 
Figure 1.4. The chemical structure of the three major short chain fatty acids.  
Source: (Al-Lahham et al. 2010) 
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Gut bacteria possess a wide range of hydrolytic enzymes which are able to depolymerise the 
large macromolecular structures of NDCs, allowing them to ferment their component sugars 
(Flint et al. 2012a). Despite the diversity of carbon sources used as fermentation substrates 
by bacteria in the large intestine, they are catabolised in a relatively small number of 
biochemical pathways, as summarised in the simplified diagram shown in Figure 1.5 
(Macfarlane & Macfarlane 2003).  
There are two major bacterial metabolic routes by which monosaccharides are converted 
into phosphoenolpyruvate (PEP): the Embden-Meyerhof-Parnas pathway (glycolysis, hexose 
sugars) and the pentose-phosphate pathway (pentose sugars) (Cummings 1981, den 
Besten et al. 2013, Miller & Wolin 1996). PEP is converted into pyruvate and acetyl-CoA, key 
metabolites which are subsequently converted into a wide range of end-products, including 
SCFAs (Flint et al. 2012b, Macfarlane & Macfarlane 2003). 
Acetate is typically formed by the oxidative decarboxylation of pyruvate and hydrolysis of 
acetyl-CoA, or via the ‘Wood-Ljungdahl pathway’ using formate, whereas butyrate formation 
involves the condensation of two molecules of acetyl-CoA (Cummings 1981, Jorgensen et 
al. 1997). Propionate is produced by two main routes; through fixation of carbon dioxide to 
form succinate, which is subsequently decarboxylated (the ‘succinate decarboxylation 
pathway’) (Blackburn & Hungate 1963, Paynter & Elsden 1970), or via the reduction of 
lactate and acrylate (the ‘acrylate pathway’)(Ladd & Walker 1965, Wallnofer & Baldwin 
1967).  
 
49 
 
 
Figure 1.5. Simplified diagram of non-digestible carbohydrate breakdown and the main 
routes of its fermentation in the large intestine. CH4, methane; CO2, carbon dioxide; H2, 
hydrogen; H2S, hydrogen sulfide; NAD
+, nicotinamide adenine dinucleotide (NADH, reduced 
form of NAD+); PEP, phosphoenolpyruvate; SO4, sulfate (Macfarlane & Macfarlane 2003) 
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1.4.2 Absorption and transport  
The absorption of all three major SCFAs (C2-C4) in the colon is highly efficient (>95%) 
(McNeil et al. 1978) and occurs by both passive diffusion and via specific transporters 
(Miyauchi et al. 2004, Rajendran & Binder 2000, Ritzhaupt et al. 1998, Sellin 1999). There 
are three known major forms of SCFA transport across the mammalian large intestine: 
bicarbonate (HCO3
-)-coupled, proton-coupled and sodium-coupled transport (Fig. 1.6). The 
identity of the HCO3
- exchanger is currently unknown (Harig et al. 1996, Harig et al. 1991, 
Mascolo et al. 1991, Vidyasagar et al. 2005). At present, the contribution of these pathways 
to total SCFA absorption by the distal gut is poorly understood.   
 
H+-coupled transport 
To date, four proton-coupled SCFA transporters have been identified, monocarboxylic acid 
transporters 1-4 (MCT1-4), which belong to the solute carrier family 16 (SLC16) (Kekuda et 
al. 2013). Their expression has been demonstrated in the rodent and human intestinal 
epithelium (Dimmer et al. 2000, Gill et al. 2005, Ritzhaupt et al. 1998, Tamai et al. 1999). 
However, the identity of the major apical H+-dependent SCFA transporter is unclear. MCT1 
and MCT4 are the prime candidates but their cellular location in colonic cells (basolateral vs. 
apical) remains controversial (Gill et al. 2005, Iwanaga et al. 2006, Kekuda et al. 2013). As 
MCT function is coupled to a transmembrane proton gradient, these transporters are not 
very active since the magnitude of the gradient across the colonocyte apical membrane is 
negligible. Therefore, the driving force for the uphill entry of SCFAs via MCTs from the gut 
lumen is minimal. Moreover, the H+/substrate stoichiometry for MCTs is 1:1, rendering the 
transport process electroneutral (Kekuda et al. 2013). Interestingly, it has recently been 
proposed that transporter function in the large intestine may be modulated by luminal SCFA 
levels (Borthakur et al. 2012), a mechanism best described for the intestinal sugar 
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transporter GLUT2 which is recruited to the apical surface in response to high 
concentrations of sugars (Kellett et al. 2008).     
 
Na+-coupled transport 
An important route for SCFA transport from the gut lumen into colonocytes is via sodium-
coupled monocarboxylate transporter 1 (SMCT1, Slc5a8). SMCT1 transporters are 
selectively located on the luminal membrane of enterocytes in the terminal ileum and large 
intestine (Takebe et al. 2005). Proposed affinities for its primary substrates are in the order: 
butyrate>propionate>lactate>>acetate. The absorption of SCFAs is electrogenic and 
obligatorily coupled to co-transport of sodium ions with a Na+/substrate stoichiometry of 2:1 
(Coady et al. 2004). 
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Figure 1.6. Short chain fatty acid transport in colonocytes. Short chain fatty acids 
(SCFAs) are generated from dietary fibre by bacterial fermentation in the colonic lumen. 
SCFAs can be transported into colonocytes by passive diffusion or via one of three transport 
mechanisms: (1) a bicarbonate (HCO3
-) exchanger of unknown identity, (2) monocarboxylate 
transporters (MCT) or (3) sodium-coupled monocarboxylate transporter 1 (SMCT1). The 
identity of the transporters involved in SCFA transport across the basolateral surface 
remains unclear.  
Adapted from: (den Besten et al. 2013) 
 
  
53 
1.4.3 SCFA metabolism  
Once inside the cell, butyrate is almost exclusively utilised by colonocytes as their preferred 
energy source (Roediger 1980). Using isolated human colonic epithelial cells, Roediger 
demonstrated that butyrate is the preferred energy source for the colonic mucosa, even in 
the presence of other SCFAs or glucose (Roediger 1980). However, subsequent work using 
isolated human and rat colonocytes demonstrated that under physiological conditions, with a 
higher relative colonic concentration of acetate compared with butyrate, acetate is at least as 
important as butyrate for the energy supply of colonocytes (Clausen & Mortensen 1995, 
Jorgensen et al. 1997). In contrast, acetate and propionate drain into the portal vein and are 
largely taken up by the liver (Bloemen et al. 2009, Cummings et al. 1987, Dankert et al. 
1981). Acetate is utilised as an energy source or as a substrate for the synthesis of 
cholesterol, long-chain fatty acids, glutamine and glutamate (Desmoulin et al. 1985, Reilly & 
Rombeau 1993). Propionate is converted into propionyl-CoA followed by succinyl-Co, which 
enters the citric acid cycle and is converted into oxaloacetate, the precursor of 
gluconeogenesis (Bloemen et al. 2010, McNeil et al. 1978, Reilly & Rombeau 1993, Wolever 
et al. 1989) (Fig. 1.7). Circulating SCFAs can then also be metabolised by other tissues 
including adipose tissue and muscle (Knowles et al. 1974, Robertson et al. 2005). 
Consequently, peripheral plasma levels are relatively low under normal physiological 
conditions: 100-200µmol/L for acetate, 4-5µmol/L for propionate and 1-3µmol/L for butyrate 
(Pouteau et al. 2001, Wolever et al. 1997). However, four weeks of NDC supplementation 
(30g/d) has been shown to almost double fasting plasma propionate concentrations in 
humans (Robertson et al. 2005).    
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1.4.4 The role of SCFAs in colonic homeostasis  
SCFAs are the major anions present in the distal gut lumen and play a fundamental role in 
maintaining ‘normal’ colonic function (Cummings 1997, Topping & Clifton 2001). This is likely 
to be achieved through a host of concerted actions within the colonic milieu and may be 
linked to events such as changes in luminal pH, GPCR activation, carrier-mediated transport 
and intracellular metabolism.  
SCFAs stimulate fluid and electrolyte uptake by the colonic mucosa (Ruppin et al. 1980, 
Topping & Clifton 2001), as well as colonic blood flow in isolated human colonic segments in 
vitro and in surgical patients (Mortensen et al. 1991, Mortensen et al. 1990). The enhanced 
blood flow is predicted to improve tissue oxygenation and facilitate the transport of absorbed 
nutrients from the gut. Furthermore, SCFAs modify colonic motility, though whether their 
effects are stimulatory or inhibitory is unclear as they vary under different experimental 
conditions (Cherbut et al. 1998, Yajima 1985). Both effects would serve important functions; 
slowing the rate of food passage in the proximal intestine would maximise nutrient 
absorption, whereas increasing gut transit would improve laxation and reduce exposure to 
intraluminal carcinogens (Fung et al. 2013). The mechanisms underlying the effects of 
SCFAs on intestinal motility are poorly understood. There is evidence to suggest that SCFAs 
directly influence neurons of the enteric nervous system (Bertrand et al. 1997, Neunlist et al. 
1999, Soret et al. 2010). Alternatively, it is possible that SCFAs modify intestinal motility 
indirectly, via the stimulation of PYY (Cherbut et al. 1998) or 5-hydroxytryptamine (5-HT) 
release (Fukumoto et al. 2003). SCFAs are also thought to have beneficial roles in the 
regulation of intestinal inflammation and cancer cell proliferation (Donohoe et al. 2012, Fung 
et al. 2013, Hinnebusch et al. 2002, Maslowski et al. 2009, Smith et al. 2013, Vinolo et al. 
2011). Therefore, through multiple actions, SCFAs form an integral component of large 
intestinal physiology.  
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1.4.5 SCFA receptors: GPR41 (FFAR3) and GPR43 (FFAR2)  
SCFAs have been identified as ligands for two G-protein coupled receptors (GPCRs), 
GPR41 and GPR43, originally cloned in 1997 (Sawzdargo et al. 1997). These related 
receptors (52% similarity, 43% identity) were de-orphanised in 2003 by three independent 
groups (Brown et al. 2003, Le Poul et al. 2003, Nilsson et al. 2003). The activation and 
signalling of the SCFA receptors are discussed in Chapter IV, Section 4.1.1.    
 
1.4.5.1 Tissue distribution and physiological role 
GPR41 and GPR43 expression has been demonstrated in a variety of tissues and cell types 
including immune cells, adipose tissue, pancreatic islets and the gastrointestinal tract (Brown 
et al. 2003, Covington et al. 2006, Ge et al. 2008, Hong et al. 2005, Kimura et al. 2013). The 
first physiological role attributed to SCFA receptors concerned innate immunity and 
neutrophil chemotaxis (Le Poul et al. 2003, Nilsson et al. 2003). However, multiple functions 
for GPR43 and GPR41 have since emerged. The putative physiological roles of SCFA 
receptors in tissues implicated in energy homeostasis are discussed below. 
 
Adipose tissue 
Hong et al. were the first to investigate the role of GPR43 in adipose tissue. Their 
experiments using 3T3-L1 cells suggested that SCFAs stimulate expression of GPR43 and 
of peroxisome proliferator-activated receptor gamma (PPARγ), a regulator of adipocyte 
differentiation (Hong et al. 2005). This effect was reduced by GPR43 siRNA transfection. 
However, the physiological relevance of these results has been brought into question by a 
recent paper that was unable to replicate these findings using human primary adipocyte 
cultures (Dewulf et al. 2013). Subsequently, SCFAs were demonstrated to suppress 
isoproterenol-induced lipolysis in wild type but not Gpr43-deficient adipocytes (Ge et al. 
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2008). In addition, in vivo activation of the Gpr43 receptor by acetate in mice resulted in a 
reduction in plasma free fatty acid levels, an effect associated with improved insulin 
sensitivity (Boden 2011, Ge et al. 2008). Interestingly, a recent study demonstrated that 
overexpression of Gpr43 in adipose tissue protected mice from HFD-induced obesity 
(Kimura et al. 2013). These findings support a role for GPR43 in adipose tissue physiology 
and in the regulation of energy homeostasis.  
 
The putative physiological role for GPR41 in adipose tissue is controversial. Xiong et al. 
reported that activation of GPR41 in adipocytes stimulated secretion of the adipokine leptin 
from adipocytes in vitro (Xiong et al. 2004). Leptin plays an important role in energy 
homeostasis, as exemplified by the phenotype of mice lacking the ob gene (coding for leptin) 
which are severely hyperphagic and obese (Zhang et al. 1994). Subsequent experiments 
indicated that leptin secretion from murine primary adipose tissue cultures increased 
following treatment with SCFAs, and that oral administration of propionate in mice was 
associated with increased circulating leptin levels eight hours post administration (Xiong et 
al. 2004). However, several groups have since been unable to detect the presence of 
GPR41 in adipose tissue (Hong et al. 2005, Zaibi et al. 2010).  
 
Gastrointestinal tract 
GPR43 and GPR41 mRNA expression has recently been detected in the rat (Karaki et al. 
2006) and human colonic mucosa (Karaki et al. 2008) and specifically within 
enteroendocrine  L cells (Karaki et al. 2006, Tazoe et al. 2009, Tolhurst et al. 2012a). The 
general consensus was that GPR43 is widely expressed in L cells, whereas GPR41 is only 
expressed in a small percentage (4%) of these cells (Tazoe et al. 2009, Tolhurst et al. 
2012a). However, this concept was recently challenged by Nohr et al. who showed evidence 
to suggest that GPR41 expression in enteroendocrine cells is more extensive (Nohr et al. 
2013). L cells are distributed throughout the gastrointestinal tract, with high concentrations 
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found in the colon (Eissele et al. 1992), where SCFAs are most abundant. Consequently, 
they are ideally located to sense changes in the luminal concentrations of nutrients, such as 
SCFAs, in the distal intestine. Indeed, several studies demonstrate that SCFAs can trigger 
the release of PYY and GLP-1, suggesting a potential role in appetite regulation and the 
potentiation of insulin secretion (Anini et al. 1999, Cherbut et al. 1998, Tolhurst et al. 2012a). 
In practice however, the exact localisation of SCFA receptors within L cells (apical vs. 
basolateral) is unknown and complicates speculation regarding their physiological function. 
Interestingly, Sykaras et al. recently reported that duodenal enteroendocrine I cells, 
traditionally associated with CCK release, are also highly enriched in mRNA encoding both 
GPR41 and GPR43 (Sykaras et al. 2012). However, once again, the localisation of the 
receptors is uncertain. Furthermore, the levels of SCFAs in the duodenal lumen are low, as 
fermentation is thought to occur predominantly in the large intestine. In light of this, it is 
possible that GPR41 and GPR43 in duodenal I cells may sense circulating plasma SCFAs to 
modulate I cell function, rather than SCFAs in the duodenal lumen.  
Recent data suggest that GPR41 is also expressed in enteric neurons, in both submucosal 
and myenteric ganglia (Nohr et al. 2013). Counter staining with antibodies against the 
neuropeptide vasoactive intestinal peptide (VIP) revealed co-localisation of VIP and GPR41, 
indicating that SCFAs may be sensed on secretomotor neurons involved in the regulation of 
water and electrolyte secretion from enterocytes (Nohr et al. 2013).  
 
Sympathetic nerve ganglia 
GPR41 is abundantly expressed in sympathetic nerve ganglia, in mice and humans, and 
propionate in particular is able to directly activate the sympathetic nervous system to 
enhance noradrenaline release, suggesting a potential role for SCFAs in energy expenditure 
(Kimura et al. 2011). However, these findings have yet to be confirmed by independent 
groups. 
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Energy homeostasis in global GPR43 knockout mice 
The wider role of GPR43 in energy homeostasis is poorly understood. While there is a 
general consensus that Gpr43-/- mice on a normal chow diet are healthy and do not display 
an altered energy homeostasis phenotype (Bjursell et al. 2011, Kimura et al. 2013), there are 
conflicting reports from two studies regarding how Gpr43-/- mice fare on a high fat diet (HFD) 
background compared to their wild type (WT) littermates (Bjursell et al. 2011, Kimura et al. 
2013) (Table 1.3). In the first study, HFD-fed Gpr43-/- mice displayed no difference in 
phenotype compared to HFD-fed WT mice in the first 15-20 weeks. From then onwards, the 
Gpr43-/- mice were hyperphagic but exhibited reduced body fat mass and improved glucose 
tolerance (Bjursell et al. 2011), as the increase in food intake was counteracted by an 
increase in energy expenditure. The second study also reported hyperphagia in the GPR43-/- 
mice. However in this study, the Gpr43-/- mice exhibited significantly increased adiposity and 
reduced energy expenditure compared to their HFD-fed WT littermates (Kimura et al. 2013). 
These contradictory findings may reflect the different housing environments and genetic 
backgrounds of the knockout mice (Kimura et al. 2013). Further work is therefore required to 
clarify the role of GPR43 in energy homeostasis in an obesogenic context. 
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Table 1.3. Energy homeostasis in Gpr43 receptor knockout mice on a high fat diet 
(HFD) background.  
 
A. Study Design and Characteristics 
Reference Generation of 
KO (targeting 
vector) 
Genetic 
background 
Diet  
(% energy) 
Duration of 
diet 
Age at start  
Bjursell et 
al. 2011 
Homologous 
recombination 
(LacZ-PGK-neo) 
C57BL/6JOlaHsd 
 
HFD: R638 
39.9% fat  
35 weeks 4 weeks 
Kimura et 
al. 2013 
Homologous 
recombination 
(LacZ-PGK-neo) 
129/Sv HFD: 58Y1 
61.6% fat  
12 weeks 4 weeks 
 
 
B. Phenotypes and Study Results 
Reference Food intake Body weight/ 
adiposity 
Glucose 
Tolerance 
Energy 
Expenditure 
SCFAs 
Bjursell et 
al. 2011 
No difference at 
15 wk of age 
Increased in 
Gpr43-/- (at 38 
wk of age) 
Reduced in  
Gpr43-/- beyond 
25 wk of age 
Improved  
in Gpr43-/- 
Increased in 
Gpr43-/- (at 25 wk 
of age) 
Not 
measured 
Kimura et 
al. 2013 
Increased in 
Gpr43-/- 
Increased in 
Gpr43-/- 
Impaired in  
Gpr43-/- 
Reduced in dark 
phase in Gpr43-/- 
Increased 
faecal 
propionate in 
Gpr43-/-  
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1.5 Summary 
There are fundamental gaps in our current understanding of the physiological roles of 
SCFAs and their receptors in energy homeostasis, and of their specific effects in different 
endocrine tissues. This thesis determines the effect of colonic SCFAs on PYY and GLP-1 
release, and investigates the underlying mechanisms, focusing on the role of the GPR43 
receptor using Gpr43 knockout mice. This field offers the exciting possibility of identifying a 
more physiological method of treating obesity by stimulating the endogenous secretion of 
anorexigenic gut hormones.  
 
1.6 Hypotheses 
I hypothesised that: 
 SCFAs stimulate the release of the anorectic gut hormones PYY and GLP-1 from 
enteroendocrine L cells.  
 SCFA/propionate-induced gut hormone release is mediated via a GPR43-dependent 
mechanism. 
 
1.7 Aims 
The aims of this research project were: 
1. To develop and validate murine and human primary L cell models.   
2. To establish the effect of colonic SCFAs, and in particular propionate, on PYY and 
GLP-1 release   
a. In vitro, from human and murine primary colonic L cells and 
b. In vivo, in mice and rats. 
3. To determine the signalling mechanisms underlying propionate-mediated gut 
hormone release 
a. In vitro, from murine primary colonic L cells and 
b. In vivo, in wild type and Gpr43 knockout mice.  
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Chapter II: 
Development of a primary 
L cell model 
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2.1  Introduction 
2.1.1 L cell distribution and morphology 
 
Enteroendocrine cells (EECs) are scattered throughout the intestinal mucosa and comprise 
as little as 1% of cells lining the gut epithelium (Cheng & Leblond 1974). Therefore, EECs 
differentiate in tissues where the overwhelming majority of surrounding cells are non-
endocrine, including absorptive enterocytes, goblet cells and Paneth cells (Schonhoff et al. 
2004). EECs differentiate from common pluripotent stem cells within intestinal crypts (Cheng 
& Leblond 1974) (Fig. 2.1 and 2.2). Tritiated thymidine (3H-thymidine) labelling after 
continuous infusion of the isotope, revealed that cells deep within the crypt were the first to 
label, followed by an increased number of differentiated cells moving out of the crypt. These 
data suggest that enterocytes, goblet cells and EECs differentiate as they migrate up the 
crypt-villus axis with a turnover of 3-4 days (Cheng & Leblond 1974). As mature EECs 
migrate to the tips of the villi, they are thought to undergo apoptosis before they are shed 
into the gut lumen (Simon & Gordon 1995).  
PYY- and GLP-1-secreting L cells increase in number distally along the intestinal axis, with 
the highest density found in the colon and rectum (Eissele et al. 1992, Larsson et al. 1975). 
However, relatively little is known about how the different EEC lineages segregate as they 
differentiate. Whereas L cells are found in higher numbers in the distal intestine, some EEC 
types are primarily found in the stomach and proximal intestine (gastrin, ghrelin, GIP, 
secretin, CCK), and others are located throughout the gastrointestinal tract (somatostatin, 
serotonin, substance P). The cues that influence the rostro-caudal distribution of each EEC  
type are poorly understood (Schonhoff et al. 2004). Microarray-determined expression of 
transcription factors in different enteroendocrine cell types and different regional populations 
may provide novel candidate genes for future investigation (Habib et al. 2012).  
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Figure 2.1 Schematic representation of the large intestine showing the structure and 
location of crypts in the colonic mucosa. Adapted from: (Encyclopaedia-Britannica 2003) 
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Figure 2.2 Schematic overview of enteroendocrine cell differentiation in the intestinal 
tract. Stem cells located in the crypts differentiate into all four cell types present in the 
intestinal epithelium. Math1 (also known as Atoh1) expression restricts cells to the secretory 
lineage and NGN3 restrict cells to the endocrine lineage, whereas the transcription of 
specific hormones is regulated by several late acting transcription factors such as Pax4, 
Pax6, and BETA2 (also known as NeuroD1). Adapted from: (Schonhoff et al. 2004)  
Atoh1, atonal homolog 1; CCK, cholecystokinin; GLP-1, glucagon-like peptide 1, NeuroD1, 
neuronal differentiation 1; NGN3, neurogenin 3; Pax4/6, paired box gene 4/6  
 
 
 
 
EECs are typically thought of as cone-shaped. In the case of ‘open type’ EECs such as L 
cells, a narrow apical surface faces the intestinal lumen and gut hormones are exocytosed 
from dense-core secretory granules at the broader basolateral base (Eissele et al. 1992). In 
addition, EECs often possess basal, ‘dendrite-like’ cytoplasmic processes which serve 
paracrine and sensory functions (Larsson et al. 1975). L cells are therefore ideally situated to 
function as intestinal nutrient sensors tailoring the secretion of gut hormones to the 
nutritional composition of the intestinal lumen. 
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2.1.2 Neural and hormonal stimulation 
 
The activity of L cells is influenced by numerous signals; derived from the gut lumen, from 
other EECs, as well as from the enteric nervous system (Reimann et al. 2012). The enteric 
nervous system is a network of nerve fibres and ganglia innervating the intestine which 
interacts with branches of both the parasympathetic and sympathetic nervous systems 
(Furness 1996, 2000). Signalling within the enteric nervous system relies predominantly on 
GPCR activation and employs the use of acetylcholine and noradrenaline, as well as peptide 
neurotransmitters including calcitonin gene-related peptide (CGRP), vasoactive intestinal 
peptide (VIP), pituitary adenylate cyclase-activating protein (PACAP), gastrin-releasing 
peptide (GRP) and galanin (Furness 1996, 2000, Reimann et al. 2012) (Fig. 2.3). Autonomic 
modulation of gut hormone release, via muscarinic M1 receptors, has been demonstrated to 
influence the secretion of GLP-1 from rats in vivo (Anini et al. 2002).  
 
Enteric neuro-hormonal circuits are thought to play a role in relaying information between 
different regions of the gut. For example, proximal-distal crosstalk has been proposed to 
underlie the rapid increase in plasma GLP-1 observed following nutrient delivery to the 
proximal small intestine (Rocca & Brubaker 1999). Proximal signals could be conveyed 
distally via the peptide neurotransmitter PACAP, which is localised throughout the stomach 
and intestine (Vaudry et al. 2000), and has been reported to enhance the secretion of a 
number of gut hormones including GLP-1 and PYY (Chang et al. 1996, Herrmann-Rinke et 
al. 1995, Simpson et al. 2007). However, L cells have since also been identified in the small 
intestine, albeit at lower levels than the distal intestine (Habib et al. 2012).  
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Figure 2.3. L cell stimulation by the enteroendocrine and enteric nervous systems. A 
number of G-protein coupled receptors (GPCRs) have been identified on enteroendocrine L 
cells. They are activated by hormones and neurotransmitters released from other 
enteroendocrine cells and the enteric nervous system, and they recruit the same intracellular 
signalling pathways as the nutrient-sensing GPCRs. This modulates the release of L cell 
peptides glucagon-like peptide 1 and 2 (GLP-1, GLP-2) oxyntomodulin (Oxyn) and peptide 
YY (PYY), which in turn activate GPCRs shown to be expressed on afferent nerves. Adapted 
from: (Reimann et al. 2012)  
 
Ach, acetylcholine; Adr, adrenaline; βAR; β-adrenergic receptor; BB2R, GRP receptor; CCK, 
cholecystokinin; CGRP, calcitonin gene-related peptide; Gal1R, galanin 1 receptor; GIP, 
glucose-dependent insulinotropic polypeptide; GRP, gastrin-releasing peptide; M2R, 
muscarinic acetylcholine receptor M2; NMB, neuromedin B; PACAP, pituitary adenylate 
cyclase-activating protein; Sst, somatostatin; SST5R, somatostatin 5 receptor; VIP, 
vasoactive intestinal peptide; VPACR, VIP and PACAP receptor 
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2.1.2 Nutrient-sensing in the gut 
Nutrient sensors can either sense changes in the composition of the gut lumen, or increased 
concentrations of nutrients absorbed across the intestinal epithelium. Activation of nutrient 
sensors can trigger processes including membrane depolarisation, increased intracellular 
calcium (Ca2+) concentrations and second messenger cascades that ultimately result in the 
secretion of gut hormones or changes in gene expression (Tolhurst et al. 2012b). The three 
main pathways by which nutrients are ‘sensed’ involve GPCRs, surface membrane solute 
transporters, and intracellular metabolism. To date, a large number of GPCRs have been 
identified as nutrient sensors in the gut (Wellendorph et al. 2010) (Fig. 2.4).  
Colonic L cells are known to express the bile acid receptor TGR5, the oleoylethanolamide 
receptor GPR119, the medium/long chain fatty acid receptors GPR40/120, the SCFA 
receptors GPR41/43 and components of the sweet taste receptor pathway (Table 2.1). 
However, L cells are also electrically active and alterations in membrane potential leading to 
Ca2+ infux have been associated with nutrient-stimulated gut hormone secretion (Rogers et 
al. 2011, Tolhurst et al. 2011). 
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Figure 2.4. GPCR-mediated nutrient sensing in enteroendocrine cells. A number of 
GPCRs have been identified as putative nutrient “sensors”. These receptors stimulate the 
release of gut hormones via coupling to Gαs, which elevates intracellular cAMP, and Gαq, 
which results in Ca2+ mobilisation and protein kinase C (PKC) activation. Inhibitory influences 
are exerted by signalling through Gαi pathways that decrease cAMP levels. Adapted from: 
(Reimann et al. 2012) 
 
AC, adenylyl cyclase; CaSR, calcium-sensing receptor; DAG, diacylglycerol; Epac2, 
exchange protein activated by cAMP; FFAR, free fatty acid receptor; IP3, inositol 1,4,5-
trisphosphate; PKA, protein kinase A; PLC, phospholipase C; TRPM5, transient receptor 
potential cation channel subfamily M member 5 
 
 
 
 
 
 
 
 
69 
 
Table 2.1 Chemosensory receptors expressed in enteroendocrine L cells.   
 
Ligands Receptor Species Reference 
Sweet tastants T1R2/T1R3,  
α-gustducin 
Mouse (Reimann et al. 2008) 
(Li et al. 2013) 
SCFAs GPR43  
GPR41 
Mouse 
Mouse 
(Tolhurst et al. 2012a) 
(Samuel et al. 2008) 
(Tolhurst et al. 2012a) 
MCFAs/LCFAs GPR40 
 
GPR120 
Mouse 
 
Mouse 
Human 
(Edfalk et al. 2008) 
(Reimann et al. 2008) 
(Reimann et al. 2008) 
(Hirasawa et al. 2005) 
OEA 
2-OG 
GPR119 
 
Mouse 
Rat 
(Cox et al. 2010) 
(Lauffer et al. 2009) 
Bile acids TGR5 Mouse (Reimann et al. 2008) 
 
MCFAs, medium-chain fatty acids; LCFAs, long-chain fatty acids; OEA, oleoylethanolamide; 
2-OG, 2-oleoylglycerol; SCFAs, short-chain fatty acids 
 
 
2.1.2.1 Immortalised cell lines for the study of nutrient sensing 
The study of EEC physiology has been impeded in the past by the scarcity of these cells in 
the intestinal epithelium and the difficulties associated with accurately identifying them. 
Consequently, a large proportion of our knowledge of how EECs function and signal 
originates from immortalised cell lines such as GLUTag (Drucker et al. 1994), STC-1 (Abello 
et al. 1994) and NCI-H716 cells (Reimer et al. 2001). GLUTag and NCI-H716 cells are used 
as murine and human GLP-1-secreting L cell models, respectively. However, neither of 
these cell lines secretes PYY, which is thought to be co-secreted from L cells in vivo along 
with GLP-1 (Habib et al. 2013). On the other hand, the STC-1 cell line has been reported to 
secrete a variety of hormones including CCK, GIP, GLP-1, PYY and secretin, a hormonal 
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profile also unrepresentative of native colonic L cells (Geraedts et al. 2009, Hand et al. 
2013).  
Furthermore, enteroendocrine cell lines often exhibit different nutrient sensitivities, and do 
not necessarily act as accurate models of the native L cell (Reimann et al. 2008). As isolated 
FACS-sorted primary L cells do not survive in culture, mixed-cell population primary culture 
appears to be essential (Reimann et al. 2008). This primary cell culture method enables the 
study of gut hormone release from this elusive cell type, while to a certain extent maintaining 
its physiological micro-environment and proximity to neighbouring cells.  
  
2.1.2.2 Glucose and L-glutamine sensing in primary L cells 
Using a novel primary L cell model, isolated from transgenic mice in which proglucagon-
expressing cells were labelled by the YFP Venus (Nagai et al. 2002), Reimann et al. 
demonstrated that detection of luminal glucose involves membrane depolarisation and action 
potential firing. This was triggered by the electrogenic activity of sodium glucose co-
transporter 1 (SGLT1), which led to a voltage-dependent influx of Ca2+ ions (Reimann et al. 
2008). The same techniques were successfully employed to study the mechanisms 
underlying amino acid-stimulated GLP-1 secretion. Tolhurst et al. demonstrated that L-
glutamine also triggers primary L cell membrane depolarisation and voltage-dependent influx 
of Ca2+ ions, via L- and Q-type calcium channels, following their electrogenic uptake 
(Tolhurst et al. 2011).  
This method of primary colonic cell isolation was selected for experiments investigating the 
effects of SCFAs on gut hormone release and the mechanisms underpinning these effects. 
Therefore, the first aim of this thesis was to establish this method in our laboratory, to 
optimise procedures associated with it, and to replicate experiments in the literature to 
validate the primary L cell model. 
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2.2 Aims and Hypotheses 
2.2.1 Aim 
To establish a primary L cell model that can be employed to determine the effects of 
nutrients on the release of the anorectic gut hormones GLP-1 and PYY. 
 
Objectives:  
1. To successfully isolate murine colonic crypts. 
2. To optimise radioimmunoassay methods for measurement of GLP-1 and PYY in 
supernatants and cell lysates. 
3. To validate this model by replicating published work with nutrients, glucose and 
glutamine, and agents that increase intracellular cAMP levels.  
4. To apply and tailor the murine primary L cell model methodology to the development 
of a novel human primary L cell model. 
 
2.2.2 Hypotheses 
I hypothesised that the method pioneered by Reimann et al. would enable the isolation of 
intact and viable colonic crypts from mouse and human colonic tissue. Furthermore, I 
hypothesised that the nutrients, glucose and glutamine, and the combination of 3-isobutyl-1-
methylxanthine (IBMX) and forskolin leading to an increase in intracellular [cAMP], would 
stimulate the release of GLP-1 and PYY from murine and human primary L cells.  
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2.3 Methods 
2.3.1 Primary cell culture 
2.3.1.1 Murine colonic crypt isolation  
The method of primary murine colonic crypt isolation was based on the method published by 
Professor Fiona Gribble of the University of Cambridge (Reimann et al. 2008).  
Adult male C57BL6 mice (8 weeks of age or older) were culled and the colon, distal to the 
caecum, was removed, cleaned and placed into ice-cold L-15 (Leibowitz) medium (PAA, 
UK). The intestinal tissue was thoroughly cleaned with L-15 medium and digested with 
0.4mg/ml collagenase XI (Sigma, UK) in high glucose Dulbecco’s Modified Eagle Medium 
(DMEM, Sigma, UK) at 37oC. Resulting cell suspensions were centrifuged (5 min, 500 × g) 
and the pellets were re-suspended in DMEM (supplemented with 10% foetal calf serum and 
1% antibiotics, 100 U/ml penicillin and 0.1mg/ml streptomycin). The digestion process was 
repeated four times and the combined cell suspensions were filtered through a nylon mesh 
(pore size 250 µM) and plated onto 24-well, 1% Matrigel (BD Matrigel, VWR, UK)–coated 
plates. The plates were incubated overnight at 37oC in an atmosphere of 95% O2 and 5% 
CO2. 
 
2.3.1.2 Human colonic crypt isolation 
Ethical approval for the use of human colonic tissue biopsies was obtained from the 
Hammersmith & Queen Charlotte’s Research Ethics Committee (2000/5795). Healthy 
colonic tissue was obtained from subjects undergoing diagnostic colonoscopy at 
Hammersmith Hospital. Common reasons for undergoing the procedure included suspicion 
of benign polyps or haemorrhoids, and follow up after a previous history of colitis. Eight to 
ten biopsies, measuring approximately 2mm2, were obtained from each patient by Professor 
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Julian Walters or Dr Ian Johnston of Imperial College London. The colonic crypts were 
isolated as described above. However, as the human colonic crypts were larger in diameter, 
the last filtration step was omitted.    
 
2.3.1.3 Secretion experiments 
Gut hormone secretion experiments were carried out within 24 hours after plating, unless 
otherwise stated. The cells were washed three times with standard bathing solution referred 
to as secretion buffer (4.5mM KCl, 138mM NaCl, 4.2mM NaHCO3, 1.2mM NaH2PO4, 2.6mM 
CaCl2, 1.2mM MgCl2, and 10mM HEPES, which was adjusted to pH 7.4 with NaOH; refer to 
Appendix I) supplemented with 0.1% fatty acid free bovine serum albumin (BSA, Sigma UK). 
The cells were then incubated in secretion buffer containing the test reagents (300µl/well) for 
2 hours at 37oC in an atmosphere of 95% O2 and 5% CO2. Test reagents were all obtained 
from Sigma (UK) unless otherwise stated. The adenylyl cyclase activator forskolin and the 
phosphodiesterase inhibitor IBMX were prepared as 10mM stock solutions in dimethyl 
sulfoxide (DMSO) and used as positive controls at a final concentration of 10μM (Reimann 
et al. 2008). Test solutions were prepared on the day of the secretion experiment.  
Following incubation, the cell supernatants were collected and centrifuged at 4oC to remove 
any dead cells (3 min, 100 × g). The resulting supernatants were then stored at -20oC 
pending analysis. The cells remaining in the plates were treated with 250µl/well cell lysis 
buffer (refer to Appendix I) and were frozen at -80oC overnight. The plates were then 
scraped and washed using 250µl secretion buffer and lysates were stored at -20oC pending 
analysis.  
Gut hormone secretion is expressed as a fraction of the total hormone (secreted + extracted) 
measured from a well. 
                  
 hormone measured in supernatant 
(hormone measured in supernatant   hormone measured in lysed cells)
  100 
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2.3.2 Radioimmunoassay 
GLP-1 and PYY release was measured by radioimmunoassay. The principle of the 
radioimmunoassay (RIA) is based on competition between unlabelled peptide (in the 
sample) and a known amount of radiolabelled peptide for binding to a fixed concentration of 
antibody. The concentrations of radiolabelled peptide and antibody remain constant. 
Therefore, increasing the concentration of unlabelled peptide will decrease the binding sites 
available for binding of the radiolabelled peptide. Thus, the amount of radiolabelled peptide 
bound to the antibody is inversely proportional to the amount of unlabelled peptide in the 
sample being assayed. Unknown peptide concentration values were interpolated from a 
standard curve prepared using known concentrations of unlabelled peptide (standard).  
Antibody-bound peptide was separated from unbound peptide by charcoal adsorption (GLP-
1) or using a primary/secondary antibody complex (PYY). All cell supernatant samples were 
assayed in singlet, whereas cell lysates were assayed in duplicate. 
 
2.3.2.1 Radioimmunoassay controls 
To assess non-specific binding (NSB), tubes which do not contain antibody were included at 
the beginning of the assay. Tubes containing either half or twice the volume of radio-labelled 
peptide were included to assess the quality of the label. Tubes with no sample (zero tubes) 
were placed throughout the assay to monitor baseline drift. Quality control (QCs) samples 
containing plasma spiked with low, medium or high known concentrations of peptide were 
also added to the beginning and end of each assay. Freeze-dried QCs were reconstituted in 
GDW on the day.  
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2.3.2.2 GLP-1 
GLP-1-like immunoreactivity was measured using an established, specific and sensitive 
radioimmunoassay (Kreymann et al. 1987). The antibody was produced in rabbits against 
GLP-1 coupled to BSA. The antibody shows 100% cross-reactivity with all amidated forms of 
GLP-1 but does not cross react with glycine extended forms (GLP-11-37 and GLP-17-37) or any 
other known gastrointestinal peptides. 125I-GLP-1 was prepared by Professor Mohammad 
Ghatei using the iodogen method (Wood et al. 1981) and purified by high pressure liquid 
chromatography (HPLC). The assay was performed in a total volume of 350µl of 0.06M 
sodium barbitone buffer (pH 8) (refer to Appendix I) containing 0.3% BSA. The standard 
curve was constructed by adding 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100µl of GLP-1 at a 
concentration of 0.125pmol/ml. Supernatants were added at a volume of 100µl and lysates 
were added at a volume of 5µl, as determined by optimisation assays (refer to Results 
Section 2.4.2). The assay was incubated over four nights at 4oC before separation of the 
free from antibody-bound labelled peptide by charcoal adsorption. Free and bound 
radioactivity was measured using γ scintillation counters (model NE1600, Thermo Electron 
Corporation, Ohio, USA) (intra-assay variation 5.4%; inter-assay variation 11.7%).  
 
2.3.2.3 PYY 
PYY-like immunoreactivity was measured using a specific and sensitive radioimmunoassay 
(Adrian et al. 1985). The antiserum (Y21) was produced in rabbits against synthetic porcine 
PYY coupled to BSA by glutaraldehyde. The Y21 antibody cross-reacts fully with the 
biologically active forms of PYY: full length PYY1-36 and the truncated fragment PYY3-36. It 
does not cross-react with other gastrointestinal peptides. 125I-PYY was prepared by 
Professor Mohammad Ghatei using the iodogen method (Wood et al. 1981) and purified by 
HPLC. The assay was performed in a total volume of 350µl of 0.06M phosphate buffer (pH 
7.3) (refer to Appendix I) containing 0.3% BSA. The standard curve was constructed by 
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adding 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100µl of synthetic PYY at a concentration of 
0.5pmol/ml. Supernatants were added at a volume of 150µl and lysates were added at a 
volume of 20µl, as determined by optimisation assays (refer to Results Section 2.4.2). The 
assay was incubated over three nights at 4oC before separation of the free from antibody-
bound label by immunoprecipitation using sheep anti-rabbit antibody. Free and bound 
radioactivity was measured using γ scintillation counters as above (intra-assay variation 
4.2%; inter-assay variation 10.4%). 
 
2.3.3 Statistical Analysis 
Normality was determined using the D'Agostino-Pearson omnibus test where n≥8 per group. 
Statistical significance was calculated using either an unpaired t-test (2 groups) or one-way 
ANOVA (≥3 groups). ANOVA pairwise comparisons were carried out using the Dunnett post 
hoc test, unless otherwise stated. Statistical significance was accepted at P<0.05 
throughout. Data are presented as mean ± standard error of the mean (SEM). Analysis was 
carried out using Graph Pad Prism software, version 5.0. 
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2.4 Results 
2.4.1 Primary colonic crypt isolation: murine and human 
Initial experiments demonstrated that the digestion protocol was effective in isolating 
individual colonic crypts from mouse colonic tissue. The digestion method resulted in the 
isolation of largely intact crypts from both murine (Fig. 2.5) and human colonic tissue (Fig. 
2.6). The human crypts were broader and approximately 2.5× the length of the mouse crypts 
(~250µm vs. 100µm, respectively). The crypts had a clearly defined morphology following 
digestion. However, the crypt structure was lost overnight, as the crypt cells began migrating 
out of the crypt creating a partial monolayer of cells (Fig. 2.7).  
 
Figure 2.5 Isolated murine primary L cell-containing murine colonic crypts. 
Photomicrograph of mouse colonic crypts obtained following tissue digestion (×40 
magnification). The scale bar represents 50µm. 
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Figure 2.6 Isolated human primary L cell-containing human colonic crypts. 
Photomicrograph of human colonic crypts obtained following tissue digestion (×20 
magnification). The scale bar represents 100µm. 
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Figure 2.7 Partial monolayer of primary colonic cells. Photomicrograph of mouse colonic 
cells that have migrated out of their crypt structures overnight following tissue digestion (×20 
magnification). The scale bar represents 100µm. 
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2.4.2 Optimisation of radioimmunoassay methods  
During the initial process of assaying the lysed cell samples it became apparent that the cell 
lysis buffer was interfering with the radioimmunoassays, thus distorting the percentage 
binding levels. To identify the volume of lysis buffer which does not interfere with the PYY 
and GLP-1 assays, test assays were constructed with either three or four standard curves 
containing different volumes of lysis buffer. The results showed significant distortion of the 
standard curve when containing 20µl or 5µl lysis buffer in the PYY and GLP-1 assay, 
respectively (Fig. 2.8). However, 10µl and 2.5µl lysis buffer caused minimal interference in 
the PYY and GLP-1 assay, respectively.  
Lysates are diluted 1:1 with secretion buffer during the plate scraping process. 
Consequently, the lysates were added at volumes of 20µl and 5µl, containing 10µl and 2.5µl 
lysis buffer, respectively.  Nevertheless, a standard curve containing the same volume of 1:1 
lysis buffer/secretion buffer was added prior to lysate sample tubes into future assays and 
was used for data reduction purposes to correct for potential assay interference.  
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Figure 2.8 The effect of cell lysis buffer on PYY (A) and GLP-1 (B) radioimmunoassay 
performance. Average percentage binding represents the percentage of antibody-bound 
125I-labelled PYY or GLP-1 when competing with unlabelled PYY or GLP-1 (standard) for 
primary antibody binding sites.  
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2.4.3 Validation of primary L cell culture method 
2.4.3.1 The effect of D-glucose on gut hormone release from murine primary L 
cells 
To validate the primary L cell culture method, key experiments conducted by Reimann et al. 
were replicated to confirm that the L cells respond to certain nutrients in a manner consistent 
with the original publications (Reimann et al. 2008). The first experiment tested the effect of 
a 2-hour incubation of primary colonic cells with varying concentrations of D-glucose on PYY 
and GLP-1 release.  
As shown in Figure 2.9, the primary L cells secreted both PYY and GLP-1 in response to a 
low (1mmol/L) and high (100mmol/L) concentration of glucose. Basal PYY secretion over the 
2-hour incubation period was 5.1 ± 0.8%. PYY secretion rose to 8.2 ± 2.0% following 
treatment with 1mmol/L glucose and was significantly increased to 8.9 ± 3.1% with the 
100mmol/L dose of glucose (Fig. 2.9A).  Basal GLP-1 secretion over the 2-hour incubation 
period was 1.2 ± 1.0%. Incubation with both doses of glucose led to a significant 3-fold 
increase in GLP-1 secretion (Fig. 2.9B).  
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Figure 2.9 The effect of D-glucose on gut hormone secretion from murine primary L 
cells. Mixed primary colonic cultures were incubated in secretion buffer containing 
increasing glucose concentrations. PYY (A) and GLP-1 (B) secretion in each well is 
expressed as a percentage of total PYY or GLP-1 contained within the well and compared to 
the basal secretion measured in parallel within the same experiment. Data represent means 
± SEM (n=6 wells). Significance is shown relative to basal secretion using One-way ANOVA 
with a Dunnett post hoc test (*P<0.05; **P<0.01).  
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2.4.3.2 The effect of L-glutamine on gut hormone release from murine primary 
L cells 
The second set of experiments tested the effect of incubating murine primary colonic cells 
with two different concentrations of the amino acid L-glutamine on PYY and GLP-1 release. 
Figure 2.10 shows that the L-glutamine stimulated gut hormone secretion from murine 
primary L cells, with some evidence of a dose-response relationship.  
Basal PYY and GLP-1 secretion over the 2-hour incubation period was 5.6 ± 2.8% and 3.2 ± 
1.4%, respectively. At a concentration of 1mmol/L, L-glutamine increased PYY and GLP-1 
secretion to 8.6 ± 3.0% and 4.2 ± 1.6%, respectively (Fig. 2.10). Furthermore, incubation of 
the colonic cells with 10mmol/L L-glutamine significantly increased both PYY and GLP-1 
release to 11.6 ± 2.3% and 6.5 ± 1.9%, respectively.    
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Figure 2.10 The effect of L-glutamine on gut hormone secretion from murine primary L 
cells. Mixed primary colonic cultures were incubated in secretion buffer containing 
increasing L-glutamine concentrations. PYY (A) and GLP-1 (B) secretion in each well is 
expressed as a percentage of total PYY or GLP-1 contained within the well and compared to 
the basal secretion measured in parallel within the same experiment. Data represent means 
± SEM (n=6 wells). Significance is shown relative to basal secretion using One-way ANOVA 
with a Dunnett post hoc test (*P<0.05; **P<0.01).  
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2.4.3.3 The effect of increasing intracellular [cAMP] on gut hormone release 
from murine primary L cells 
Experiments were carried out to test the effect of increasing intracellular cAMP levels on gut 
hormone release from isolated murine L cells. This was achieved using a combination of 
forskolin, which activates adenylyl cyclase, and IBMX, a competitive non-selective 
phosphodiesterase inhibitor. IBMX and forskolin were both added at a concentration of 
10µmol/L (Ong et al. 2009).  
Increasing intracellular cAMP concentrations, using a combination of IBMX and forskolin, 
potently stimulated gut hormone release from primary murine L cells. Basal secretion of PYY 
was 3.6 ± 0.4%, which increased significantly in response to IBMX/forskolin treatment, to 
23.2 ± 3.0% (Fig. 2.11A). Basal GLP-1 secretion was lower, 1.7 ± 0.2%, and rose to 10.3 ± 
1.6% following incubation with IBMX/forskolin (Fig. 2.11A).    
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Figure 2.11 The effect of increasing intracellular cAMP levels on gut hormone 
secretion from murine primary L cells. Mixed primary colonic cultures were incubated in 
secretion buffer containing 10µmol/L IBMX and forskolin. PYY and GLP-1 secretion in each 
well is expressed as a percentage of total PYY or GLP-1 contained within the well and 
compared to basal secretion (control) measured in parallel within the same experiment. PYY 
and GLP-1 data are from separate experiments. Data represent means ± SEM (2 separate 
experiments, n=2 mice, 11-14 wells). Significance is shown relative to basal secretion using 
an unpaired t-test (***P<0.001).  
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2.4.3.4 The effect of D-glucose and an increase in intracellular [cAMP] on GLP-
1 release from human primary L cells 
Following the successful isolation of viable human primary L cells, the effect of glucose and 
of IBMX/forkolin, on GLP-1 release was determined. As shown in Figure 2.12, the human L 
cells dose-dependently secreted GLP-1 in response to D-glucose. Basal GLP-1 secretion 
over the 2-hour incubation period was 0.5 ± 0.2%. GLP-1 secretion rose to 1.0 ± 0.3% (2.1-
fold increase) and 1.3 ± 0.2% (2.7-fold increase) following treatment with 1mmol/L and 
10mmol/L glucose, respectively. The highest dose of glucose (100mmol/L) significantly 
increased GLP-1 secretion to 1.9 ± 0.3%, representing a 3.9-fold increase. Furthermore, 
incubation of human primary L cells with IBMX/forskolin also significantly increased %GLP-1 
secretion to 1.8 ± 0.4%, reflecting a 3.8-fold increase from basal. 
 
Figure 2.12 The effect of D-glucose and increasing intracellular [cAMP] on gut 
hormone secretion from human primary L cells. Mixed human primary colonic cultures 
were incubated in secretion buffer containing increasing glucose concentrations or IBMX and 
forskolin (10µmol/L each). GLP-1 secretion in each well is expressed as a percentage of 
total GLP-1 contained within the well and compared to the basal secretion measured in 
parallel within the same experiment. Data represent means ± SEM (n=4-5 wells). 
Significance is shown relative to basal secretion using One-way ANOVA with a Dunnett post 
hoc test (*P<0.05; **P<0.01).  
0 1 10 100 IBMX/for
0.0
0.5
1.0
1.5
2.0
2.5
** *
Glucose (mmol/L)
%
G
L
P
-1
 r
e
le
a
s
e
d
89 
2.5 Discussion  
2.5.1 Summary of results 
 The colonic digest method pioneered by Reimann et al. led to the successful isolation 
of colonic crypts from both mouse and human colonic tissue. 
 Glucose (1 and 100mmol/L) and L-glutamine (10mmol/L) significantly stimulated the 
release of GLP-1 and PYY from murine primary colonic L cells.  
 Increasing intracellular cAMP levels potently stimulated the release of GLP-1 and 
PYY from murine primary colonic L cells. 
 For the first time, it was demonstrated that glucose and increasing intracellular cAMP 
levels induced GLP-1 secretion from human primary colonic L cells.  
 
2.5.2 Detailed discussion 
The aim of the work described in this chapter, was to establish a primary L cell model in our 
laboratory based on the method for isolating primary colonic crypts originally published by 
Reimann et al. (Reimann et al. 2008). I showed that the colonic digest method leads to the 
isolation of largely intact and viable colonic crypts from mouse colon, and with minor 
adjustments, the method was also effective for human colonic crypt isolation to create a 
novel human primary L cell model.  
Professor Fiona Gribble’s group in Cambridge has successfully used this method to study 
GLP-1 release from murine primary L cells using an active GLP-1 ELISA (Parker et al. 2012, 
Reimann et al. 2008, Rogers et al. 2011). Therefore, it was necessary to set up and optimise 
protocols for the assessment of total GLP-1 and PYY levels in supernatants and lysed cells 
using our in-house radioimmunoassays. Assay interference caused by the lysis buffer in the 
lysed cell samples was overcome by identifying and not exceeding the volumes of lysis 
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buffer which caused minimal interference, and by adding a lysis buffer-containing standard 
curve to each assay to account for any potential interference.  
The third objective was to validate the primary L cell model by replicating published work that 
demonstrated the effect of various stimuli on active GLP-1 secretion (Reimann et al. 2008, 
Rogers et al. 2011). The results of the above experiments confirm that viable L cells, which 
release PYY and GLP-1, are present within murine and human isolated colonic crypts and 
are nutrient responsive.  
 
Basal gut hormone secretion from primary L cells 
Reassuringly, basal secretion of gut hormones from this primary L cell model appears 
relatively consistent across experiments. However, what is apparent is that basal PYY 
secretion (4-6%) is higher than GLP-1 secretion (1-3%). Basal secretion reflects a basal tone 
of electrical activity, which L cells maintain in culture, reported as infrequent Na+-dependent 
action potentials (Reimann et al. 2008). These action potentials serve to sustain a 
background level of gut hormone secretion. It is difficult to know whether the difference in 
basal secretion between the two gut hormones is genuine or whether it merely reflects a 
difference in the half-lives of the two peptides; PYY has a reported half-life of ~8-9min, 
whereas GLP-1 has a reported half-life of ~1-2min (Adrian et al. 1986, Kieffer et al. 1995, 
Lluis et al. 1989). Publications from Professor Gribble’s laboratory routinely display GLP-1 
release data as ‘relative to basal secretion’ and not as percentage release. However, in a 
recent publication they reported average basal active GLP-1 release to be approximately 
1.3% (Habib et al. 2013), which closely resembles the values presented here. Basal GLP-1 
release from human primary L cells appears slightly lower than that of murine L cells, with a 
mean of 0.5% compared to 2.0% (across experiments presented in this Chapter), 
respectively. 
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The effect of glucose on gut hormone release from primary L cells 
The stimulatory effect of glucose on GLP-1 and PYY release in vivo and from whole 
intestinal preparations is well established in the literature (Fu-Cheng et al. 1995, Herrmann 
et al. 1995, Mace et al. 2012, Plaisancie et al. 1995). Glucose-induced GLP-1 secretion has 
also been demonstrated using GLUTag cells (Reimann & Gribble 2002). However, 
experiments conducted using fetal rat intestinal cultures and primary cultured canine L cells, 
suggested a lack of response to glucose and brought into question whether L cells are 
glucose-sensitive (Brubaker & Vranic 1987, Damholt et al. 1998).   
Using a perforated patch recording set up, the original primary L cell model publication 
showed that L cells are electrically excitable and respond to glucose (10 mmol/L) by 
increasing action potential frequency (Reimann et al. 2008). In addition, the authors 
demonstrated that L cells exhibit elevations in [Ca2+]i  following addition of glucose (10 
mmol/L). Glucose had a significantly greater stimulatory effect on intracellular calcium in L 
cells, compared to colonic non-L cells, suggesting that the response to glucose does in fact 
originate within the L cell.    
The results presented in this chapter are in agreement with the findings of the original 
primary L model publication; glucose triggers the release of GLP-1 at concentrations as low 
as 1mmol/L, which is within the physiological range for the rodent large intestine (Ferraris et 
al. 1990). I have shown for the first time that this is also true for PYY. Furthermore, the fold 
increase in GLP-1 and PYY secretion in response to glucose at both concentrations is 
similar to that reported for active GLP-1 using the same primary L cell model (Table 2.2) 
(Reimann et al. 2008). 
There is some evidence to suggest that glucose in the large intestine is able to increase 
plasma gut hormone levels in humans (Qualmann et al. 1995), though not all studies have 
arrived at this conclusion (Printz et al. 1998). The effect of glucose on GLP-1 secretion from 
isolated human primary L cells has not been previously demonstrated. The data presented in 
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this chapter suggest that human L cells are responsive to glucose, which appears to 
stimulate GLP-1 in a dose-dependent manner.  However, despite a 2-fold and 2.7-fold 
increase in GLP-1 release with 1 and 10mmol/L glucose, respectively, the increase in GLP-1 
release only reached statistical significance at 100 mmol/L, a highly supraphysiological 
concentration for the human large intestine (Ferraris et al. 1990). The lack of a statistically 
significant GLP-1 response to glucose in this instance may reflect the low n numbers used 
due to the limited amount of human colonic tissue available.  
 
Table 2.2 Comparison of observed relative PYY and GLP-1 secretion from murine 
primary colonic cultures, in response to different stimuli, with values reported in the 
literature. 
Stimulant Relative* 
↑PYY 
Relative* 
↑GLP-1 (total) 
Reported 
↑GLP-1 (active) 
Reference 
Glucose 
1mmol/L 
100mmol/L 
 
1.6-fold 
1.8-fold 
 
2.7-fold 
2.6-fold 
 
1.8-fold 
2.1-fold 
 
(Reimann et al. 2008) 
L-Glutamine 
1mmol/L 
10mmol/L 
 
1.5-fold 
2.1-fold 
 
1.3-fold 
2.0-fold 
 
1.7-fold 
1.9-fold 
 
(Tolhurst et al. 2011) 
IBMX/forskolin 
10µmol/L 
 
6.5-fold 
 
6.0-fold 
 
9.0-fold 
6.0-fold (PYY) 
 
(Reimann et al. 2008) 
 
*Relative to basal secretion measured in parallel within the same experiment 
GLP-1, glucagon-like peptide 1; IBMX, 3-isobutyl-1-methylxanthine; PYY, peptide YY 
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The effect of L-glutamine on gut hormone release from primary L cells 
Certain individual amino acids as well as amino acid mixtures are known to stimulate GLP-1 
and PYY secretion in vivo (Fu-Cheng et al. 1995, Greenfield et al. 2009), from primary 
intestinal preparations (Mace et al. 2012) and from GLUTag cells (Oya et al. 2013, Reimann 
et al. 2004). Using the primary L cell model employed in the work described in this chapter, 
Tolhurst et al. recently demonstrated that L-glutamine dose-dependently stimulates active 
GLP-1 secretion (0.1 – 10mmol/L) (Tolhurst et al. 2011).  
Further studies revealed that this response to L-glutamine consisted of two components: 
membrane depolarisation and an increase in [cAMP]i. The first pathway involves the Na
+-
dependent electrogenic entry of L-glutamine into the L cell which triggers membrane 
depolarisation and voltage-gated Ca2+ influx. The identity of the L-glutamine transporter(s) 
involved remains unclear. The amino acid transporters most highly expressed in colonic L 
cells are SNAT2 (sodium-coupled neutral amino acid transporter 2, Slc38a2) and B0AT1 
(system B (0) neutral amino acid transporter 1, Slc6a19), which is specific to L cells (Tolhurst 
et al. 2011). These co-transporters are both Na+-dependent and electrogenic. The second 
component consists of an amplifying pathway, now known to be mediated by an increase in 
[cAMP]i, presumed to be triggered by GPCR activation (Tolhurst et al. 2011).  
The data presented in this chapter confirm that L-glutamine dose-dependently stimulates the 
secretion of GLP-1, but also show for the first time that it stimulates PYY release to a similar 
extent. The observed fold increases in gut hormone secretion following 1 and 10mmol/L L-
glutamine were consistent with those reported by Tolhurst et al. using the same L cell model 
(Table 2.2). 
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The effect of elevating intracellular cAMP concentrations on gut hormone release 
from primary L cells 
An intracellular rise in cAMP within EECs is a well-recognised stimulus for gut hormone 
release; studies using various model systems, such as murine and human cell lines 
[GLUTag (Simpson et al. 2007) and NCI-H716 cells (Reimer et al. 2001)], primary colonic 
cultures (Brubaker 1988, Damholt et al. 1998), and isolated perfused intestinal preparations 
(Ballantyne et al. 1993), consistently demonstrate this. Furthermore, a number of 
neurotransmitters and gut peptides found within the enteric nervous system and intestinal 
epithelium, such as CGRP and GIP, are known to activate adenylyl cyclase (Furness 2000) 
and to trigger gut hormone secretion (Brubaker 1991, Dumoulin et al. 1995, Plaisancie et al. 
1994). Therefore, it is plausible that hormonal and/or enteric nervous circuits may play a role 
in modulating L cell secretion via a cAMP-dependent pathway.    
A study by Simpson et al. revealed that elevated intracellular cAMP modulates ion channel 
activity in the plasma membrane, leading to depolarisation, action potential firing and an 
increase in intracellular Ca2+ (Simpson et al. 2007). Elevated cAMP was shown to 
specifically modulate hyperpolarisation-activated currents and the background potassium 
current, rendering L cells more excitable and thus also enhancing responses to other 
depolarising stimuli.     
In the experiment investigating the effect of increasing intracellular cAMP described in this 
chapter, a combination of IBMX and forskolin led to a 6-fold increase in total GLP-1 and a 
6.5-fold increase in PYY secretion (Table 2.2). The PYY response was similar to that 
reported by Reimann et al. (6-fold). However, despite the robust 6-fold increase in GLP-1 
(P<0.001) following IBMX/foskolin treatment observed in the current work, it was lower than 
the increase in active GLP-1 reported by Reimann et al. The reason for this is unclear but 
may reflect a difference between total and active GLP-1. 
95 
On the other hand, IBMX/forskolin-induced GLP-1 secretion from the human L cells was 
higher than that recently published by Habib et al., who used larger surgical specimens as 
opposed to the mucosal biopsies used in this work, obtained during diagnostic colonoscopy. 
They reported a 2.5-fold increase in active GLP-1 secretion following IBMX/forkolin 
treatment, compared to the 3.7-fold increase in total GLP-1 observed here. Therefore, there 
does appear to be a degree of variation in the magnitude of gut hormone responses to 
certain stimuli.  
 
Conclusion 
This chapter describes the successful application of a method for the isolation of intact 
colonic crypts containing viable L cells. Radioimmunoassay protocols were optimised to 
detect the secretion of the anorectic gut hormones PYY and GLP-1 from these primary L 
cells. The preliminary data presented in this chapter demonstrate that glucose and L-
glutamine, as well as agents which increase intracellular cAMP levels, all trigger the release 
of PYY and GLP-1. This suggests that the process of isolating the crypts does not 
significantly disrupt intracellular signalling pathways. Moreover, the observed fold increases 
in gut hormone secretion were broadly in line with those reported in previous publications 
employing the same primary L cell model, suggesting that nutrient-stimulated responses are 
reproducible and that our model may therefore be considered valid.  
In conclusion, these results supported the further use of this L cell model for the study of the 
effect of SCFAs on gut hormone release. 
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Chapter III:  
The effect of short chain 
fatty acids on gut 
hormone release  
 
 
 
 
 
 
 
 
 
 
97 
3.1 Introduction  
Fermentable fibres have been proposed to at least partly exert their satiating effects via the 
luminal sensing of short chain fatty acids (SCFAs), triggering the release of the anorexigenic 
gut hormones PYY and GLP-1 from enteroendocrine L cells (Sleeth et al. 2010). NDCs up-
regulate expression of proglucagon and PYY in the colon and caecum, and increase plasma 
gut hormone levels both in rodents and humans (Cani et al. 2009, Delzenne et al. 2005, 
Freeland et al. 2010, Keenan et al. 2006, Zhou et al. 2006, Zhou et al. 2008). However, 
whether SCFAs mediate this increased gut hormone secretion remains to be established. 
Investigation into the effect of SCFAs on gut hormone release began with a number of 
studies in the 90’s using various in vivo models. While the results of these studies, discussed 
below, were inconsistent; the findings largely supported a role for SCFAs in the stimulation 
of gut hormone release (Anini et al. 1999, Cherbut et al. 1998, Fu-Cheng et al. 1995, Longo 
et al. 1991, Plaisancie et al. 1996).       
The discovery of two SCFA receptors, GPR41 and GPR43, in 2003, and demonstration of 
their expression in rodent and human enteroendocrine L cells in 2006 and 2008, 
respectively, sparked new interest in the effect of SCFAs on gut hormone release and, 
crucially, in their mechanism of action, which to date remains incompletely understood 
(Karaki et al. 2006, Karaki et al. 2008, Tazoe et al. 2009).   
 
3.1.1 The effect of SCFAs on gut hormone release  
Early in vivo/ex vivo studies in anaesthetised animals 
The first investigation into the effect of SCFAs on gut hormone release was carried out by 
Longo et al. in rabbits (Longo et al. 1991). Infusion of acetate and butyrate (10-100mmol/L) 
into the isolated, vascularly-perfused left colon led to a significant increase in PYY levels in 
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plasma collected from the interior mesenteric vein. This work was followed by a number of 
studies conducted by a group from the French National Institute for Medical Research 
(INSERM) examining the effect of SCFAs on gut hormone release from the rat ileum and 
colon, employing ileal and colonic cannulas, as well as innervated isolated intestinal loops 
(Anini et al. 1999, Cherbut et al. 1998, Dumoulin et al. 1998, Fu-Cheng et al. 1995, 
Plaisancie et al. 1995, 1996). Colonic administration of a mixed SCFA bolus (150mmol/L) via 
an ileal or colonic cannula in rats led to a significant increase in circulating plasma PYY 
levels (Fu-Cheng et al. 1995). A significant and sustained rise in plasma PYY was also 
reported following a one hour colonic infusion of a mixture of SCFAs (500mmol/L, 2mmol/h) 
in rats (Cherbut et al. 1998).  
When administered to an isolated, vascularly-infused rat colon as a bolus, butyrate and 
propionate (5 and 20mmol/L, respectively) stimulated PYY secretion, but not GLP-1 
(Plaisancie et al. 1995, 1996). This finding led the authors to speculate that SCFAs may 
differentially induce the release of PYY and GLP-1. Interestingly, a SCFA-triggered increase 
in circulating PYY without a concurrent GLP-1 response has also been reported by Anini et 
al. in the rat colon and Cuche et al. in the porcine ileum (Anini et al. 1999, Cuche et al. 
2000). However, the reasons for this discrepancy remain unclear. Despite the findings that 
PYY and GLP-1 are predominantly co-localised in the mouse intestine, and that both 
hormones are elevated postprandially, there is precedent in the literature for conditions that 
favour the secretion of one hormone over the other (Nilsson et al. 1991). However, whether 
this might be due to the the differential secretion of the two hormones from the same L cells, 
or the existence of PYY-positive but GLP-1 negative L cells remains unknown. 
 
 
Recent ex vivo studies 
  
Surprisingly, recent work found no effect of SCFAs on PYY and GLP-1 release from porcine 
ileal and colonic tissue. However, it is plausible that the concentration tested (5mmol/L) was 
insufficient to induce a gut hormone response from whole ex vivo tissue (Voortman et al. 
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2012). In contrast, Mace et al. demonstrated that infusion of propionate into isolated loops of 
rat small intestine (up to the ileo-caecal valve) dose-dependently increased both GLP-1 and 
PYY release from the tissue at the higher concentrations of 10-50mmol/L (Mace et al. 2012).  
 
 
Recent in vivo studies in non-anaesthetised rodents  
 
Animal studies examining the effect of SCFAs on gut hormone release and appetite have 
largely relied upon dietary supplementation with the sodium salts of SCFAs. Vidrine et al. 
demonstrated that resistant starch (28%) but not sodium butyrate (3.2%) in the diet 
increased plasma GLP-1 and PYY levels in Sprague Dawley rats over a period of 12 weeks 
(Vidrine et al. 2013). In a further study, which attempted to determine the effect of SCFAs on 
the development of diet-induced obesity, C57BL6 mice were put on a HFD supplemented 
with sodium salts of butyrate (5%w/w), propionate (4.3%) or acetate (3.7%) for 4 weeks. At 
the end of the study, propionate and butyrate-fed mice had gained no weight and the body 
weight gain in the acetate group was suppressed by 40%, compared to the control group 
which gained >10g (Lin et al. 2012). However, due to the volatile nature of SCFAs, their 
presence in the diet gives it a distinctive odour and taste, and has a negative impact on 
palatability (Darzi et al. 2011). Therefore, it is impossible to determine whether the reduced 
food intake is a direct result of the putative anorexigenic effect of SCFAs or an indirect 
consequence of poor palatability.  
 
In the same study, oral administration of sodium butyrate was found to acutely increase 
plasma GLP-1, GIP and PYY at 10 minutes, and sodium propionate significantly increased 
GIP. However, while it is plausible that the SCFAs reached the proximal small intestine 
within 10 minutes, as gastric emptying of a liquid bolus in mice is rapid and can exceed 80% 
within 15 minutes (Firpo et al. 2005), it is highly unlikely that the SCFA boluses reached the 
distal small intestine or colon. Nevertheless, it is possible that SCFAs stimulated gut 
hormone release from proximal small intestinal L cells, though such cells are relatively 
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sparse. This highlights another limitation of supplementing the diet with SCFAs; following 
oral delivery, SCFAs are absorbed in the small intestine (Schmitt et al. 1976, Schmitt et al. 
1977) before reaching the large intestine, the site containing the largest density of L cells.  
 
 
Human studies 
 
Evidence for an effect of colonic SCFAs on gut hormone release from human studies is very 
limited. Two small studies (n=6-7) have investigated the effect of rectal infusion of SCFAs on 
gut hormone release in humans. Ropert et al. observed no change in plasma gut hormone 
levels of GLP-1 or oxyntomodulin following a 180ml SCFA infusion (300 or 500 mmol/L) over 
one hour into the proximal colon (3ml/min) (Ropert et al. 1996). Furthermore, while plasma 
PYY concentrations rose significantly over time, there was no significant difference 
compared to the saline infusion.  
 
Freeland and Wolever conducted a small single-blind randomised cross-over study in 
hyperinsulinaemic overweight women to determine the effect of a 300ml rectal infusion of 
sodium acetate (200mmol/L) vs. saline over 8 minutes on plasma GLP-1 and PYY levels 
(Freeland & Wolever 2010). The authors reported a slight increase in plasma GLP-1 
following administration of both sodium acetate and saline, suggesting a non-specific effect 
of rectal distension. However, in contrast to the findings of the previous study, infusion of 
acetate into the rectum elicited a gradual and sustained release of PYY which was 
significantly greater than the transient rise in PYY in response to mechanical distension. 
Based on this limited data, it is difficult at present to draw any conclusions regarding the 
utility of targeting SCFA pathways to trigger gut hormone release in humans. Colonic or 
rectal infusion studies in humans are fraught with challenges. A human primary L cell model 
would, therefore, be valuable as an intermediate step.   
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Recent in vitro investigations  
Following renewed interest in the role of gut microbiota and SCFA receptors in glucose and 
energy homeostasis, a number of recent studies have investigated the effect of SCFAs on 
gut hormone release from both enteroendocrine cell lines and primary murine L cells. In vitro 
investigations using the murine STC-1 cell line, which has been demonstrated to express 
both SCFA receptors (Hudson et al. 2013), suggest that while propionate has no effect on 
GLP-1 or PYY release at the relatively low concentration of 100μmol/L (Hand et al. 2013, 
Hudson et al. 2013), it significantly stimulates GLP-1 release from these cells at 1 and 
10mmol/L (Hudson et al. 2013). The findings of the limited studies that have been conducted 
using primary colonic L cells are inconsistent. While acetate and propionate have previously 
been shown to significantly increase GLP-1 release from murine primary L cells (Nohr et al. 
2013, Tolhurst et al. 2012a), another recent study using an alternative digestion method was 
unable to show an increase in GLP-1 release from primary colonic tissue in response to 
propionate (0.8, 8, 24 and 48 mmol/L) and only found a significant effect with acetate at 
concentrations of 80 and 160mmol/L (Li et al. 2013).  
 
In conclusion, there are discrepancies in the findings of studies investigating the effects of 
SCFAs on PYY and GLP-1 release both in vitro and in vivo. Furthermore, there is a lack of 
data regarding the effect of SCFAs on PYY secretion in vitro presumably because there are 
no validated PYY-secreting cell lines and work using primary L cells has focused mainly on 
GLP-1. In light of the differential release of GLP-1 and PYY observed under certain 
conditions in response to SCFAs in vivo, measurement of both gut hormones in parallel from 
primary L cells would yield valuable information. Moreover, it is important to determine the 
effect of SCFAs on GLP-1 and PYY release from human primary L cells, to confirm that the 
effects observed in rodents are likely to be applicable to humans. Lastly, despite the fact that 
the majority of in vitro work has been carried out in murine primary L cells and mouse-
derived cell lines, the effect of colonic administration of SCFAs on plasma gut hormone 
levels in mice has not been investigated. 
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3.2 Aims and Hypotheses 
3.2.1 Aim 
To determine the effect of SCFAs on PYY and GLP-1 release from murine and human 
primary colonic L cells in vitro, and on plasma levels of PYY and GLP-1 following intra-
colonic administration in rats and mice.  
 
Objectives: 
1. To determine the effect of SCFAs  on PYY and GLP-1 release from murine and 
human primary L cells. 
2. To determine the effects of propionate on cytotoxicity and the effects of 
osmolarity/sodium concentration on gut hormone release. 
3. To develop an in vivo model for simultaneously sampling from the portal vein and 
jugular vein following intra-colonic administration of a test substance. 
4. To determine the effect of intra-colonic administration of propionate on portal and 
systemic PYY and GLP-1 concentrations in rats. 
5. To  determine the effect of intra-colonic administration of propionate on portal vein 
plasma PYY and GLP-1 concentrations in mice. 
3.2.2 Hypotheses 
i) SCFAs will stimulate the release of both GLP-1 and PYY from murine and human primary 
L cells. 
ii) The stimulatory effect of SCFAs on gut hormone release will be independent of any 
osmotic or cytotoxic effects. 
iii) Intra-colonic administration of propionate will increase portal and circulating plasma gut 
hormone levels in vivo in both rodent models. 
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3.3 Methods 
3.3.1 In vitro methods 
Primary cell culture: Refer to Chapter II, Section 2.3.1 
Radioimmunoassay: Refer to Chapter II, Section 2.3.2 
 
3.3.1.1 Lactate dehydrogenase (LDH) cytotoxicity assay  
Materials 
CytoscanTM LDH cytotoxicity assay (Cat. #786-210, G-Biosciences, MO, USA) 
Free fatty acid-free bovine serum albumin (BSA) (Sigma, UK)  
Posphate-buffered saline (PBS) 1× (Refer to Appendix I) 
Glass distilled water (GDW) 
 
Principle 
The cytotoxicity of cell culture test reagents was measured using an LDH cytotoxicity assay. 
The assay quantitatively measures the stable cytosolic enzyme, lactate dehydrogenase 
(LDH), which is released upon cell lysis. The released LDH is measured with a coupled 
enzymatic reaction that results in the conversion of a tetrazolium salt, iodonitrotetrazolium 
(INT) into a red coloured agent, formazan (Fig. 3.1). The LDH activity is determined as 
NADH oxidation or INT reduction over a defined time period. The resulting formazan absorbs 
maximally at 492nm.  
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Figure 3.1. The principle of the lactate dehydrogenase (LDH) cytotoxicity assay. 
NAD+/NADH, nicotinamide adenine dinucleotide oxidised/reduced form 
 
 
Preparation of reagents 
The positive control was prepared according to the manufacturer’s instructions; 1μl LDH 
(supplied) was added to 10ml 0.1% PBS (1x) supplemented with 1% free-fatty acid free 
BSA. The substrate mix was made up by dissolving one vial in 11.4ml GDW and mixing 
gently. The light-sensitive assay buffer (0.6ml) was allowed to warm to room temperature 
and was then added to the reconstituted substrate mix and was mixed thoroughly. 
 
Experimental procedure 
Murine or human primary colonic cultures were incubated with test reagents for a period of 
2-4 hours to assess the cytotoxicity induced during the secretion experiments. The 
cytotoxicity incurred by the treatments was normalised to maximum LDH release obtained 
from lysed wells. Maximum LDH release was determined as the mean LDH levels in the 
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supernatants of 6 wells per experiment set aside as lysis wells. These wells were washed 
with secretion buffer three times along with all treatment wells before incubation. One hour 
prior to the end of the incubation period, 20% (60μl) lysis buffer (supplied) was added to 
each well and returned to the incubator for a further hour. At the end of the incubation 
period, the plates were centrifuged at 270 x g for 10 minutes. 
All controls, untreated and treated cell samples, and lysed cell samples (maximum LDH) 
were assayed in triplicate in a 96-well plate format. Controls within the assay included: 
secretion buffer alone as a negative control, the spontaneous LDH release control 
(supernatants from cells incubated with secretion buffer only) and the LDH positive control. 
A total of 50μl of control solution, supernatant or cell lysate was added per well, in triplicate. 
This was superseded by a 50μl addition of reconstituted substrate mix. The plates were then 
wrapped in foil and incubated at 37oC for 20 minutes. Following the addition of 50μl stop 
solution per well, absorbance was recorded at 490nm using a micro-plate reader (BioTek 
Model No. ELx808, VT, USA).  
 
Percentage cytotoxicity was calculated as follows:     
               
                                  
                        
      
(OD, optical density) 
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3.3.2 In vivo methods 
3.3.2.1 Animals and housing 
All animal procedures undertaken were carried out under the British Home Office Animals 
Scientific Procedures Act 1986 (Project Licence numbers: 70/7236 and 70/7596). On arrival, 
male Wistar rats (Charles River, UK) or male C57BL6 mice (Harlan Laboratories, UK) were 
housed in pairs and maintained at 21-23oC on a 12-hour light, 12-hour dark cycle (light 
period 07:00-19:00). During the 72-hour acclimatisation period, all rodents were given ad 
libitum access to water and RM1 standard chow (RM1 diet, Special Diet Services Ltd., 
Witham, Essex).  
 
3.3.2.2 Rat intra-colonic administration study 
Male Wistar rats (200-250g) were fasted overnight and anaesthetised under isoflurane. The 
animals were kept on a heat pad and pedal reflexes were monitored throughout the 
procedure. Following confirmation of anaesthesia, a jugular vein cannulation was performed 
[PORTEX fine bore polythene tubing, 0.28mm inner diameter and 0.61mm outer diameter 
(Smiths Medical ASD, USA)]. A laparatomy was then carried out to gain access to the 
abdominal cavity; the caecum was located and the portal vein exposed. The abdominal 
cavity was covered with a swab containing warm saline. Ten minutes later, the first baseline 
jugular vein blood sample was collected (t= -15min, Fig. 3.2). A second baseline sample was 
collected at 0min, after which 2.5ml of either saline control or propionic acid (180mmol/L, pH 
5.5 using NaOH) was injected into the rat proximal colon distal to the caecum. At t=15min, a 
portal vein sample and a jugular vein sample were collected. The last two jugular vein 
samples were collected at t=30 and t=60min.  
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 Figure 3.2. Rat intra-colonic study design: colonic injection and blood sampling time 
points. JV, jugular vein; PV, portal vein 
 
 
Blood samples were collected into eppendorfs containing DPPIV inhibitor (Millipore, 
1µl/100µl blood, 100µmol/L final concentration) and protease inhibitor cocktail (Sigma, 
1µl/100µl blood, refer to Appendix II), and centrifuged for 10 minutes at 3000 x g for 
separation of plasma. Plasma was collected into a fresh eppendorf and placed on dry ice. 
Samples were stored at -20oC pending gut hormone analysis by RIA, as described 
previously.  
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3.3.2.3 Mouse intra-colonic administration studies 
Male C57BL6 mice (13 weeks of age, 25-28g) were fasted overnight and anaesthetised 
under isoflurane. Pedal reflexes were monitored throughout. A laparotomy was performed 
and the colon and portal vein were located and exposed. The abdominal cavity was covered 
with a swab containing warm saline, as above. Ten minutes later, the mice received an intra-
colonic injection (300μl) of either saline control or propionic acid (180mmol/L, pH 5.5). Portal 
vein blood was collected 15 minutes post-injection. Plasma was separated and stored as 
above. Plasma concentrations of PYY and GLP-1 were measured by RIA. 
 
3.3.3 Statistical Analysis 
Normality was assessed using the D'Agostino-Pearson omnibus test where n≥8 per group. 
Statistical significance of normally distributed data was calculated using either a t-test (2 
groups) or one-way ANOVA (≥3 groups). ANOVA pairwise comparisons were carried out 
using either the Dunnett or Bonferroni post hoc tests. The statistical significance of data that 
were not normally distributed (AUC data for the rat study) was determined using the Mann-
Whitney U test for non-parametric data. Statistical significance was accepted at P<0.05 
throughout. Data are presented as mean ± standard error of the mean (SEM). Analysis was 
carried out using Graph Pad Prism software, version 5.0. 
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3.4 Results 
3.4.1 The effect of SCFAs on gut hormone release in vitro 
3.4.1.1 The effect of acetate, butyrate and propionate on PYY and GLP-1 
release from murine primary L cells 
 
Following validation of the primary L cell model described in Chapter II, the first aim was to 
determine the effect of a 2-hour incubation of murine primary colonic cells with varying 
concentrations of the SCFAs acetate (C2), propionate (C3) and butyrate (C4) on PYY and 
GLP-1 release.  
 
Acetate  
As shown in Figure 3.3, PYY and GLP-1 release from murine primary L cells was 
significantly increased in response to treatment with acetate. Basal PYY and GLP-1 
secretion over the 2-hour incubation period was 4.2 ± 0.4% and 1.8 ± 0.2%, respectively. 
The secretion of both hormones was significantly elevated at all three concentrations tested. 
PYY secretion increased ~3-fold to 13.4 ± 0.7%, 13.2 ± 1.9% and 11.3 ± 0.6% with 50, 100 
and 200mmol/L acetate (all, P<0.001), respectively (Fig. 3.3A). Furthermore, GLP-1 
secretion rose to 6.0 ± 0.6% (P<0.001), 5.9 ± 0.5% (P<0.001) and 3.7 ± 0.3% (P<0.05) 
following stimulation with 50, 100 and 200mmol/L acetate, respectively (Fig. 3.3B). While still 
significant, 200mmol/L acetate only led to a 2-fold increase in GLP-1 release compared to 
the 3-fold increase observed with the lower doses. 
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Figure 3.3 The effect of acetate on gut hormone secretion from murine primary L cells. 
Mixed primary colonic cultures were incubated in secretion buffer containing vehicle alone or 
sodium acetate (50, 100 or 200mmol/L). PYY (A) and GLP-1 (B) secretion in each well is 
expressed as a percentage of total PYY or GLP-1 contained within the well and compared to 
the basal secretion measured in parallel within the same experiment. Data represent means 
± SEM (n=2 mice, 7-9 wells per group). Significance is shown relative to basal secretion 
using one-way ANOVA with a Dunnett post hoc test (*P<0.05, ***P<0.001).  
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Butyrate  
Butyrate significantly increased PYY and GLP-1 secretion from murine primary L cells (Fig. 
3.4). Basal PYY and GLP-1 secretion over the 2-hour incubation period was 4.2 ± 0.4% and 
1.8 ± 0.2%, respectively. Interestingly, while 50mmol/L butyrate significantly increased GLP-
1 release (P<0.05), the higher dose of 200mmol/L was required to significantly stimulate 
PYY release (P<0.001). However, it is worth noting that the magnitude of the increase in 
secretion of both PYY and GLP-1 in response to 50mmol/L butyrate was the same, 
approximately 2-fold (Fig. 3.4A and B).   Furthermore, whereas the PYY response appeared 
to be dose-dependent, there was no evidence of a dose-dependent effect on the GLP-1 
response, which did not increase in magnitude with concentrations above 50mmol/L.  
 
 
Propionate  
As displayed in Figure 3.5, treatment of primary murine L cells with propionate significantly 
increased PYY and GLP-1 release. Basal PYY and GLP-1 secretion over the 2-hour 
incubation period was 3.6 ± 0.2% and 3.6 ± 0.5%, respectively. Following incubation with 25, 
50, 100 and 200 mmol/L propionate, PYY secretion increased ~2-fold, to 6.7 ± 0.7%, 7.5 ± 
0.6% (P<0.001), 7.8 ± 0.6% (P<0.001) and 8.2 ± 0.9% (P<0.001), respectively (Fig. 3.5A). 
Similarly, GLP-1 increased between 2- and 3-fold in response to increasing propionate 
concentrations. GLP-1 release was significantly increased following stimulation with 25 
(P<0.05), 50 (P<0.05) and 200mmol/L propionate (P<0.01) (Fig. 3.5B).  
112 
 
 
Figure 3.4. The effect of butyrate on gut hormone secretion from murine primary L 
cells. Mixed primary colonic cultures were incubated in secretion buffer containing vehicle 
alone or sodium butyrate (50, 100 or 200mmol/L). PYY (A) and GLP-1 (B) secretion in each 
well is expressed as a percentage of total PYY or GLP-1 contained within the well and 
compared to the basal secretion measured in parallel within the same experiment. Data 
represent means ± SEM (n=2 mice, 5-9 wells per group). Significance is shown relative to 
basal secretion using one-way ANOVA with a Dunnett post hoc test (*P<0.05, ***P<0.001).  
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Figure 3.5. The effect of propionate on gut hormone secretion from murine primary L 
cells. Mixed primary colonic cultures were incubated in secretion buffer containing vehicle 
alone or sodium propionate (25, 50, 100 or 200mmol/L). PYY (A) and GLP-1 (B) secretion in 
each well is expressed as a percentage of total PYY or GLP-1 contained within the well and 
compared to the basal secretion measured in parallel within the same experiment. Data 
represent means ± SEM (2 separate experiments, n=2 mice, 5-19 wells per group). 
Significance is shown relative to basal secretion using one-way ANOVA with a Dunnett post 
hoc test (*P<0.05, **P<0.01, ***P<0.001).  
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3.4.1.2 The effect of acetate, butyrate and propionate on PYY and GLP-1 
release from human primary L cells 
 
Using the human L cell model described in Chapter II, the effect of SCFAs on the release of 
gut hormones from human colonic tissue was determined for the first time.  
 
Acetate and butyrate significantly stimulated the release of PYY from human primary L cells 
(Fig. 3.6). PYY release was increased following incubation with both acetate and butyrate at 
a concentration of 200mmol/L, 1.8-fold (3.6±1.3% to 6.5±1.6%) and 1.7-fold (7.3±1.1% to 
12.6±1.0%), respectively. However, the increase in PYY secretion was only statistically 
significant at the higher dose of 400mmol/L (acetate, 2.9-fold increase, P<0.05; butyrate, 2-
fold increase, P<0.05). With regard to PYY release following butyrate treatment, it is possible 
that the results were affected by the relatively high basal release measured in that 
experiment.    
Propionate significantly increased PYY and GLP-1 secretion from human primary L cells 
(Fig. 3.7). As with acetate and butyrate, GLP-1 secretion was elevated in response to 
200mmol/L propionate (%GLP-1, 2.8±0.3% to 5.2±0.9%, 1.9-fold increase) and PYY 
increased significantly (%PYY, 3.3±0.9 to 8.1±1.0%, 2.4-fold increase, P<0.01). Following 
incubation with 400mmol/L propionate, PYY and GLP-1 release were both significantly 
increased by 4-fold (4.1±0.5% to 13.8±1.3%, P<0.001) and 2.9-fold (2.8±0.3% to 8.1±1.1%, 
P<0.001), respectively.    
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Figure 3.6. The effect of acetate and butyrate on PYY secretion from human primary L 
cells. Mixed primary colonic cultures derived from healthy human colonic biopsies were 
incubated in secretion buffer containing vehicle alone, sodium acetate (100, 200, 
400mmol/L) or sodium butyrate (100, 200, 400mmol/L). PYY secretion in each well is 
expressed as a percentage of total PYY contained within the well and compared to the basal 
secretion measured in parallel within the same experiment. Data represent means ± SEM 
(n 2 patients’ biopsies, 4-5 wells per group). Significance is shown relative to basal 
secretion using one-way ANOVA with a Dunnett post hoc test (*P<0.05).  
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Figure 3.7. The effect of propionate on gut hormone secretion from human primary L 
cells. Mixed primary colonic cultures were incubated in secretion buffer containing vehicle 
alone or sodium propionate (100, 200, 400mmol/L). PYY (A) and GLP-1 (B) secretion in 
each well is expressed as a percentage of total PYY or GLP-1 contained within the well and 
compared to the basal secretion measured in parallel within the same experiment. Data 
represent means ± SEM (PYY, n 3 patients’ biopsies, 3-13 wells per group; GLP-1, n=2 
patients’ biopsies, 3-6 wells per group). Significance is shown relative to basal secretion 
using one-way ANOVA with a Dunnett post hoc test (**P<0.01, ***P<0.001).  
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3.4.1.3 The effect of propionate on cytotoxicity: LDH assay results 
 
To confirm that the increased gut hormone release following treatment with propionate was 
not secondary to increased cell death, the effect of propionate on cell health was determined 
using a lactate dehydrogenase (LDH) cytotoxicity assay. LDH release following propionate 
treatment was compared to spontaneous LDH release over the same time period from cells 
incubated with secretion buffer alone, and was expressed as a percentage of mean 
maximum LDH release from lysed wells.  
The results of the LDH assay suggested that incubation with 200mmol/L propionate over a 
2- or 4-hour period had no significant impact on cytotoxicity in either human or murine 
colonic cells (Fig. 3.8).  
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Figure 3.8. The effect of propionate on cytotoxicity in human and murine primary 
colonic cultures. Mixed murine (A) or human (B) primary colonic cultures were incubated 
over a 2- or 4-hour period in secretion buffer containing 200mmol/L propionate (Pro). 
Cytotoxicity is expressed as a percentage of mean maximum cytotoxicity from lysed wells 
(Max), and relative to spontaneous cytotoxicity (Spont) measured in parallel within the same 
experiment. Data represent means ± SEM (human, 3 patients’ biopsies, n 9 wells and 
mouse, 2 colons, n=11 wells per group). 
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3.4.1.4 The effect of propionate vs. sodium chloride on gut hormone release 
 
As all SCFAs tested as part of this work were sodium salts, it was necessary to demonstrate 
that propionate had a stimulatory effect on gut hormone release beyond any effects of 
osmolarity or sodium ion content. This was achieved by comparing the effect of different 
concentrations of propionate with equivalent concentrations of sodium chloride, on gut 
hormone release from human and murine primary L cells. 
 
Murine L cells 
As shown in Figure 3.9, there was a significant effect of osmolarity on gut hormone release 
beyond 100mmol/L. Incubation with 200mmol/L NaCl significantly increased both PYY 
(P<0.001) and GLP-1 (P<0.05) release above basal levels. Furthermore, at that 
concentration, there was no difference between the gut hormone responses elicited by NaCl 
and propionate. However, at concentrations of 100mmol/L and below, the effect of 
osmolarity on gut hormone release is minimal, and there is a significant 2-fold difference in 
response between NaCl and propionate at 50mmol/L (PYY, 3.7±0.3% vs. 7.5±0.6%, 
P<0.001, and GLP-1, 4.4±0.8% vs. 9.4±1.7%, P<0.05) and 100mmol/L (PYY, 4.8±0.5% vs. 
7.8±0.6%, P<0.05). 
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Figure 3.9. The effect of sodium chloride vs. propionate on PYY and GLP-1 secretion 
from primary murine L cells. Mixed primary colonic cultures were incubated in secretion 
buffer containing varying concentrations of either sodium propionate (P) or sodium chloride 
(NaCl). PYY (A) and GLP-1 (B) secretion in each well is expressed as a percentage of total 
PYY or GLP-1 contained within the well and compared to the basal secretion (C) measured 
in parallel within the same experiment. Data represent means ± SEM (2-3 separate 
experiments, n=4 mice, total wells per group displayed within columns). Significance is 
shown relative to basal secretion using one-way ANOVA with a Bonferroni post hoc test 
(*P<0.05; ***P<0.001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
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Human L cells 
Due to the limited amount of human tissue available, the effect of sodium chloride vs. 
propionate was only tested at 200mmol/L. As previously demonstrated, propionate 
significantly stimulated PYY release from human primary L cells (Fig. 3.10). NaCl at this 
concentration in human tissue did not significantly increase PYY secretion. Furthermore, 
there was a significant ~2-fold increase in PYY release with propionate, beyond that induced 
by NaCl (8.4±1.4% vs. 4.7±0.9%, respectively).   
 
 
Figure 3.10. The effect of sodium chloride vs. propionate on PYY secretion from 
human primary L cells. Mixed primary colonic cultures were incubated in secretion buffer 
containing 200mmol/L sodium chloride (NaCl) or propionate. PYY secretion in each well is 
expressed as a percentage of total PYY contained within the well and compared to the basal 
secretion (control) measured in parallel within the same experiment. Data represent means ± 
SEM (2 separate experiments, n 4 patients’ biopsies, 7-9 wells per group). Significance was 
determined using One-way ANOVA with a Bonferroni post hoc test (*P<0.05, **P<0.01).  
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3.4.1.5 The effect of low concentrations of propionate on gut hormone release 
 
Due to the saturated gut hormone response observed with concentrations above 50mmol/L 
propionate, the effect of lower concentrations of propionate was determined.  
Propionate, even at 1 and 5mmol/L, significantly stimulated both PYY and GLP-1 release 
from murine primary L cells (Fig. 3.11). Following incubation with 1 and 5mmol/L propionate, 
PYY secretion increased from 4.3±0.5% basal to 7.8±0.8% (1.8-fold, P<0.05) and 8.2±0.7% 
(1.9-fold, P<0.01), respectively. Furthermore, 1 and 5mmol/L propionate led to a GLP-1 
increase from 3.3±0.3% basal to 5.6±0.5% (1.7-fold, P<0.05) and 6.3±0.5% (1.9-fold, 
P<0.01), respectively.  
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Figure 3.11. The effect of low doses of propionate on gut hormone secretion from 
murine primary L cells. Mixed primary colonic cultures were incubated in secretion buffer 
containing increasing concentrations of sodium propionate. PYY (A) and GLP-1 (B) secretion 
in each well is expressed as a percentage of total PYY or GLP-1 contained within the well 
and compared to the basal secretion measured in parallel within the same experiment. Data 
represent means ± SEM (n=1 mouse, 5-7 wells per group). Significance is shown relative to 
basal secretion using one-way ANOVA with a Dunnett post hoc test (*P<0.05, **P<0.01, 
***P<0.001).  
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3.4.1.6 The effect of chronic prior exposure to low doses of propionate on 
acute propionate-stimulated gut hormone secretion    
 
Primary murine colonic cultures were incubated over 24 hours in media with or without a low 
concentration of 1mmol/L propionate, to minimise the risk of cytotoxicity, and were then 
stimulated acutely with 50mmol/L propionate to determine whether chronic exposure to 
propionate impairs subsequent gut hormone release. Following 24-hour exposure to 
propionate, the L cells retained their ability to respond to propionate by secreting both PYY 
and GLP-1 (Fig. 3.12).  
The absolute values of both basal and stimulated PYY and GLP-1 measured in the 
supernatants were reduced following the 24-hour exposure to propionate (Fig. 3.12B+D). 
Absolute basal PYY and GLP-1 release was 1.9-fold lower following long term propionate 
exposure and stimulated release of PYY and GLP-1 was 1.4- and 1.3-fold lower, 
respectively. However, these differences were not statistically significant. 
Furthermore, both %PYY and %GLP-1 release, basal and stimulated, were practically 
identical irrespective of prior propionate exposure (Fig. 3.12A+C). %PYY rose from 
4.4±0.3% to 13.3±1.9% (P<0.001) and 4.0±0.5% to 13.0±1.2% (P<0.001) with acute 
stimulation, with or without prior exposure to propionate, respectively. Similarly, %GLP-1 
increased from 2.0±0.3% to 4.7±0.7% (P<0.001) and 2.7±0.2% to 5.4±0.6% (P<0.001) with 
acute stimulation, with or without prior exposure to propionate, respectively. 
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Figure 3.12. The effect of chronic prior exposure to propionate on acute propionate-
stimulated gut hormone secretion from murine primary L cells. Mixed primary colonic 
cultures were pre-incubated in DMEM with or without 1mmol/L propionate for 24 hours. 
Colonic cultures were then acutely treated with sodium propionate (50mmol/L) or secretion 
buffer alone (control). PYY (A) and GLP-1 (C) secretion in each well is expressed as a 
percentage of total PYY or GLP-1 contained within the well and compared to the basal 
secretion measured in parallel within the same experiment. Absolute PYY (B) and GLP-1 (D) 
levels were measured in the supernatants. Data represent means ± SEM (n=2 mice, 10-12 
wells per group). Significance is shown relative to basal secretion using one-way ANOVA 
with a Bonferroni post hoc test (*P<0.05, **P<0.01, ***P<0.001).  
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3.4.2 The effect of colonic propionate on gut hormone release in vivo 
3.4.2.1 The effect of intra-colonic administration of propionate on portal and 
circulating PYY and GLP-1 concentrations in male Wistar rats 
 
An in vivo model was developed to allow the simultaneous measurement of gut hormone 
levels in the portal and general circulation following intra-colonic administration of a test 
substance. Cannulation of the jugular vein followed by a laparotomy in isoflurane-
anaesthetised male Wistar rats allowed access to the colon and portal vein and enabled 
sampling from both the jugular and the portal vein in parallel. 
 
A 2.5ml intra-colonic bolus of propionate (180mmol/L, pH 5.5 using NaOH) induced a 
significant increase in systemic circulating plasma PYY and GLP-1 levels over a 60-minute 
period compared to saline (treatment effect, P<0.05), though there was no significant 
difference in area under the curve (AUC; PYY, propionate 913 ±363 vs. saline 204 ±275 
pmol/L, GLP-1, 167± 444 vs. -40± 46pmol/L) (Fig. 3.13C and Fig. 3.14C).  
Following intra-colonic administration, plasma PYY rose from a baseline of 28.3 ±3.6 pmol/L, 
to 40.4 ±5.8, 47.0 ±7.8, and 49.3 ±8.0 pmol/L at 15, 30 and 60 minutes, respectively (Fig. 
3.13A). Plasma PYY reached a plateau at 30 minutes and remained elevated at the end of 
the study, representing a 21 pmol/L change from baseline. Saline, on the other hand, had a 
minimal effect on plasma PYY, which rose only by 4 pmol/L from baseline and remained at 
similar levels throughout the 60-minute period. 
The effect of the propionate bolus on circulating GLP-1 levels appeared slower and more 
transient (Fig. 3.14A and B). Plasma GLP-1 peaked at 30minutes, at 17.9 ±4.5 pmol/L, 
reflecting a 5.7 ±3.0 pmol/L change from baseline (12.2±2.0 pmol/L). By 60 minutes, plasma 
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GLP-1 was markedly lower (14.1±5.0 pmol/L). However, it remained elevated compared to 
baseline and saline (propionate, 2.0 ±3.3 pmol/L vs. saline, -3.3 ±0.7 pmol/L compared to 
baseline). 
At 15 minutes following propionate administration, there was a significant increase in portal 
vein PYY compared to saline (76.5±9.4 vs. 46.5±9.5pmol/L) (Fig. 3.15A). Portal vein PYY 
levels were markedly higher compared to the peripheral circulation. Portal vein GLP-1 levels, 
however, were either at the same level or lower and were not significantly different between 
propionate and saline at 15 minutes (propionate, 13.8±4.1 vs. saline, 8.7±1.9pmol/L) (Fig. 
3.15B).         
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Figure 3.13. The effect of intra-colonic administration of propionate on circulating 
plasma PYY concentrations in male Wistar rats. Blood samples were collected over a 60-
minute period, via a jugular vein cannula, following an intra-colonic injection (2.5ml) of 
180mmol/L propionic acid or saline (matched for pH and sodium content) in isoflurane-
anaesthetised rats. Absolute PYY concentrations in plasma are presented in (A), change 
from baseline values and AUC data are shown in (B) and (C), respectively. Data represent 
means ±SEM (n=14 per group). Significance was determined using two-way ANOVA 
(treatment effect, *P<0.05). 
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Figure 3.14. The effect of intra-colonic administration of propionate on circulating 
plasma GLP-1 concentrations in male Wistar rats. Blood samples were collected over a 
60-minute period, via a jugular vein cannula, following an intra-colonic injection (2.5ml) of 
180mmol/L propionic acid or saline (matched for pH and sodium content) in isoflurane-
anaesthetised rats. Absolute GLP-1 concentrations in plasma are presented in (A), change 
from baseline values and AUC data are shown in (B) and (C), respectively. Data represent 
means ±SEM (n=14 per group). Significance was determined using two-way ANOVA 
(treatment effect, *P<0.05). 
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Figure 3.15. The effect of intra-colonic administration of propionate on portal vein 
plasma PYY (A) and GLP-1 (B) concentrations in male Wistar rats. Blood samples were 
collected from the portal vein 15 minutes following an intra-colonic injection (2.5ml) of 
180mmol/L propionic acid or saline (matched for pH and sodium content) in isoflurane-
anaesthetised rats. Data represent means ±SEM (n=14 per group). Significance was 
determined using an unpaired t-test (*P=0.0358).  
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3.4.2.3 The effect of intra-colonic administration of propionate on portal vein 
gut hormone concentrations in male C57BL6 mice 
The effect of intra-colonic administration of propionate on portal vein plasma PYY and GLP-1 
levels was also determined in male C57BL6 mice. Following a 300μl bolus injection of 
propionate (180mmol/L, pH 5.5 using NaOH), GLP-1 and PYY levels were markedly 
elevated in portal plasma at 15 minutes (Fig. 3.16). Plasma GLP-1 rose from 13.1±8.5pmol/L 
to 21.2±2.7pmol/L (P=0.0517) and plasma PYY increased significantly from 
95.3±12.2pmol/L to 134.1±11.6pmol/L (P=0.0307). 
 
 
 
Figure 3.16. The effect of intra-colonic administration of propionate on portal vein 
plasma PYY and GLP-1 concentrations in male C57BL6 mice. Blood samples for 
measurement of plasma (A) PYY and (B) GLP-1 were collected from the portal vein 15 
minutes following an intra-colonic injection (300µl) of 180mmol/L propionic acid or saline 
(matched for pH and sodium content) in isoflurane-anaesthetised mice. Data represent 
means ±SEM (n=11-14 per group). Significance was determined using an unpaired t-test 
(GLP-1, P=0.0517; PYY, *P=0.0307).  
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3.5 Discussion 
3.5.1 Summary of findings 
In vitro investigation 
 SCFAs (C2-C4) stimulate the release of both PYY and GLP-1 from murine and 
human primary L cells. 
 A 2-hour incubation with 200mmol/L propionate does not cause cytotoxicity in 
primary colonic cultures (murine and human). 
 Above 200mmol/L, NaCl significantly stimulates gut hormone release from murine 
primary L cells. However, at concentrations <100mmol/L, NaCl has no effect on gut 
hormone release.  
 At 200mmol/L, NaCl does not significantly increase PYY release from human primary 
L cells. 
 Prior exposure (24 hours) of murine primary L cells to a low concentration of 
propionate does not impair the ability of the cells to secrete GLP-1 and PYY in 
response to acute stimulation with propionate.  
 
In vivo investigation 
 Intra-colonic propionate administration significantly increases portal vein PYY 
concentrations and sustains elevated circulating plasma PYY levels over a 60-minute 
period in rats. 
 Intra-colonic propionate administration transiently, but significantly, increases 
circulating plasma GLP-1 levels in rats. 
 Intra-colonic administration of propionate in mice elevates portal vein GLP-1 and 
significantly increases PYY concentrations in portal vein plasma.  
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3.5.2 Detailed Discussion 
 
In vitro investigation 
SCFAs and gut hormone release from murine primary L cells 
All three major SCFAs (C2-C4), acetate, propionate and butyrate, significantly stimulated the 
release of both PYY and GLP-1 from murine colonic cultures, including at concentrations 
within the physiological range [70-130mmol/L (Mortensen & Clausen 1996)]. The effect of 
SCFAs on PYY release has not been previously investigated in primary colonic cells. The 
results presented here provide no evidence to suggest differential release of PYY vs. GLP-1.  
Experiments using lower concentrations of propionate (1-25mmol/L) demonstrated that even 
at 1mmol/L, propionate was able to significantly induce both GLP-1 and PYY release from 
murine primary L cells. These results are in accordance with previous findings for active 
GLP-1 (Tolhurst et al. 2012a). In contrast to the high physiological concentrations of SCFAs 
reported in the gut lumen, these lower concentrations are more in line with the EC50s of 
GPR43 and GPR41 for SCFAs, which are in the region of 0.5-1mmol/L (Brown et al. 2003, 
Le Poul et al. 2003). It is possible that luminal SCFAs are lower in the immediate vicinity of 
the L cells due to active uptake of SCFAs by surrounding enterocytes and/or due to the 
presence of the mucous layer, which acts as a diffusional barrier (Barthe et al. 1998, Levine 
et al. 1970, Plumb et al. 1987). Nohr et al. proposed that colonic EECs may sense the 
considerably lower concentration of SCFAs found at the basolateral surface (Nohr et al. 
2013). Alternatively, Tolhurst et al. speculated that colonic SCFAs may play a role in 
providing a chronic stimulatory tone on L cells via apical or basolateral SCFA receptors 
(Tolhurst et al. 2012a), which could account for the presence of circulating GLP-1 in the 
fasted state. However, the chronic effect of SCFAs on primary L cells has not been 
investigated. 
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Effect of chronic exposure to propionate 
To determine whether colonic L cells retain their stimulatory response to propionate following 
longer term exposure to a low but stimulatory concentration of propionate, murine L cells 
were incubated with or without 1mmol/L propionate over 24 hours (termed ‘chronic’) prior to 
acute stimulation with 50mmol/L propionate. This concentration was chosen as it was the 
highest concentration at which NaCl had no effect on gut hormone release. Prior chronic 
exposure to a low dose of propionate did not impair the L cells’ ability to respond to 
subsequent acute stimulation with propionate. Interestingly, Hand et al. reported a 3.4-fold 
increase in cellular stores of PYY following chronic propionate exposure in STC-1 cells 
(0.1mmol/L over 72 hours) (Hand et al. 2013). The results presented here, following a 
shorter incubation period and in primary cells, do not support this finding in immortalised 
cells as absolute PYY and GLP-1 release appeared reduced, reflecting, if anything, a 
potential reduction in cellular content. However, it is not possible to discount a difference in L 
cell number between wells of different treatments as the cause of this reduced gut hormone 
content. Recent work has revealed that the SCFA receptor GPR43 may undergo β-arrestin 
2-mediated internalisation following activation with an agonist (Lee et al. 2013). However, 
the data described here do not provide evidence for ‘chronic’ desensitisation under the 
conditions tested.  
 
Human primary L cells and SCFA-mediated gut hormone release 
A novel human L cell model was developed following adaptation of the murine colonic digest 
protocol (Reimann et al. 2008) to healthy human colonic tissue biopsies. Using this human L 
cell model, it was demonstrated for the first time that propionate stimulates GLP-1 secretion 
and that all three SCFAs (C2-C4) stimulate PYY release from human primary L cells, albeit 
at higher concentrations than in murine primary L cells (≥200mmol/L propionate). However, it 
is possible that a stimulatory effect may have been observed at lower concentrations if more 
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human tissue had been available to increase the n numbers investigated. Furthermore, the 
effect of acetate and butyrate on GLP-1 release from human primary L cells now merits 
investigation.  
There is a suggestion in the literature that human L cells are ~4-fold less responsive to 
stimuli including the LCFA linoleic acid than murine cultures, despite comparable basal rates 
of secretion (Habib et al. 2013). However, as previously alluded to, it is unknown whether 
this is a genuine difference in responsiveness between human and murine L cells or whether 
it reflects a difference in response to primary cell culture conditions.  
Nevertheless, the fact that human L cells appear to respond to SCFAs is an important 
finding, though the experiments described in this chapter require repetition and confirmation. 
It demonstrates that SCFA-stimulated gut hormone release is relevant to humans and 
supports further investigation in this area. Furthermore, it supports the use of the murine 
colonic crypts as a valid L cell model. On the other hand, it also suggests that there may be 
some differences between the two species’ cellular responses, which require further 
elucidation. Nevertheless, this human L cell model could prove a useful tool for investigating 
differences between murine and human L cells and for screening stimulants to evaluate their 
translational potential.  
 
Cell health and Osmolarity 
Additional experiments were carried out to eliminate potential effects of cytotoxicity or 
osmolarity as a cause of gut hormone release from primary colonic cultures. Cell health was 
assessed following a 2- or 4-hour incubation with propionate. LDH assay results revealed 
that there was no increase in cytotoxicity following the 2-hour incubation with 200mmol/L 
propionate in either murine or human colonic cells. These results support and extend the 
findings by Hand et al., which demonstrated no effect on cytotoxicity following treatment of 
STC-1 cells with SCFAs over a 30-minute period (Hand et al. 2013). However, their study 
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reported a 2-fold increase in cytotoxicity in response to treatment with SCFAs over 72 hours. 
There was a slight, non-significant increase in cytotoxicity observed in the murine crypt 
cultures after 4 hours, however there was no impact on cell viability in the human colonic 
crypts. The slight increase in cytotoxicity observed in the murine cells is not detrimental as 
200mmol/L was the maximal dose tested and all incubations lasted 2 hours. Furthermore, 
subsequent in vitro murine L cell experiments described in this thesis only use 
concentrations of 1-50mmol/L propionate. Ideally, an additional test for the assessment of 
cell viability would have also been employed, such as an MTT test (Sato & Clevers 2013). 
Crucially, it should be noted that it is the viability of the entire mixed cell population within a 
given well that is being assessed and may not be representative of the L cell population.   
The effect of osmolarity on gut hormone release was also examined; primary murine cultures 
were incubated with different concentrations of sodium chloride (NaCl) alongside equivalent 
concentrations of sodium propionate. The data derived from these experiments indicate that 
while 200mmol/L NaCl has a potent stimulatory effect on gut hormone release, at 
concentrations <100mmol/L, the effect on gut hormone release is negligible. Therefore, at 
50mmol/L for example, propionate significantly increases GLP-1 and PYY secretion from 
murine primary L cells compared to 50mmol/L NaCl (~2-fold difference). Furthermore, 
investigation of the effect of 200mmol/L propionate vs. 200mmol/L NaCl on PYY release 
from human colonic crypts indicated that NaCl per se did not significantly stimulate PYY 
release and that there was a significant difference between the %PYY released following 
propionate and NaCl treatment.  
These experiments suggest that the effect of propionate on gut hormone release is specific, 
and is not the result of either increased osmolarity or cytotoxicity. 
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In vivo investigation 
Colonic propionate and gut hormone release in rats 
Development of a novel in vivo model enabled the measurement of gut hormone levels in 
both the portal and peripheral circulation following intra-colonic administration of propionate 
in anaesthetised rats. The observed 18.6- and 20.9pmol/L rise in circulating plasma PYY 
levels at 30 and 60 minutes was similar in magnitude to that reported following intra-colonic 
administration of a mixture of SCFAs in the same strain of rats (18pmol/L rise above 
baseline at 30min) (Fu-Cheng et al. 1995). The SCFA mixture used in this previous study 
was at a similar concentration (150mmol/L) and was administered as a 3ml bolus, similar to 
the 2.5ml bolus used in this study. The results of this work also mirror those of the Fu-Cheng 
et al. study in that the elevated plasma PYY levels were sustained over the duration of the 
study, 60min and 120min. Furthermore, a 20pmol/L rise in PYY was also reported by 
Cherbut et al. in the same strain of rats following a one-hour colonic infusion with a 
500mmol/L SCFA mixture (4ml/h) (Cherbut et al. 1998). In both studies there was a marked 
increase in plasma PYY from 30 minutes onwards. 
However, in contrast to previous studies that failed to show an effect on GLP-1 (Anini et al. 
1999, Cuche et al. 2000, Plaisancie et al. 1995), the data presented here suggest that both 
PYY and GLP-1 were elevated in parallel following intra-colonic administration of propionate. 
One difference between the studies described in this chapter and those which did not show 
a GLP-1 response is the use of protease inhibitors including a DPP-IV inhibitor, which in this 
study were added to whole blood upon collection (Cherbut et al. 1998, Plaisancie et al. 
1995). However, the GLP-1 response was more transient in nature; GLP-1 peaked at 30min 
but the levels were not maintained and were reduced at 60min.  
Furthermore, while there was a significant increase in portal vein PYY levels at 15min, the 
increase in portal vein GLP-1 was not significant, despite the fact that both gut hormones 
were increased 1.6-fold compared to saline. It is possible that the time point chosen was too 
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delayed to detect the peak in portal vein GLP-1 or it may also reflect the greater inter-
individual variation observed. Control portal vein GLP-1 concentrations recorded in this study 
(8.7±1.9pmol/L) were in line with those reported in the literature [7.8±0.7pmol/L (Cani et al. 
2004a), 9.0±0.7pmol/L (Cani et al. 2004b)]. Portal vein PYY concentrations at t=15min were 
higher compared to circulating concentrations at t=15min (saline, 1.3-fold higher, stimulated, 
1.9-fold higher) and remained higher at t=30 and 60min (saline, 1.3-fold higher, stimulated 
1.6-fold higher). Portal vein GLP-1 concentrations at t=15min, on the other hand, were lower 
than the circulating levels measured at the same time point. The reason for this is unclear, 
but may be due to an earlier peak in portal vein GLP-1 (Sato et al. 2009).  
Conflicting results in the literature may derive from the use of different species/strains and 
experimental designs (mode of administration e.g. bolus [volume] vs. infusion [volume, 
duration], site of administration, sampling site and time points), the level of anaesthesia, the 
feeding state of the animal and the faecal content of the large intestine, as well as the form 
and concentration of SCFAs supplied; i.e. acids vs. sodium salts, low vs. 
(supra)physiological concentrations and pH values (mildly acidic to neutral). In the set of in 
vivo experiments described in this chapter, the propionate solution used was mildly acidic 
(pH 5.5) to match the pH of normal saline, which also closely resembles rodent caecal and 
proximal colonic pH (Lin et al. 2012).  
 
Colonic propionate and portal vein gut hormone levels in mice 
The effect of intra-colonic administration of SCFAs on gut hormone secretion in vivo in mice 
has not been previously investigated. The rat portal vein sampling procedure described 
above was adapted for use in mice, to enable the measurement of portal vein plasma gut 
hormone levels following intra-colonic administration of propionate. Basal GLP-1 values 
(13.1±8.5pmol/L) were similar to those reported in the literature [~16pmol/L (Delmee et al. 
2006)]. Notably, mouse portal vein gut hormone levels, basal and stimulated, were higher 
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than those in rats (basal PYY, 2-fold, GLP-1, 1.5-fold). The results obtained demonstrate 
that colonic propionate increases the portal vein levels of both PYY (1.4-fold, P<0.05) and 
GLP-1 (1.6-fold) in mice, as in rats, to a similar extent. However, the increase in portal vein 
GLP-1 only approached significance (P=0.0517). Demonstrating that SCFAs have the same 
stimulatory effect on gut hormone release in vivo in mice is critical as it enables investigation 
of this system in genetically modified animals.  
 
Conclusion 
The work described in this chapter demonstrates that propionate stimulates the release of 
both PYY and GLP-1 in vitro from murine and human primary L cells and also in vivo in 
rodents. However, the mechanisms underlying SCFA/propionate-stimulated gut hormone 
release remain poorly characterised. The next chapter investigates these mechanisms, with 
a focus on the role of Gpr43 in propionate-mediated gut hormone release, in vitro and in 
vivo.  
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Chapter IV:  
The mechanisms 
underlying propionate-
mediated gut hormone 
release 
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4.1 Introduction 
A large number of G-protein coupled receptors (GPCRs) have been identified as nutrient 
sensors in the gut (Wellendorph et al. 2010). These include the SCFA receptors, GPR41 and 
GPR43, which are expressed in rodent (Karaki et al. 2006) and human colonic tissue (Karaki 
et al. 2008, Tazoe et al. 2009), and which are enriched in enteroendocrine L cells (Tolhurst 
et al. 2012a).  
GPCRs are seven-transmembrane receptors, which transduce external stimuli by generating 
intracellular signalling cascades. GPCRs are subdivided into three classes (A-C) based on 
their sequence homology. SCFA receptors belong to the largest class, the rhodopsin-like 
family A (Stoddart et al. 2008). Extracellular binding of ligands to a GPCR induces 
conformational changes that modify the receptor’s interface with cytosolic effectors, 
predominantly the membrane-bound heterotrimeric guanine nucleotide-binding G-proteins 
(α, β, γ) which dissociate and activate specific downstream pathways (Reimann et al. 2012). 
GPCRs are primarily classified based on their α-subunits and the respective intracellular 
signalling pathways they recruit.  
 
4.1.1 SCFA receptors: activation and signal transduction 
Activation of the human orthologs of GPR41 and GPR43 by SCFAs has been demonstrated 
in several recombinant cellular systems, including yeast-based reporter gene assays and 
transiently transfected human embryonic kidney cell (HEK-293) and chinese-hamster ovary 
K1 (CHO-K1) cell assays (Brown et al. 2003, Le Poul et al. 2003, Xiong et al. 2004). Rank 
order potencies (Table 4.1) derived from these different cell systems and assay formats 
have generally been consistent (EC50s ≈ 0.5-1 mmol/L). Propionate (C3) is the most potent 
agonist at both receptors. All three SCFAs (C2-C4) activate GPR43 with similar potency. 
However, acetate displays greater selectivity for GPR43, whereas butyrate is more potent at 
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GPR41. This discrepancy enables functional discrimination between the two human 
receptors, as acetate is 100-fold less potent at GPR41 compared with propionate and 
butyrate (Brown et al. 2003, Le Poul et al. 2003).  
Structure-activity relationships of the receptor ligands revealed that the carboxylic moiety is 
essential for receptor activation. The carboxylic moiety must be present at the end of an 
aliphatic chain containing one to six carbon atoms, linear or branched (Le Poul et al. 2003). 
However, compounds comprising two or more carboxyl groups were not tolerated, 
irrespectively of carbon chain length. 
 
Table 4.1 Rank order of short chain fatty acid potencies at human GPR41 and GPR43 
based on published data (Brown et al. 2003, Le Poul et al. 2003). 
 
Receptor Rank order of short chain fatty acid potencies 
GPR41 propionate (C3) = pentanoate (C5) = butyrate (C4) > acetate (C2) > formate (C1) 
GPR43 propionate (C3) = acetate (C2) ≥ butyrate (C4) > pentanoate (C5) > formate (C1) 
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During the original investigations, both receptors were found to be associated with inositol 
1,4,5-triphosphate (IP3) formation, elevation of intracellular Ca
2+, activation of extracellular 
signal-related kinase 1 and 2 (ERK1/2) and inhibition of cAMP accumulation (Brown et al. 
2003, Le Poul et al. 2003). However, they exhibited different coupling to G proteins; GPR41 
exclusively activates the Gi family, as evidenced by the absence of a signal following 
treatment with pertussis toxin (PTX), whereas GPR43 is capable of dual coupling through 
both Gi and the PTX-insensitive Gq proteins (Brown et al. 2003, Le Poul et al. 2003). Gαi is 
largely associated with inhibition of adenylyl cyclase and a consequent reduction in 
intracellular cAMP. Gαq activates phospholipase C (PLC), leading to the generation of 
diacylglycerol (DAG) and IP3, which activate protein kinase C (PKC) and trigger Ca
2+ release 
from intracellular stores, respectively. The putative roles of SCFA receptor-associated Gα-
proteins in secretion and exocytosis are illustrated in Figure 4.1. 
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Figure 4.1 Short chain fatty acid receptor-activated intracellular signalling pathways 
associated with exocytosis. GPR41 couples exclusively to the Gi signalling pathway, 
which inhibits adenylyl cyclase (AC) thus reducing intracellular cAMP. The downstream 
effectors of cAMP, Epac2 (exchange protein activated by cAMP) and protein kinase A 
(PKA), have been implicated in exocytosis mechanisms. Gi, and potentially Gq, proteins can 
also indirectly regulate MEK1/2 and in turn activate ERK1/2, which is associated with 
exocytosis and secretion in several cell types. GPR43 is thought to couple to both Gi and Gq-
coupled signalling pathways. Activation of the Gq pathway triggers the release of intracellular 
Ca2+ from the endoplasmic reticulum (ER) and stimulation of protein kinase C (PKC), both of 
which are potent secretagogues.  
PLC, phospholipase C, DAG, diacylglycerol; ERK1/2, extracellular-signal-regulated kinase 1 and 2; 
IP3, inositol 1,4,5-triphosphate; MEK1/2, mitogen-activated protein kinase kinase 1 and 2.  
? 
GPR43 GPR41/43 
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It is now well established that GPCRs can also produce Gα-independent signalling. 
Propionate-mediated Gpr41 activation was recently demonstrated to trigger noradrenaline 
(NA) release from primary murine sympathetic cervical ganglion (SCG) neurons 
independently of Gαi signalling and the cAMP pathway. The Gpr41-dependent release of NA 
was mediated instead by Gβγ signalling and activation of PLCβ and ERK1/2 (Inoue et al. 
2012).  
Both GPR41 and GPR43 activate ERK1/2, also referred to as p44-ERK and p42-ERK, or 
mitogen-activated kinase (MAPK) (Le Poul et al. 2003, Seljeset & Siehler 2012). ERK1/2 is 
activated upon dual phosphorylation of critical threonine and tyrosine residues by the 
upstream kinases MEK1/2. Interestingly, there is emerging evidence in the literature to 
suggest that ERK signalling is directly involved in GLP-1 release from enteroendocrine cell 
lines (Flock et al. 2013, Lim et al. 2009a, Lim et al. 2009b) and exocytosis in other cell types 
(Bieger et al. 2002, Cortez et al. 2012, Fierro et al. 2004, Ren & Guo 2012).  
Lastly, GPCRs can also signal independently of G-proteins altogether, through additional 
pathways such as those mediated by the β-arrestin adaptor proteins (Shenoy & Lefkowitz 
2005).  Interestingly, there has been a recent suggestion in the literature that GPR43 
interacts with β-arrestin 2 to modulate Nuclear Factor-κB (NFκB) signalling (Lee et al. 2013). 
 
4.1.2 Synthetic ligands for SCFA receptors 
The identification of selective synthetic ligands is an important step towards elucidating the 
pharmacology and therapeutic potential of GPCRs. Consequently, considerable effort has 
been expended to produce novel selective agonists and antagonists of the SCFA receptors. 
However, at present, only a limited number of these compounds are available. Although 
several synthetic ligands have been reported with selectivity for either GPR43 or GPR41, 
they have been associated with limitations, namely poor potency, low selectivity, allosteric 
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binding, or a lack of function at non-human orthologs of the receptors (Hudson et al. 2012, 
Lee et al. 2008, Schmidt et al. 2011, Smith et al. 2011). The development of novel selective 
ligands for the two SCFA receptors has been complicated further by recent observations 
describing discrepancies between the rodent and human orthologs of GPR41 and GPR43 
(Hudson et al. 2012). Acetate was reported to be non-selective at mouse Gpr41 and Gpr43, 
compared to the 100-fold difference in potency at the human GPR41 receptor vs. GPR43. 
Furthermore, propionate which was equipotent at human GPR41 and GPR43, was reported 
to be ~12-fold more selective for mouse Gpr41 over Gpr43 (Hudson et al. 2012). These 
findings highlight the need for caution when designing agonists for use in animal work but 
also when extrapolating findings between species.  
 
4.1.3 Evidence for a role for SCFA receptors in gut hormone release 
The signalling pathways underlying SCFA-stimulated gut hormone release are poorly 
understood. However, a recent publication demonstrated that propionate-triggered active 
GLP-1 secretion from colonic cultures derived from Gpr43-deficient mice was reduced by 
70% compared to wild type (WT) and GLP-1 secretion in response to acetate was abolished 
(Tolhurst et al. 2012a). Furthermore, acetate- and propionate-mediated active GLP-1 release 
was also significantly reduced in Gpr41-/- colonic cultures. GPR43-/- animals were also 
demonstrated to have reduced circulating levels of active GLP-1 and both GPR41-/- and 
GPR43-/- mice exhibited impaired glucose tolerance in vivo (Tolhurst et al. 2012a).   
Acetate and propionate transiently increased intracellular Ca2+ in primary L cells,  an effect 
also observed with the synthetic phenylacetamide GPR43 agonist (S)-2-(4-chlorophenyl)-N-
(5-fluorothiazol-2-yl)-3-methylbutanamide (CFMB) (Tolhurst et al. 2012a). However, the 
elevation in intracellular Ca2+ was not directly linked to GLP-1 release in these experiments 
and indeed Nohr et al. did not find the same GPR43 agonist to be as effective as a GP41 
agonist at stimulating GLP-1 release from primary colonic cultures (Nohr et al. 2013).  
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Interestingly, propionate-stimulated GLP-1 release was not significantly affected by the 
presence of the Gi inhibitor, PTX (Tolhurst et al. 2012a). Taken together, these results led 
the authors to suggest that SCFA signalling through Gi-coupled pathways is not critical and 
that SCFAs are likely to signal predominantly through Gq-coupled pathways to release GLP-
1. However, this does not explain the significantly reduced GLP-1 secretion in response to 
SCFAs in the Gpr41-/- tissue.  
 
The previous chapter convincingly demonstrated that SCFAs trigger the release of gut 
hormones both in vitro from primary colonic cultures and in vivo following intra-colonic 
administration. Despite recent progress in elucidating the mechanisms underlying SCFA-
mediated gut hormone release, the intracellular signalling pathways remain poorly 
characterised.  
  
148 
4.2 Aims and Hypotheses 
4.2.1 Aim 
To elucidate the mechanisms underlying propionate-mediated gut hormone release. 
 
Objectives 
Using the primary L cell model, to determine the role in propionate-mediated gut hormone 
release of: 
 Gi signalling 
 Gpr43 signalling 
 ERK1/2 activation 
Using a mouse model of intra-colonic administration and portal vein sampling, to determine: 
 The role of Gpr43 signalling in propionate-induced gut hormone release in vivo using 
global Gpr43-/- mice  
 
4.2.2 Hypotheses 
i) Propionate stimulates the release of gut hormones via a Gpr43-dependent mechanism. 
Therefore, propionate-induced gut hormone secretion will be impaired in Gpr43-deficient 
primary L cells in vitro and in Gpr43-/- mice in vivo. 
Iii) Inhibition of Gi signalling and ERK1/2 activation will reduce propionate-induced gut 
hormone release.  
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4.3 Methods 
Primary colonic cell culture: Refer to Chapter II, Section 2.3.1  
Radioimmunoassay: Refer to Chapter II, Section 2.3.2 
The in vivo study involving intra-colonic administration of propionate followed by portal vein 
sampling described in this Chapter was conducted as in Chapter III, Section 3.3.2.3 with the 
only difference that portal vein blood was collected at t=5 min instead of t=15 min.  
 
4.3.1 Generation of global Gpr43 knockout (GPR43-/-) mice 
Gpr43 global knockout (Gpr43-/-) mice were originally acquired from Deltagen 
(www.deltagen.com). Figure 4.2 shows the strategy by which Gpr43 was knocked out. Mice 
were bred for five generations on a C57BL6 background. Mice were maintained as 
heterozygote breeding pairs, allowing use of littermate WT mice to compare with Gpr43-/- 
mice. There was no difference in body weight between the GPR43-/- and WT littermates on a 
normal chow diet.  
 
4.3.2 Preparation of ear DNA  
Ear tissue (2mm2) was placed in sterile eppendorf tubes. DNA was extracted by digestion in 
sodium hydroxide (50mmol/L, 30µl/tube) at 90oC for 10 minutes. A volume of 5µl 1M Tris-
HCL (pH 8) was then added to each tube to neutralise the solution. Polymerase chain 
reaction (PCR) was then carried out. 
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Figure 4.2 Strategy for Gpr43 gene targeted deletion. Murine Gpr43 on chromosome 7 
consists of 3 exons (black box: coding sequence; empty boxes: untranslated sequences) 
and 2 introns. The targeting construct contains a 4.4 kb 5’ arm, a β-gal-neo cassette and a 
2.1 Kb 3’arm. The homologous recombination replaces a 55bp of Gpr43 exon 1 by the β-gal-
neo cassette and shifts the downstream amino acid sequence out of the reading frame. 
Adapted from: (Maslowski et al. 2009). 
 
 
4.3.3 Genotyping by PCR 
Detection of WT and KO alleles utilised a 3-primer set (Table 4.2): one forward primer, 
targeted at the endogenous sequence that was not intended to be knocked out (E1), and 
two reverse primers, one in an endogenous area targeted to be knocked out (ET) and the 
other targeted to a section of the knock-in construct (Neo). Each primer (0.5µl) was added to 
12.5µl MasterMix (ThermoScientific, UK), to which 1µl sample DNA was then added. After 
an initial denaturation for 5 min at 95°C, the reaction mixes were run for 35 cycles at 95°C 
(45s), 68°C (45s), and 72°C (1min). All reactions were performed on the Peltier Thermal 
Cycler PTC-200 (MJ Research). PCR products were analysed by electrophoresis on a 1% 
agarose gel in 1x TAE buffer (refer to Appendix I) containing 500 ng/ml ethidium bromide 
(VWR, UK). Single bands at 200bp or 400bp represent the WT and KO genotype, 
respectively. Bands at both 200bp and 400bp represent a heterozygous genotype (Fig. 4.3). 
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Table 4.2 Primer sequences for Gpr43-/- genotyping  
Name Primer Sequence PCR product (bp) 
F: E1 
R: ET 
gcg-gaa-gtt-gga-tgc-tgc-ttc-cac-g 
gca-cag-ttc-ctt-gat-cct-cac-ggc-c 
200 
F: E1 
R: Neo 
gcg-gaa-gtt-gga-tgc-tgc-ttc-cac-g 
ggg-cca-gct-cat-tcc-tcc-cac-tca-t 
400 
 
F, forward; R, reverse; bp, base pairs 
 
 
Figure 4.3 Example of genotyping results. Bands at 200bp or 400bp represent wild type 
(WT) and knockout (KO) genotype, respectively. Bands at both 200 and 400bp represent a 
heterozygous (HET) genotype. Ladder, 1 Kb Plus DNA Ladder™ (Life Technologies) 
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4.4 Results 
4.4.1 Investigation into the mechanisms underlying propionate-mediated gut 
hormone release in vitro 
4.4.1.1 The role of Gi signalling in propionate-mediated gut hormone release 
To determine the role of Gi signalling in mediating the stimulatory effect of propionate on 
GLP-1 and PYY secretion, primary colonic cultures were pre-treated overnight with the Gi 
inhibitor, pertussis toxin (PTX, 200ng/ml) (Saifia et al. 1998, Tolhurst et al. 2012a).  
 
Murine primary L cells 
PTX treatment reduced the magnitude of the effect of propionate on gut hormone secretion 
from murine primary L cells (Fig. 4.4). The 2-fold increase in PYY observed with propionate 
(P<0.001) was reduced to a 1.4-fold increase in the presence of PTX. However, basal 
secretion was also elevated following PTX treatment (3.0±0.3% vs. 2.3±0.3% without PTX), 
though this difference was not statistically significant. The GLP-1 response to propionate 
was significantly attenuated following PTX treatment (P<0.05). In the absence of Gi 
inhibition, propionate significantly increased %GLP-1 secretion from 1.7±0.2% to 2.9±0.3% 
(1.7-fold, P<0.001). However, following pre-treatment with PTX, only a 1.2-fold increase in 
GLP-1 release was observed (1.8±0.2 to 2.1±0.2%). 
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Figure 4.4 The effect of inhibiting Gi signalling on propionate-stimulated gut hormone 
secretion from murine primary L cells. Mixed primary colonic cultures were incubated ± 
sodium propionate (50mmol/L) following pre-treatment overnight in DMEM ± 200ng/ml 
pertussis toxin (PTX).  PYY (A) and GLP-1 (B) secretion in each well is expressed as a 
percentage of total PYY or GLP-1 contained within the well and compared to the basal 
secretion measured in parallel within the same experiment. Data represent means ± SEM 
(n=2 mice, 8-11 wells per group). Significance was determined using one-way ANOVA with 
a Bonferroni post hoc test (***P<0.001).  
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Human primary L cells 
Inhibiting Gi signalling in human primary colonic cultures did not abolish PYY secretion in 
response to propionate (Fig. 4.5). Propionate-stimulated PYY secretion was 4.5±1.6% and 
4.2±1.0%, with and without PTX pre-treatment, respectively. However, there was an 
increase in basal %PYY release with PTX (1.7±0.6% vs. 0.9±0.6% without PTX). 
Furthermore, while PYY secretion was increased in response to propionate under control 
conditions, this increase was not statistically significant. 
 
 
 
Figure 4.5 The effect of inhibiting Gi signalling on propionate-stimulated PYY secretion 
from human primary L cells. Mixed primary colonic cultures were incubated ± propionate 
(200mmol/L) following pre-treatment overnight in DMEM ± 200ng/ml pertussis toxin (PTX).  
PYY secretion in each well is expressed as a percentage of total PYY contained within the 
well and compared to the basal secretion measured in parallel within the same experiment. 
Data represent means ± SEM (n 2 patients’ biopsies, 2-6 wells per group).  
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4.4.1.2 The role of Gpr43 signalling: The effect of propionate on gut hormone 
release from Gpr43-/- vs. WT murine primary L cells 
 
To determine the role of Gpr43 in propionate-induced gut hormone release, primary murine 
colonic cultures were isolated from global Gpr43-/- mice and WT littermates. As expected, in 
the WT colonic cultures, incubation with propionate led to a significant increase in both PYY 
and GLP-1 secretion compared to basal secretion (%PYY, 2-fold increase, P<0.001; %GLP-
1, 2.2-fold increase, P<0.01) (Fig. 4.6). In contrast, the propionate-induced gut hormone 
response from Gpr43-/- L cells was significantly attenuated compared to WT L cells (%PYY, 
P<0.001 and %GLP-1, P<0.05). Incubation of Gpr43-/- colonic cultures with propionate only 
led to 1.3-fold and 1.5-fold increases in %PYY and %GLP-1, respectively, which were not 
statistically significant compared to basal secretion.  
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Figure 4.6. The effect of propionate on gut hormone secretion from Gpr43-/- murine 
primary L cells. Mixed primary colonic cultures isolated from wild type (WT) or Gpr43-/- mice 
were incubated ± propionate (50mmol/L). PYY (A) and GLP-1 (B) secretion in each well is 
expressed as a percentage of total PYY or GLP-1 contained within the well and compared to 
the basal secretion measured in parallel within the same experiment. Data represent means 
± SEM (3 separate experiments, n=4-5 mice; PYY, 22-27 and GLP-1, 18-29 wells per 
group). Significance was determined using one-way ANOVA with a Bonferroni post hoc test 
(*P<0.05, **P<0.01, ***P<0.001).  
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4.4.1.2.1 The effect of L-glutamine or increasing intracellular [cAMP] on gut 
hormone release in Gpr43-/- vs. WT murine primary L cells 
 
To determine whether the reduced propionate-stimulated gut hormone response of Gpr43-/- L 
cells was specific, Gpr43-/- and WT primary colonic cultures were incubated either with L-
glutamine, or with a combination of IBMX and forskolin to investigate gut hormone release in 
response to elevated intracellular cAMP concentrations. At a concentration previously shown 
to significantly induce gut hormone release (refer to Chapter II, Section 2.4.3.2), L-glutamine 
led to a significant increase in PYY and GLP-1 release from both WT and Gpr43-/- cultures 
compared to basal (P<0.05) (Fig. 4.7). Increasing [cAMP]i in Gpr43
-/- colonic cultures also led 
to a significant increase in both PYY and GLP-1 secretion compared to basal (%PYY, 
P<0.01; %GLP-1, P<0.001), which was similar in magnitude to the response produced in the 
WT cultures (Fig. 4.8).  
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Figure 4.7. The effect of L-glutamine on gut hormone secretion from Gpr43-/- and WT 
murine primary L cells. Mixed primary colonic cultures isolated from wild type (WT) or 
Gpr43-/- mice were incubated in the presence or absence of L-glutamine (10 mmol/L). PYY 
(A) and GLP-1 (B) secretion in each well is expressed as a percentage of total PYY or GLP-
1 contained within the well and compared to the basal secretion measured in parallel within 
the same experiment. Data represent means ± SEM (n=2 mice, 3-6 wells per group). 
Significance was determined using one-way ANOVA with a Bonferroni post hoc test 
(*P<0.05).  
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Figure 4.8. The effect of increasing intracellular cAMP on gut hormone secretion from 
Gpr43-/- and WT murine primary L cells. Mixed primary colonic cultures isolated from wild 
type (WT) or Gpr43-/- mice were incubated in the presence or absence of IBMX and forskolin 
(10µmol/L each). PYY (A) and GLP-1 (B) secretion in each well is expressed as a 
percentage of total PYY or GLP-1 contained within the well and compared to the basal 
secretion measured in parallel within the same experiment. Data represent means ± SEM (2 
separate experiments, n=2 mice, 4-7 wells per group). Significance was determined using 
one-way ANOVA with a Bonferroni post hoc test (**P<0.01, ***P<0.001).  
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4.4.1.3 The role of ERK1/2 activation in propionate-mediated gut hormone 
release  
 
To investigate the role of ERK1/2 activation in propionate-mediated gut hormone release, 
primary murine colonic cultures were pre-treated for 2 hours in DMEM containing the 
MEK1/2 inhibitor, U0126 (10µmol/L) or 0.1% DMSO (vehicle control). They were then 
incubated with either 50mmol/L propionate, IBMX/forskolin (10µmol/L) or secretion buffer 
alone. No differences in basal PYY or GLP-1 release were observed following incubation 
with U0126 compared to control (Fig. 4.9).  
As shown in Figure 4.9A, pre-treating the colonic cultures with U0126 did not prevent 
propionate from significantly increasing PYY release, from 2.3 ± 0.2% to 4.5 ± 0.4% 
(P<0.05). However, the magnitude of the effect appeared to be reduced compared to control 
conditions, 2-fold vs. 2.4-fold increase (2.6 ± 0.3% to 6.3 ± 0.8%, P<0.001), respectively. As 
expected, elevating intracellular cAMP effectively stimulated the release of PYY despite 
MEK1/2 inhibition.       
In contrast, pre-treatment of the murine colonic cultures with U0126 abolished the 
stimulatory effect of propionate on GLP-1 release (Fig. 4.9B). Under control conditions, 
propionate led to a 1.9-fold increase in %GLP-1 secretion (3.0 ± 0.3% to 5.6 ± 0.4%, 
P<0.001). However, following MEK1/2 inhibition, there was no GLP-1 release in response to 
stimulation with propionate. Elevating intracellular cAMP, on the other hand, retained its 
ability to trigger GLP-1 release (P<0.001), despite MEK1/2 inhibition, to levels identical to 
those observed under control conditions (7.0 ± 1.6% vs. 7.0 ± 1.2%, respectively).    
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Figure 4.9. The effect of inhibiting ERK1/2 on propionate-induced gut hormone 
secretion from murine primary L cells. Mixed primary colonic cultures were incubated ± 
propionate (50mmol/L) or IBMX/forskolin (10µmol/L each) following a 2-hour pre-treatment 
with the MEK1/2 inhibitor U0126 (10µmol/L) or 0.1% DMSO control. PYY (A) and GLP-1 (B) 
secretion in each well is expressed as a percentage of total PYY or GLP-1 contained within 
the well and compared to the basal secretion measured in parallel within the same 
experiment. Data represent means ± SEM (2 separate experiments, n=2 mice, 2-10 wells 
per group). Significance was determined using one-way ANOVA with a Bonferroni post hoc 
test (*P<0.05, ***P<0.001).  
C PRO IBMX/for C PRO IBMX/for
0
2
4
6
8
10
***
*
U01260.1% DMSO
%
 P
Y
Y
 r
e
le
a
s
e
d
C PRO IBMX/for C PRO IBMX/for
0
2
4
6
8
10
***
U01260.1% DMSO
%
 G
L
P
-1
 r
e
le
a
s
e
d
A
B
162 
4.4.2 The role of Gpr43 in vivo: the effect of intra-colonic administration of 
propionate on portal vein gut hormone concentrations in Gpr43-/- vs. WT mice   
 
The primary objective of this work was to elucidate the role of Gpr43 in propionate-induced 
gut hormone release. To assess the role of Gpr43 in vivo, Gpr43-/- mice or WT littermates 
received an intra-colonic injection of either 180mmol/L propionic acid (pH 5.5) or saline. At 
t=5min, portal vein blood was collected for assessment of plasma PYY and GLP-1 levels.  
Propionate significantly increased portal vein plasma PYY and GLP-1 in WT animals (Fig. 
4.10, both P<0.05). In contrast, propionate-mediated gut hormone secretion was significantly 
impaired in the Gpr43-/- mice; no increase in plasma PYY and only a slight, non-significant 
increase in GLP-1 were observed following intra-colonic propionate administration.  
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Figure 4.10 The effect of intra-colonic administration of propionate on portal vein 
plasma PYY and GLP-1 concentrations in male Gpr43-/- and WT mice. Blood samples 
were collected from the portal vein for measurement of plasma (A) PYY and (B) GLP-1, 5 
minutes following an intra-colonic injection (300µl) of 180mmol/L propionic acid or saline 
(matched for pH and sodium content) in isoflurane-anaesthetised Gpr43-/- or wild type (WT) 
mice. Data represent means ±SEM (n=5-7 per group). Significance was determined using 
one-way ANOVA with a Bonferonni post hoc test (*P<0.05). 
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4.5 Discussion 
4.5.1 Summary of findings 
 Inhibition of Gi signalling reduced, but did not abolish, the increase in PYY release 
induced by propionate in murine and human primary L cells. However, inhibition of Gi 
signalling reduced propionate-mediated GLP-1 secretion to a greater extent than 
PYY in murine colonic cultures.  
 Inhibition of ERK1/2 activation abolished the increase in GLP-1 secretion, but not 
PYY secretion, observed in response to propionate in murine primary colonic 
cultures. 
 Propionate-stimulated secretion of both GLP-1 and PYY was significantly impaired in 
GPR43-/- murine primary colonic cultures compared to WT. 
 GPR43-/- murine primary colonic cultures retained their response to an increase in 
intracellular cAMP levels, suggesting that their intracellular signalling pathways are 
intact.  
 In vivo, intra-colonic administration of propionate did not significantly increase portal 
vein plasma GLP-1 and PYY concentrations in GPR43-/- mice, but did in WT mice.  
 
4.5.2 Detailed discussion  
The role of Gi signalling in propionate-induced gut hormone release 
To ascertain the contribution of Gi signalling to the gut hormone release triggered by 
propionate, murine and human primary colonic cultures were pre-treated overnight with PTX 
at a concentration previously found to be effective in murine colonic tissue (Tolhurst et al. 
2012a). The effect of PTX treatment on PYY release from murine tissue and on gut hormone 
release from human colonic tissue has not been previously investigated.  
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In murine and human colonic cultures, propionate appeared to maintain its ability to 
stimulate PYY release in the presence of PTX. However, the magnitude of the response was 
reduced, in part due to an increase in basal PYY release. Similarly, basal GLP-1 secretion 
was also slightly elevated in the presence of PTX and the response to propionate was 
impaired to a greater extent (1.2-fold vs. 1.7-fold). It is also difficult to draw conclusions from 
the human colonic culture experiment because of the small n number and the lack of a 
statistically significant difference in PYY secretion between propionate and control in the 
absence of PTX. In addition, as NaCl at 200mmol/L was previously demonstrated to have a 
slight effect on gut hormone release, a NaCl control would be useful in future experiments. 
Experiments with both human and murine colonic cultures would require independent 
repetition to confirm the results (minimum of n=3 independent experiments). However, a 
similar pattern, i.e. the increased basal gut hormone release and the attenuated response to 
propionate following PTX treatment were also observed by Tolhurst et al. in murine cultures 
(1.3-fold increase in active GLP-1 with PTX vs. 1.8-fold increase without PTX) (Tolhurst et al. 
2012a). However, the reduction reported by Tolhurst et al. was not statistically significant.  
Ideally, the effect of overnight pre-treatment with PTX on cell viability would have been 
examined prior to the experiment. The increase in basal release following PTX treatment 
observed in the work presented here and in the literature, may indicate cytotoxicity. This 
work would have also benefited from a positive control and an experiment to verify that Gi 
signalling had indeed been effectively knocked down under these conditions. This could 
have been achieved using IBMX and somatostatin, a potent inhibitor of gut hormone 
secretion, which activates a Gi-coupled pathway to reduce intracellular cAMP levels (Moss et 
al. 2012). IBMX should stimulate gut hormone secretion, via an increase in intracellular 
cAMP, irrespectively of PTX. In the absence of PTX, somatostatin should significantly 
reduce IBMX-stimulated gut hormone secretion, whereas in the presence of PTX, 
somatostatin should not be able to inhibit gut hormone release and thus IBMX should retain 
its stimulatory effect (Tolhurst et al. 2012a).  
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The role of ERK1/2 activation in propionate-mediated gut hormone release 
ERK1/2 signalling has previously been associated with GLP-1 release from enteroendocrine 
cell lines in response to a number of stimuli (Flock et al. 2013, Lim et al. 2009a, Lim et al. 
2009b). The effect of ERK1/2 inhibition on PYY release has not been investigated. To 
determine whether ERK1/2 also plays a role in propionate-mediated gut hormone release, 
primary murine colonic cultures were pre-treated with U0126, an inhibitor of MEK1/2, the 
upstream activator of ERK1/2. Surprisingly, in the presence of U0126, the stimulatory effect 
of propionate on PYY release was reduced (2.4-fold to 2-fold), whereas the GLP-1 response 
appeared to be completely abolished. If confirmed, these results would suggest that ERK1/2 
plays a role in propionate-mediated GLP-1 secretion.   
The mechanisms by which ERK1/2 regulates exocytosis and gut hormone release are 
largely unknown. Interestingly, recent evidence suggests that ERK1/2 directly affects 
exocyst function (Ren & Guo 2012). The exocyst, present in murine intestinal stem cells 
(Sakamori et al. 2012), is an evolutionarily conserved octameric protein complex that 
mediates the initial interaction between secretory vesicles and the plasma membrane, a 
process known as ‘vesicle tethering’, which precedes membrane fusion (He & Guo 2009). 
Ren and Guo recently identified Exo70, one of the exocyst proteins thought to associate with 
the plasma membrane and interact with the rest of the exocyst components on the arriving 
vesicles, as a direct substrate of ERK1/2 (He & Guo 2009, Ren & Guo 2012). It has also 
been postulated that the exocyst interacts with and regulates the assembly of the SNARE 
protein complex, which catalyses membrane fusion and exocytosis. Experiments using 
U0126 and Exo70 mutants suggest that inhibition of ERK1/2 phosphorylation of Exo70 
prevents exocytosis by affecting the interaction of Exo70 with other exocyst subunits (Ren & 
Guo 2012). Further work to elucidate the potential roles of ERK1/2 and the exocyst in SCFA-
mediated gut hormone release is warranted. 
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The reason why ERK1/2 inhibition did not impair PYY secretion to the same extent as GLP-1 
secretion, should this be confirmed to be a true finding, is a matter of speculation. A recent 
study investigating the receptor-specific regulation of ERK1/2 activation by GPR41 and 
GPR43 reported that Gi signalling is involved in the activation of ERK1/2 by both receptors. 
ERK1/2 activation mediated by GPR41 stimulation was fully dependent on Gi and MEK1/2, 
whereas ERK1/2 phosphorylation in response to GPR43 activation was fully dependent on 
MEK1/2 and reduced by 75% in the presence of PTX (Seljeset & Siehler 2012). 
Consequently, while there is some Gq-mediated activation of ERK1/2, it appears to be 
predominantly linked to Gi signalling. Therefore, it is conceivable that the impaired GLP-1 
release in the presence of U0126 may be related to the reduced GLP-1 secretion following 
Gi inhibition. While both sets of results require confirmation, they warrant further examination 
of the role of Gi signalling and ERK1/2 activation in SCFA-mediated gut hormone release.  
This line of investigation would be strengthened by demonstrating that propionate increases 
ERK1/2 activation in L cells, which could be achieved by quantifying phosphorylated ERK1/2 
(p-ERK), as a proportion of total ERK1/2 (t-ERK) by immunoblotting. This approach would 
require the use of an immortalised cell line, such as the GLUTag cell line. Furthermore, this 
set of experiments would have benefited from a positive control for ERK1/2 inhibition. 
Following optimisation, this could perhaps have been achieved using insulin. Insulin-
stimulated GLP-1 secretion was abolished in the presence of a MEK1/2 inhibitor in the 
enteroendocrine cell line NCI-H716 (Lim et al. 2009a).  
The concept of differential PYY and GLP-1 release is controversial. GLP-1 and PYY are 
predominantly thought to be co-localised both at the cellular and vesicular level in colonic L 
cells (Habib et al. 2013, Nilsson et al. 1991), which would suggest that they are 
simultaneously released. Indeed, in the work presented in this thesis, all stimuli that have 
triggered PYY release have also triggered GLP-1 release to a similar extent. However, there 
are several examples in the literature which would suggest that under certain conditions, 
there is selective release of only one of the two hormones (Anini et al. 1999, Aponte et al. 
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1988, Ballantyne et al. 1989, Cuche et al. 2000). Several hypotheses have been proposed in 
the literature, as previously discussed, including the differential release of the two gut 
hormones from the same L cell, or the existence of PYY-positive but GLP-1 negative L cells 
(Anini et al. 1999, Habib et al. 2013).  
Given the reported presence of secretory granules within L cells containing PYY only (~15%) 
(Nilsson et al. 1991), it could be speculated that spatial organisation of signalling 
components may be arranged in such a way as to lead to release of discrete pools of 
individual hormones from an L cell that expresses both. Alternatively, it is possible to 
speculate that there are different subsets of colonic L cells, including ones which may not 
produce both hormones, and which may be differentially regulated. This would be much less 
surprising in light of the recent findings by Habib et al., who reported marked differences 
between small intestinal (SI) and colonic proglucagon-expressing L cells (Habib et al. 2012). 
Furthermore, this study did not only find differences between SI and colonic L cells, but also 
between proximal and distal SI L cells, including a higher percentage of cells co-expressing 
PYY in the distal SI. Therefore, it is possible that there are also differences between L cell 
populations along the length of the large intestine, where L cell numbers are higher (Eissele 
et al. 1992, Larsson et al. 1975). Nevertheless, these recent findings by Habib et al. revealed 
the diverse nature of the L cell population across different regions of the proximal and distal 
gut, highlighting the complexity of the enteroendocrine system and the current limits to our 
understanding of it.   
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The role of Gpr43 in propionate-induced gut hormone release 
While the two published studies that have investigated energy homeostasis in Gpr43-/- mice 
to date led to different conclusions, both reported hyperphagia on a HFD compared to WT 
(Bjursell et al. 2011, Kimura et al. 2013). One of the mechanisms potentially underlying this 
increase in food intake in Gpr43-deficient mice is a reduced release of anorectic gut 
hormones from Gpr43-expressing enteroendocrine L cells. In support of this hypothesis, 
Gpr43-/- animals were also reported to have lower basal circulating levels of GLP-1 (Tolhurst 
et al. 2012a).    
The results presented in this chapter, demonstrate in vitro, and for the first time in vivo, that 
Gpr43 deficiency impairs SCFA-induced PYY and GLP-1 secretion. Incubation of primary 
colonic cultures derived from Gpr43-/- mice with propionate led to significantly reduced PYY 
and GLP-1 release compared to WT cultures. An obvious question which arose from these 
results, and which is not addressed by the current literature, is whether the secretory 
function of Gpr43-/- L cells was somehow impaired so that the reduced secretion observed in 
response to propionate was non-specific. However, the Gpr43-/- colonic cultures maintained 
a robust gut hormone response to both L-glutamine and elevated intracellular cAMP 
concentrations, suggesting that their intracellular machinery is intact.  
It is tempting to speculate that the remaining non-significant increase in gut hormone 
secretion observed following treatment of the Gpr43-/- colonic cultures with propionate may 
be a consequence of Gpr41 activation. However, an effect of propionate transport across the 
cell membrane or metabolism within the cell cannot be ruled out. A limitation of this work 
was that Gpr41 expression in Gpr43-/- vs. WT colonic tissue has not yet been assessed. This 
information is important, particularly in light of the previously reported reduced expression of 
Gpr41 in Gpr43-deficient mice (Tolhurst et al. 2012a).         
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Intra-colonic administration of propionate significantly increased portal vein plasma levels of 
both PYY and GLP-1 at t=5 min in WT mice. The increase in portal vein plasma GLP-1 in 
response to propionate described in Chapter III only bordered statistical significance at t=15 
min post-administration (P=0.0517). However, portal vein sampling at 5 minutes resulted in 
higher plasma GLP-1 concentrations (~10%), presumably as a result of reduced 
degradation.  
In Gpr43-/- mice, intra-colonic administration of propionate led to a significantly reduced 
portal vein plasma PYY and GLP-1 response. Although this might be expected, it has not 
been previously demonstrated. In contrast to the reduced basal circulating GLP-1 
concentrations observed by Tolhurst et al., there was no difference in portal vein GLP-1 or 
PYY between Gpr43-/- and WT animals following intra-colonic administration of saline.  
It is critical to demonstrate that findings in vitro also translate into the in vivo setting and are 
of physiological relevance. In this context, given that the precise cellular location of Gpr43 is 
unknown, it was important to demonstrate that propionate was able to stimulate gut hormone 
release when administered into the gut lumen.  
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4.5.3 Conclusions and novel insight 
The role of Gi signalling and ERK1/2 in SCFA-mediated gut hormone release is not clear. 
Preliminary data suggest that they may play a role in GLP-1 secretion from primary murine 
cultures. However, further work is required to confirm these results and to investigate the 
effect of Gi signalling on GLP-1 release, and ERK1/2 inhibition on GLP-1 and PYY release, 
from human primary L cells. Nevertheless, the findings presented here highlight the 
importance of measuring the release of both PYY and GLP-1 in parallel in response to 
different stimuli and inhibitors.  
The work described in this chapter demonstrated for the first time that propionate-stimulated 
PYY release from primary Gpr43-/- colonic cultures is significantly attenuated. Furthermore, 
this work also demonstrated for the first time that Gpr43-/- mice have significantly lower portal 
vein PYY and GLP-1 levels following intra-colonic administration of propionate compared to 
their WT littermates. These findings support the concept of SCFAs, derived from the 
fermentation of dietary fibre, acting as signalling molecules via GPR43 to stimulate anorectic 
gut hormone release and, by extension, reduce appetite (Sleeth et al. 2010).  
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Chapter V: 
General Discussion 
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5.1 Introduction 
Obesity and its associated co-morbidities pose a daunting challenge to public health. 
Despite signs of stabilisation (Sperrin et al. 2013), the consequences of the dramatic rise in 
obesity experienced over the past few decades remain extensive. In England, approximately 
25% of adults (aged 16 years and over) are currently classified as obese (HSE 2011). 
Therefore, there is an urgent need for strategies to improve appetite regulation and aid 
weight loss which can be applied at a population level.  
Bariatric surgery remains the most effective treatment for the very obese (Sjostrom et al. 
2004). However, due to its associated mortality risk, bariatric surgery is largely limited to 
treating morbid obesity (Flancbaum & Belsley 2007). Nevertheless, a better understanding of 
the mechanisms by which surgical operations such as the RYGB induce such dramatic 
weight loss, may enable us to exploit them therapeutically. One of the factors contributing to 
enhanced satiety following gastric bypass is the increased delivery of nutrients to distal 
regions of the small intestine, thereby increasing the secretion of the appetite-suppressing 
gut hormones GLP-1 and PYY (Beckman et al. 2011, Korner et al. 2005, le Roux et al. 2006, 
le Roux et al. 2007). However, it is increasingly evident that additional mechanisms are also 
involved (Pournaras et al. 2012, Saeidi et al. 2013). Intriguingly, recent evidence suggests 
that alterations in the relative abundance of certain gut microbial populations following RYGB 
may play a role in mediating the RYGB-associated weight loss (Liou et al. 2013), an effect 
which was also associated with increased caecal SCFAs and a shift in the microbial 
production of SCFAs favouring propionate. In keeping with these findings, another recent 
study reported a significant negative correlation between adiposity and caecal butyrate and 
propionate concentrations in germ-free mice receiving faecal transplants from human twin 
donors discordant for obesity (Ridaura et al. 2013). SCFAs may, therefore, play a role in 
influencing host energy homeostasis. 
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Given the present success of GLP-1 mimetics in reducing body weight as well as improving 
glucose control, targeting L cell secretion is an exciting prospect (Tong & Sandoval 2011). 
There is also evidence to suggest that co-administration of two gut hormones may be a more 
effective strategy for suppressing appetite and reducing energy intake (Field et al. 2010b). 
However, exogenous administration of gut hormones has several drawbacks: it can result in 
adverse effects, such as nausea and vomiting (Degen et al. 2005, Kanoski et al. 2012, le 
Roux et al. 2008), and may face difficulties with compliance, as it usually requires a needle-
based delivery system which can cause discomfort. Furthermore, the injection of gut 
hormones is associated with a risk of eliciting an immune reaction and antibody formation. 
Consequently, there is considerable interest in evaluating the therapeutic potential of 
promoting the secretion of endogenous GLP-1 and PYY. 
SCFAs have been proposed to account for the reduced food intake and the increased 
circulating levels of GLP-1 and PYY observed following a high intake of NDCs (Cani et al. 
2009, Delzenne et al. 2005, Keenan et al. 2006, Zhou et al. 2008); a hypothesis fuelled by 
the discovery that the SCFA receptors, GPR41 and GPR43, are enriched in enteroendocrine 
L cells (Karaki et al. 2006, Tolhurst et al. 2012a). However, experimental evidence 
demonstrating a direct link between SCFAs, GPR43 activation and L cell secretion is limited.  
The main hypotheses examined in this thesis, and discussed below, were i) that SCFAs 
would stimulate gut hormone release and ii) that this would occur via a GPR43-dependent 
mechanism. 
 
5.2 The role of SCFAs in gut hormone release  
Existing immortalised enteroendocrine ‘L cell’ lines do not accurately represent colonic 
physiology, in part due to their lack of PYY production (Reimann et al. 2008). Chapter II of 
this thesis described the development, optimisation and validation, of a murine primary L cell 
model for the assessment of GLP-1 and PYY release. These primary colonic cultures 
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contained a mixed cell population. This was necessary as isolated L cells do not survive in 
culture (Reimann et al. 2008) and indeed, may be advantageous, as the L cells remain in 
close proximity to neighbouring cells and may retain a degree of exposure to paracrine 
signals. The methodology was adapted to permit the isolation of L cell-containing human 
primary colonic cultures. Human L cells in culture were demonstrated for the first time to 
secrete both GLP-1 and PYY in response to glucose and to an increase in intracellular 
cAMP.  
The primary L cell model has limitations. Firstly, L cells are polarised cells, with an apical 
surface in contact with the gut lumen and a basolateral surface typically in contact with the 
microvasculature of the gut (Eissele et al. 1992). In vitro, L cell polarity is disrupted and both 
surfaces are exposed to the culture medium and to subsequent experimental treatments 
targeted at the luminal surface. Therefore, assuming that the test substances are acting 
solely via interaction with the luminal surface could be misleading.  
There are two main, alternative primary in vitro intestinal cell models which attempt to 
maintain the polarity of intestinal cells. The first is the ex vivo ‘everted gut sac’ technique, 
which briefly consists of gently everting an isolated rat intestine, filling it with oxygenated 
tissue culture medium at 37oC, and dividing into ‘sacs’ (~2.5cm length) using braided suture 
silk. Individual sacs are then placed in flasks containing oxygenated culture medium at 37oC 
(Barthe et al. 1998). However, this technique relies on the integrity of the sacs and on the 
viability of the intestinal tissue, which may be very poor as disruption of the epithelium and 
severe interstitial oedema have been described to occur within 30-60 min (Levine et al. 
1970, Plumb et al. 1987). A new technique, which has been gaining momentum, is that of 
the three-dimensional (3D) intestinal epithelial organoids also referred to as ‘epithelial mini-
guts’ (Sato & Clevers 2013). These intestinal organoids grow from isolated Lgr5-expressing 
intestinal stem cells embedded in Matrigel, a 3D laminin- and collagen-rich matrix, in the 
presence of culture medium containing a cocktail of growth factors, Noggin and R-spondin 
(Wnt signal enhancer and Lgr5 ligand). These organoids occur as ‘cysts’ with a central 
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lumen flanked by a simple, highly polarised villus epithelium with multiple crypt-like 
structures projecting outwards (Sato et al. 2009). Therefore, to a certain extent, crypt 
architecture and cellular polarity are maintained. Additional advantages of this technique 
include the ability to maintain these cultures long term, enabling the study of epithelial cell 
fate determination and identification of factors which increase L cell numbers in vitro 
(Petersen et al. 2013). 
A disadvantage of all three models is that L cells ex vivo lose their connection to the GI 
neuroendocrine network, which may be fundamental in the normal regulation of L cell 
function (Reimann et al. 2012). Despite these limitations, the data presented suggest that 
primary colonic cultures serve as a useful and valid model for studying gut hormone release 
from colonic L cells.  
The primary L cell model was employed in Chapter III to determine the effect of SCFAs on 
GLP-1 and PYY release. This work demonstrated that, as hypothesised, SCFAs trigger the 
release of both gut hormones in parallel from murine primary L cells. SCFA-stimulated PYY 
release from primary colonic cultures had not been previously investigated. Moreover, these 
findings were demonstrated for the first time in human primary L cells. The stimulatory effect 
of propionate on both PYY and GLP-1 release was also reproduced in vivo, as described in 
Chapter III, supporting the validity of the murine L cell model. The in vivo data derived from 
both rat and mouse studies support the simultaneous secretion of both gut hormones in 
response to propionate, in contrast to previous findings in rats and pigs, which showed an 
increase in circulating PYY but not GLP-1 in response to SCFAs (Anini et al. 1999, Cuche et 
al. 2000). However, the results of the rat study discussed in this thesis revealed that the 
effect on GLP-1 was transient in nature compared to the more sustained increase in 
circulating PYY observed. Based on the results presented, it may also be useful to measure 
secreted GLP-1 in portal vein blood where concentrations are higher.  
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Chapter IV describes the use of the primary L cell model to investigate components of the 
stimulus-secretion coupling mechanisms underlying propionate-stimulated gut hormone 
release. The preliminary experiments described in this thesis may suggest a potential role 
for Gi signalling and ERK1/2 activation in SCFA-mediated gut hormone release. However, 
these results require confirmation and the involvement of GPR41 and intracellular signalling 
components downstream of the cell surface receptors requires further investigation.  
In accordance with hypothesis ii, it was demonstrated for the first time that PYY release, in 
addition to GLP-1 release, from primary Gpr43-/- colonic cultures was significantly attenuated 
in response to propionate. Furthermore, this thesis presented the novel finding that Gpr43-/- 
mice also have significantly lower plasma PYY and GLP-1 levels following intra-colonic 
administration of propionate compared to their wild type littermates. These findings are in 
keeping with, and further extend the published literature (Tolhurst et al. 2012a). Taken 
together, the results support the concept that SCFAs, derived from the fermentation of 
dietary fibre, signal via GPR43 to stimulate gut hormone release and, by extension, reduce 
appetite (Fig. 5.1). However, our current understanding of the complex interrelationship 
between diet, gut microbiota and host physiology is at best rudimentary. This thesis has 
taken a reductionist approach and focused primarily on just one bacterial metabolite and 
end-product of NDC fermentation. While this work demonstrated that all three major SCFAs 
stimulate gut hormone release, further work is required to dissect the signalling pathways 
activated by each SCFA and to identify potential differences. Crucially, it is perhaps naïve to 
think that these three SCFAs (C2-C4), despite being the major anions in the colonic lumen, 
are the only bioactive signals derived from gut bacterial fermentation.  
 
178 
 
 
 
Figure 5.1 The role of short chain fatty acids and GPR43 in appetite regulation.  
Short chain fatty acids (SCFAs), produced by the fermentation of dietary fibre by gut bacteria 
in the colon (1), are proposed to activate GPR43 on enteroendocrine L cells (2) stimulating 
the release of gut hormones (3) which influence food intake at three sites: the vagus nerve, 
the brainstem and the hypothalamus (4). Within the arcuate nucleus of the hypothalamus 
two neuronal populations are thought to be critical conduits through which peripheral signals 
are integrated to alter the drive to eat: orexigenic NPY/AgRP neurons and anorexigenic 
POMC neurons. The release of GLP-1 and PYY activates anorexigenic neurons and inhibits 
orexigenic neurons, ultimately resulting in a reduction in food intake. Connections between 
hypothalamic nuclei and higher brain centres influence the hedonic aspects of food 
ingestion. Adapted from: (Bewick 2012) 
ARC, arcuate nucleus; AgRP, agouti related peptide; GLP-1, glucagon like peptide-1; NPY, 
neuropeptide Y; POMC, propiomelanocortin; PVN, paraventricular nucleus; PYY, peptide YY. 
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5.3 Colonic SCFAs and appetite regulation  
Epidemiological evidence suggests that there is an inverse association between NDC intake 
and weight gain (Liu et al. 2003, Ludwig et al. 1999). This is supported by experimental 
studies which demonstrate that increasing the consumption of NDCs can reduce appetite 
and body weight in humans (Cani et al. 2006, Howarth et al. 2001, Rigaud et al. 1990, Ryttig 
et al. 1989).  However, these beneficial effects are not consistently observed, in part due to 
the large quantities of NDCs required to elicit them, which can cause gastrointestinal side 
effects and contribute to poor adherence in the long term (Chapman 2010, Grabitske & 
Slavin 2009). It is tempting to speculate that exploiting the mechanisms by which 
fermentable fibre suppresses appetite may offer a more effective strategy for weight 
management. The findings presented in this thesis support the hypothesis that increasing 
colonic propionate levels in vivo will suppress appetite by elevating circulating levels of GLP-
1 and PYY.  
The main challenge associated with testing this hypothesis is the delivery of SCFAs to the 
colon; apart from being unpalatable (Darzi et al. 2011), orally administered SCFAs are 
absorbed in the small intestine prior to reaching the colon (Schmitt et al. 1976, Schmitt et al. 
1977). One strategy to address this is to develop novel delivery systems which when 
administered orally, are protected from digestion and absorption in the stomach and small 
intestine, and which are designed to ensure targeted release in the proximal colon (Kosaraju 
2005). This could be achieved by encapsulating SCFAs or attaching them to NDC ‘carrier 
molecules’ via ester bonds for example, ensuring that the SCFAs are only liberated upon 
bacterial fermentation in the colon (Hartzell & Rose 2011). Strategies to achieve targeted 
delivery of SCFAs to the colon could provide a way to stimulate the release of endogenous 
gut hormones and thus improve appetite regulation and energy balance.       
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5.4 Future directions 
The primary L cell model described in this thesis is a useful system for interrogating 
stimulus-secretion coupling mechanisms. There are numerous pharmacological tools 
available which can be employed within this system, and in conjunction with enteroendocrine 
cell lines, to further characterise the intracellular signalling mechanisms involved 
downstream of the receptors. My data demonstrated that SCFA-mediated gut hormone 
release is significantly impaired in Gpr43-/- mice. GPR43 signals partly via a Gq-coupled 
pathway, which is associated with an increase in intracellular Ca2+, a potent effector of 
exocytosis (Burgoyne & Morgan 2003). In support of this, Tolhurst et al. recently reported 
that acetate and propionate elevate [Ca2+]i, though a direct link to gut hormone secretion was 
not demonstrated (Tolhurst et al. 2012a). It would therefore be interesting to investigate 
SCFA-induced gut hormone secretion in the presence of a novel commercial Gq inhibitor, 
UBO-QIC. It would also be possible to investigate the role of i) intracellular [Ca2+]i stores, 
using thapsigargin, a potent, cell-permeable, non-competitive inhibitor of the 
sarco/endoplasmic reticulum Ca2+ ATPase (Treiman et al. 1998) and ii) Ca2+ influx, using the 
extracellular Ca2+ chelator, ethylene glycol tetraacetic acid (EGTA) (Chen et al. 2006) or 
specific voltage-sensitive Ca2+ channel blockers such as nifedipine (Nemoz-Gaillard et al. 
1998). Inhibitors of downstream signalling components associated with exocytosis such as 
PKA and PKC could also be used. Understanding the intricate intracellular mechanisms 
underlying gut hormone secretion in both murine and human L cells in response to 
physiological stimuli is of fundamental importance and may facilitate the harnessing of these 
pathways therapeutically. 
A critical advance in this field would also be the determination of the subcellular localisation 
of the SCFA receptors within L cells. It is currently unknown whether the receptors are 
localised to the apical or basolateral plasma membrane, or both. It also possible that the 
receptors reside intracellularly, pending recruitment to the cell surface. The location of the 
receptors would attest to their physiological role and would also influence the feasibility of 
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pharmacologically targeting SCFA receptors in vivo. Identifying the subcellular localisation of 
SCFA receptors is currently hampered by the lack of high affinity antibodies. An alternative 
strategy could be perhaps to image a fluorescently conjugated GPR43-selective ligand 
(Hudson et al. 2013).      
The recent development of these novel selective GPR43 agonists, including ‘compound 1’, 
which was shown to stimulate GLP-1 release from STC-1 cells (Hudson et al. 2013), also 
offers the exciting opportunity of being able to pharmacologically activate Gpr43 in vivo in 
rodents and consequently to evaluate its therapeutic potential.  
It is also imperative to further characterise this system in the context of obesity. Obesity is 
associated with fundamental changes in the gut microbiota and SCFA production (Kimura et 
al. 2013, Ley et al. 2005, Ley et al. 2006, Ridaura et al. 2013, Turnbaugh et al. 2006). 
Furthermore, HFD feeding has been reported to up-regulate Gpr43 expression in mouse 
adipose tissue, skeletal muscle and liver (Cornall et al. 2011, Dewulf et al. 2011, Hong et al. 
2005, Kimura et al. 2013). Paradoxically, supplementation of the HFD with fermentable 
inulin-type fructans in mice counteracted the HFD-induced increase in Gpr43 expression in 
adipose tissue, an effect associated with protection from HFD-induced body weight gain and 
fat mass accumulation (Dewulf et al. 2011). In contrast, overexpression of Gpr43 in adipose 
tissue in vivo was recently shown to protect against HFD-induced body weight gain in mice 
(Kimura et al. 2013). Only two studies have been carried out so far to investigate the energy 
homeostasis phenotype of Gpr43-/- mice on a HFD background, and have reached different 
conclusions regarding whether the global absence of Gpr43 is protective or detrimental, 
potentially as a consequence of using different genetic backgrounds or due to the variation 
in gut microbial composition under different environments (Bjursell et al. 2011, Kimura et al. 
2013). These discrepancies highlight the urgent need for further studies to address the 
tissue-specific and wider roles of SCFAs and GPR43 in energy homeostasis in the context of 
obesity.  
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The enteroendocrine system is instrumental in the regulation of post-prandial physiology and 
plays a central role in appetite regulation. The work presented in this thesis demonstrates 
that SCFAs can influence L cell function to trigger the release of the anorectic gut hormones 
GLP-1 and PYY. Propionate-induced gut hormone secretion was shown to be mediated via 
a Gpr43-dependent mechanism in vitro and in vivo using Gpr43-/- mice. This mechanism 
may underpin, at least in part, the beneficial effect of fermentable fibre on appetite 
suppression and prevention of weight gain. Further work is required to elucidate the 
intracellular signalling mechanisms underlying GPR43-mediated gut hormone release as 
well as the wider role of GPR43 in energy homeostasis. This field opens up the exciting 
possibility of harnessing these pathways, pharmacologically or with novel functional foods, to 
activate the enteroendocrine system and suppress appetite via the release of endogenous 
gut hormones.  
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Appendix I: List of solutions 
 
Cell lysis buffer: Add 0.25g C24H39NaO4.H2O (sodium deoxycholate monohydrate), 0.88g 
NaCl, 0.5ml Igepal and 2.5ml Tris HCl (1M, pH 8) to 30ml GDW. Adjust volume to 40ml and 
add 1 tablet complete EDTA-free protease cocktail inhibitor (Roche, UK) and store at 4ºC.  
 
Dextran-coated charcoal: Add 2.4g charcoal and 0.24g dextran to 100ml phosphate buffer 
with gelatin and stir for 20 minutes. 
 
Phosphate buffer: Dissolve 48g Na2HPO4.2H2O, 4.13g KHPO4, 18.61g 
C10H14H2ONa2.2H2O (EDTA) and 2.5g NaN3 (sodium azide) in 5 litres of GDW that has been 
boiled and allowed to cool. Adjust pH to 7.4 and store at 4ºC. 
 
Phosphate buffer with gelatin: The buffer is produced as above, except that 12.5g gelatine 
is added to the boiled water prior to cooling, and before addition of the other reagents. 
 
Phosphate buffered saline (PBS) (0.1M, 10x): Add 80g NaCl, 2g KCl, 14.4g Na2HPO4 and 
2.4g KH2PO4 to 800ml GDW. Adjust volume to 1L and pH to 7.4. 
 
Secretion buffer: Dissolve 0.335g KCl, 8.065g NaCl, 0.353g NaHCO3, 0.187g 
NaH2PO4.2H2O, 2.6ml 1M CaCl2, 1.2ml 1M MgCl2 and 2.383g HEPES in 800ml GDW. Make 
up to 1L and adjust pH to 7.4.  
 
0.06M sodium barbitone buffer: Dissolve 5.15g C8H11N2NaO3 and 0.15g NaN3 in 500ml 
GDW that has been boiled and allowed to cool. Adjust pH to 8.0 and store at 4ºC. 
 
50 x TAE buffer: Dissolve 242g Trizma base in 843ml water and add 57ml glacial acetic 
acid and 100ml 0.5M C10H14H2ONa2.2H2O (EDTA) pH 8. 
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Appendix II: Composition of protease inhibitor cocktail 
 
 
Table A1. Composition of protease inhibitor cocktail (Sigma, UK). 
Inhibitor Concentration 
(neat) mmol/L 
Proteases inhibited 
AEBSF 
4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride 
104 Serine proteases e.g. trypsin, 
chymotrypsin, plasmin, kallikrein and 
thrombin 
Aprotinin 0.08 Serine proteases e.g. trypsin, 
chymotrypsin, plasmin, and kallikrein 
Bestatin hydrochloride 4 Aminopeptidases e.g. leucine 
aminopeptidase and alanyl 
aminopeptidase 
E-64 
N-(trans-Epoxysuccinyl)-L-leucine 
4-guanidinobutylamide 
1.4 Cysteine proteases e.g. calpain, papain, 
cathepsin B, and cathepsin L. 
Leupeptin hemisulfate salt 2 Serine and cystein proteases e.g. 
plasmin, trypsin, papain and cathepsin B. 
Pepstatin A 1.5 Acid proteases e.g. pepsin, renin, and 
cathepsin D, and many microbial aspartic 
proteases 
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Appendix III: Publications and Presentations 
 
Publications 
 
Weight gain and insulin sensitivity: a role for the glycaemic index and dietary fibre?  
Sleeth, M.L., Psichas, A., Frost, G. (2012) Br J Nutr 27: 1-3 
 
 
Oral presentations 
 
‘Short chain fatty acids stimulate the release of the anorectic gut hormone peptide YY from 
enteroendocrine L cells in vitro and in vivo’ 
A. Psichas 
 
Rank Prize Funds Mini-Symposium on “Non-Digestible Polysaccharides in the Human Diet: 
From Farm to Pharmacy”, Cumbria, July 2012 
 
‘The mechanisms underlying the beneficial effects of short chain fatty acids’ 
A. Psichas 
 
BBSRC Diet and Health Research Industry Club (DRINC) 7th Dissemination Event, 
Manchester, October 2011 
 
 
Poster presentations 
 
‘Short chain fatty acids stimulate the release of gut hormones in vitro and in vivo via Gpr43.’ 
 
A. Psichas, M. Sleeth, K.G. Murphy, L. Brooks, G. Bewick, M. Ghatei, S.R. Bloom, G. Frost 
 
Imperial College Graduate School Research Symposium, London, July 2013 
 
 
‘Short chain fatty acids stimulate the release of gut hormone peptide YY from human primary 
L cells’ [Physiological Society Poster Prize] 
 
A. Psichas, S.E.K. Zac-Varghese, K.G. Murphy, M.A. Ghatei, S.R. Bloom, G. Frost 
 
Physiological Society Annual Meeting, Edinburgh, July 2012 
 
‘Stimulating gut hormone release using propionate: from cells to humans’ [Poster Prize] 
A. Psichas, E. Chambers, A. Viardot, D. Morrison, S. Zac-Varghese, K.G. Murphy, G. 
Bewick, G. Frost 
 
BBSRC Diet and Health Research Industry Club (DRINC) 7th Dissemination Event, 
Manchester, October 2011 
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